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ABSTRACT
In the last three decades, autohaemotherapy with blood treated with oxygen containing low 
concentrations o f ozone, either alone or in combination with an elevated temperature and 
ultraviolet irradiation (HOU), has been used in Europe for the treatment o f peripheral 
vascular diseases. Many apparently widely differing beneficial claims have been made for 
this therapeutic approach. This study has provided an objective rationale as to how 
HOU-treated blood administered as autohaemotherapy may work as a therapeutic agent.
This study has investigated the effect o f the treatment o f blood in vitro with HOU on the 
blood platelets. The results indicate that either in healthy volunteers or in patients with 
PVD and/or diabetes, HOU-treated blood causes a dose-dependent, reversible inhibition 
o f blood platelet aggregation in response to ADP and collagen, calcium ionophore A23187 
and thrombin. The treatment o f whole blood with HOU did not result in the destruction o f 
platelets, as indicated by a lack o f increase in release o f the alpha-granule component 
platelet-derived growth factor into the plasma, and a increase in total platelet count. The 
concentrations o f endothelium-derived relaxing factor (EDRF, known to be closely related 
to or identical with nitric oxide) and prostacyclin (PGI2) released from immune cells in the 
HOU-treated blood are increased by this treatment in vitro. EDRF and PGI2 are both well 
known inhibitors o f platelets aggregation and vasodilators. Evidence that the observed 
inhibition o f platelet aggregation in treated blood is at least in part caused by EDRF 
production is provided by the reversal o f the inhibition in the presence of 
oxy-haemoglobin, an EDRF inhibitor.
An In vivo clinical study was performed on normal healthy volunteers using 
autohaemotherapy with blood exposed to UV light and ozone in medical oxygen (15 fig/mL) 
at a temperature o f 42.5 °C. These volunteers were monitored by measurement o f standard 
haematological parameters, a clinical chemistry profile and clinical symptoms and signs. 
These was no evidence o f harmful effects o f the treatment.
In vivo HOU-autohaemotherapy enhanced the expression o f the activation markers EL-2R, 
Ber-Mac3 and HLA-DR on peripheral blood mononuclear cells demonstrating for the first 
time objectively -measurable systemic changes in treated individuals. There was also 
significant increase in plasma prostacyclin concentrations measured as its stable metabolite 
6-keto-PGFla after HOU-autohaemotherapy.
Endothelial dysfunction, with a reduction in the synthesis o f vasodilators, particularly nitric 
oxide and perhaps also prostacyclin, plays a critical role in many vascular diseases. If  
autohaemotherapy with HOU-treated blood can restore endothelial function, as suggested 
by the evidence o f an increase in prostacyclin levels in treated individuals, then this therapy 
could represent a major advance in the treatment o f a number o f vascular diseases.
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CHAPTER 1
Introduction
1.1 Background
Peripheral vascular disease (PVD) is an indication of generalized arterial disease. It is 
responsible for considerable morbidity in the general population, particularly amongst the 
elderly. Its prevalence increases with age and is higher in males than females (Fowkes, 
1988). In one study, carried out in Edinburgh, almost one-third of middle-aged men 
were found to have significant peripheral arterial disease, and approximately 5% 
experienced symptoms of intermittent claudication (Fowkes, et al, 1991). The risks 
associated with lower-limb atherosclerosis are not primarily due to the disease itself, but 
to concomitant ischaemic heart disease and cerebrovascular disease, with almost half of 
the deaths among this group being caused by heart disease (Jelnes, et al, 1986). Indeed, 
the distribution of coronary and cerebrovascular disease throughout the population is 
similar to that o f peripheral arterial disease (Fowkes, 1988) and represents an important 
indicator of generalized atherosclerosis. Atherosclerosis affecting the abdominal aorta is 
common and potentially lethal. Two to three percent of men over 50 have have an 
aneurysm of the abdominal aorta (Greenhalgh, 1990).
Occlusive vascular disease, which includes ischaemic heart disease and cerebrovascular 
disease is the single largest cause of death in the UK. In 1991 alone nearly 262,000 
deaths (47.7 % of the total number) were attributed to diseases o f the circulatory system 
(Office of population censuses & Surveys, 1991). In the UK. rupture or complications 
o f abdominal aorta aneurysms kill 10,000 people each year (Greenhalgh, 1990). In the 
United States of America coronary heart disease alone accounts for over half a million 
deaths annually (Munro & Cotran, 1988).
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Atherosclerosis affecting the lower limbs may require arterial by-pass surgery and, in 
serious cases, amputation and long-term rehabilitation. A study in the UK has found that 
arterial reconstruction costs around £7,750 per person (1989 prices) and amputation 
around £11,000 per person (Dmmmond & Davies, 1994). Aortic aneurysm is a major 
cause of death and the only effective treatment is sophisticated surgical operation, which 
is equally costly. Death is mostly the result o f complications following amputation and 
reconstructive surgery. Surgery is justified only if claudication is severe and intractable 
and the patient must not have other diseases that will increase the risk and limit the 
benefits o f operation - for example, angina or osteoarthritis.
1.2 Aetiology of peripheral arterial disease
As peripheral arterial disease and ischaemic heart disease are clinical manifestations of 
basically the same pathological process, it is not surprising that the risk factors for the 
two conditions are similar, particularly elevated levels of cholesterol (especially low- 
density lipoprotein LDL) and hypertension (Leng 1995).
Smoking, however, seems particularly important in the aetiology of lower-limb disease 
(Fowkes, 1989). Smoking increases the risk o f peripheral arterial disease by up to seven­
fold (Heliovaara, et al, 1978; Hughson, et al, 1978) and at least 75% of those presenting 
with intermittent claudication will be smokers (Fowkes, et al, 1991). Smoking may also 
be responsible for abnormalities in haemostatic factors, especially fibrinogen, found in 
patients with peripheral vascular disease. Smokers have lower levels o f essential fatty 
acids and lower intakes of dietary antioxidants than non-smokers. This is due to the 
many reactive oxidising species in the gas and tar phases o f tobacco smoke (Leng, 1995), 
and this may have a significant impact on smokers susceptibility to lower-limb arterial 
disease.
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Diabetes mellitus is also believed to be a particularly important risk factor for peripheral 
arterial disease. Some of the increased risk may, however, be caused by the effect of 
diabetes on the microcirculation. Evidence relating impaired glucose tolerance 
(abnormal glucose tolerance test but not diabetic) in the general population to the 
occurrence of peripheral arterial disease is somewhat conflicting (Hughson, et al, 1978; 
Fowkes, 1990).
1.3 Pathology of peripheral arterial disease
In clinical practice atherosclerosis is the commonest and most important vascular disease. 
In common parlance, the term peripheral vascular disease is often used synonymously 
with peripheral atherosclerosis (Fowkes, 1990), although there are other vascular 
disorders that are under this heading.
1.3.1 Atherosclerosis
Atherosclerosis is a degenerative disease o f large and medium-sized muscular arteries, 
such as the coronary, carotid, basilar and vertebral arteries, as well as the aorta and the 
arteries supplying the lower extremities (iliac, femoral). The lesions result from an 
excessive, inflammatory-fibroproliferative response to various forms of insult to the 
endothelium of the artery wall. Many different cell types and a large number o f growth 
factors, cytokines and vasoregulatory molecules are involved in atherogenesis. 
Atherosclerosis is the principal cause of heart attack, stroke and gangrene and loss of 
function in the extremities (Ross, 1993).
1.3.1.1 Lesions of atherosclerosis
The earliest lesion of atherosclerosis is the so-called 'fatty streak', an aggregation o f lipid-
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rich macrophages (foam cells) and T lymphocytes within the intima. Many observations 
have shown that fatty streaks precede the development of intermediate lesions (Masuda 
& Ross, 1990 [l]; [2]), which are composed of layers of macrophages and smooth muscle 
cells and, in turn, develop into the more advanced, complex, occlusive lesions called 
fibrous plaques. The fibrous plaques increase in size and, by projecting into the arterial 
lumen, may impede the flow of blood. They are covered by a dense cap of connective 
tissue matrix (including collagen, elastic fibers, and proteoglycans) with embedded 
smooth muscle cells that usually overlays a core o f lipid and necrotic debris (Davies & 
Thomas, 1984; Wick et al, 1995). The fibrous plaques contain monocyte-derived 
macrophages, smooth muscle cells and T lymphocytes, many of which are activated, as 
evidenced by HLA-DR expression (Hansson, et al, 1991; Libby & Hansson, 1991).
1.3.1.2 Response to injury and atherogenesis
The exact mechanisms that lead to atherosclerosis are not completely understood. 
However, from knowledge accumulated over several decades by a great number o f 
laboratories, most investigators believe that endothelial injury and the response to the 
injury are important factors contributing to the formation of atherosclerotic plaques 
(Ross & Glomset, 1973; Ross & Harker, 1976; Ross, 1993). Injury o f vascular 
endothelium is induced in various ways, such as hypercholesterolemia, mechanical stress 
by high blood pressure, smoking, immune reactions, toxins, viruses and homocysteine 
(Dadak, et al, 1981; Wick et al, 1995). Monocytes and T lymphocytes attach to the 
injured sites and migrate between the endothelial cells under the influence of growth- 
regulatory molecules and chemoattractants released both by the altered endothelium, its 
adherent leukocytes and underlying smooth muscle cells (Munro & Cotran, 1988).
As the process continues, migrating cells reach further beneath the arterial surface, where 
the monocytes become macrophages, accumulate lipid, become foam cells and, together
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with the accompanying lymphocytes, become the fatty streak (Masuda & Ross, 1990 [l]; 
[2]). These often form at sites of pre-existing collections o f intimal smooth muscle 
(Thomas, et al, 1985). Thereafter, continued cell influx and proliferation lead to the 
more advanced lesions, distinguished by their fibrous character, and ultimately to the 
fibrous plaque.
Postmortem studies have shown that atherosclerosis occurs commonly in arteries serving 
the lower limbs and these lesions often occur close to arterial bifurcations and bends, 
where the mural thrombi often occur (Fowkes, 1990). It might be that haemodynamic 
factors, such as shear stress or disturbed flow, damage the vascular endothelium 
(Fowkes, 1989), causing a predisposition to platelet deposition.
1.3.1.3 Molecules and their regulation
Growth factors, cytokines and other chemicals, including lipids and small molecules such 
as prostacyclin and nitric oxide (NO), induce and regulate numerous critical cell 
functions. During the process of atherogenesis, they may act in cell recruitment and 
migration, cell proliferation and the control of lipid and protein synthesis (including 
extracellular matrix proteins). Furthermore, the same modifiers are implicated in 
vascular events, such as vasodilation, vasoconstriction and coagulation. Elucidation of 
their roles in this disease provides opportunities to develop new therapeutic agents to 
induce the regression of the lesions and possibly to prevent their formation.
The terms growth factor and cytokine are often used interchangeably, although the 
cytokines were originally considered to be the mediators implicated in immunity and 
inflammation and growth factors to be involved in proliferation and chemotaxis o f cells in 
organs and tissues. With respect to atherosclerosis, these two roles are closely 
interrelated, with the same mediator sometimes acting as an inflammatory regulator and
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sometimes acting as a growth regulator, depending on the target cell (Ross, 1993). The 
molecules relating to the process o f atherogenesis and their biological actions are listed 
in Table 1-1.
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Table I-1. Molecules related the process of atherogenesis
Molecules Source Biological actions References
PD-ECGF Platelets Potent endothelial mitogen Ross, 1993
(platelet-derived endothelial
cell growth factor)
EGF / TGFa Platelets, Endothelial mitogen, Munro &
(endothelial cell growth factor / macrophages angiogenesis factor Cotran, 1988;
transforming growth factor a) Ross, 1993
TGF/3 Platelets, smooth Inhibition of endothelial RayChaudhury
(transforming growth factor fi) muscle cells, proliferation, induces gene & D'Amore,
endothelial cells, expression of PDGF by 1991
macrophages, T endothelial cells and smooth
lymphocytes muscle cells, potentially 
induces endothelial synthesis 
and secretion of connective 
tissue matrix, induces smooth 
muscle cell proliferation, 
endothelial and smooth 
muscle cell chemotaxis
VEGF Macrophages, Endothelial mitogen Ross, 1993
(vascular endothelial growth smooth muscle
factor) cells
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bFGF
(basic fibroblast growth factor)
Macrophages, 
endothelial cells, 
smooth muscle 
cells
Endothelial and smooth 
muscle cell mitogen, induces 
connective tissue and smooth 
muscle cell proliferation, 
mediates angiogenic effect, 
chemoattractant for 
endothelial cells
Klagsbrun & 
Edelman, 1989
PDGF
(platelet-derived growth factor)
Platelets, 
endothelial cells, 
macrophages, 
smooth muscle 
cells
Induces smooth muscle cell 
and connective tissue 
proliferation, chemoattractant 
for smooth muscle cells
Rubin, et al, 
1988;
Hart, et al, 
1988; Ferns, et 
al, 1991; Ross, 
et al, 1990
M-CSF / GM-CSF
(macrophage colony stimulating 
factor / granulocyte-macrophage 
colony stimulating factor)
Macrophages, T 
lymphocytes, 
endothelial cells, 
smooth muscle 
cells
Proliferation of T 
lymphocytes, endothelial cells 
and smooth muscle cells, 
maintaining cell viability and 
prevent apoptosis and cell 
death, paticipates in further 
macrophage activation and 
replication, chemoattractant 
for endothelial cells and 
monocytes, lowering of 
plasma cholesterol levels
Rosenfeld & 
Ross, 1990, 
Shimano, et al, 
1990
HB-EGF
(heparin-binding epidennal 
growth factor-like growth factor)
Smooth muscle 
cells,
macrophages
Growth agonist for 
endothelial cells, induces 
smooth muscle cell 
proliferation
Higashiyama, et 
al, 1991
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IGF-1
(insulin-like growth factor-1)
Platelets, 
endothelial cells, 
smooth muscle 
cells,
macrophages
Smooth muscle cell 
chemotaxis, induces smooth 
muscle cell proliferation
Banskota, et al, 
1989
IL-1
(interleukin-1)
Macrophages, 
endothelial cells, 
smooth muscle 
cells, T 
lymphocytes
Inhibiting endothelial 
proliferation, induces gene 
expression of PDGF by 
endothelial cells and smooth 
muscle cells, induces smooth 
muscle cell and connective 
tissue proliferation, activation 
of macrophages
Raines, et al,
1989; Wick , et 
al, 1995
IL-2
(interleukin-2)
T lymphocytes, 
macrophages
Proliferation o f endothelial 
cells, smooth muscle cells and 
T lymphocytes
Ross, 1993; 
Wick, et al, 
1995
IFN- 7
(interferon-7)
T lymphocytes, Inhibits endothelial and 
smooth muscle cell 
proliferation
Hansson & 
Holm, 1991; 
Gray, 1992; 
Delomenie, et 
al, 1993
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TNFce Macrophages, Inhibits endothelial Old, 1985;
(tumour necrosis factor a) endothelial cells, proliferation, induces gene Munro &
smooth muscle expression of PDGF by Cotran, 1988;
cells, T endothelial cells and smooth Jacob, 1989;
lymphocytes muscle cells, induces smooth 
muscle cell and connective 
tissue proliferation, 
angiogenic effect mediator, 
activation of and chemotactic 
for macrophages
Aggarwal, 1992
oxLDL Macrophages, Injury to endothelial cells, Springer, 1990;
(oxidised low-density lipoprotein) endothelial cells, mitogenic and activating Cybulsky &
smooth muscle factors for macrophages Gimbrone,
cells underlying the endothelium, 
induces formation of adhesive 
molecule VAM-1 by 
endothelium, potent 
monocyte, T lymphocyte and 
endothelial cell chemotaxis
1991; Leng, 
1995
MCP-1 Endothelial cells, Potent chemoattractant for Leonard &
(monocyte chcmotactic protein-1) smooth muscle endothelial cells and Yoshimura,
cells, monocytes 1990
macrophages
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NO
(nitric oxide)
Endothelial cells Vasodilator and inhibitor of 
platelet aggregation, inhibits 
mitogenesis and proliferation 
of vascular smooth muscle 
cells
Moncada, et al, 
1988; Vallance 
& Collier,
1994, Garg & 
Hassid, 1989; 
Luscher, 1990; 
Ignarro, 1989(2|
p g i2
(prostacyclin)
Endothelial cells Vasodilator and inhibitor of 
platelet aggregation, 
cytoprotective activity.
Vane, et al, 
1990; Vane & 
Botting, 1995;
t x a 2
(thromboxane A2)
Platelets Vasoconstrictor, induces 
platelet aggregation
Radomski, et 
al, 1987 (2), 
(3); Vane, et al, 
1990
Thrombin Plasma Stimulates the endothelium to 
a procoagulant state
Ross, 1993; 
Lutomski, et al, 
1995
Factor Xa Plasma Stimulates the endothelium to 
a procoagulant state
Ross, 1993; 
Lutomski, et al, 
1995
Angiotensin Plasma Vasoconstrictor Vane, et al, 
1990
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The growth-regulatory molecules can induce multiple and, in some instances, apparently 
divergent effects. They can stimulate cell proliferation, can in some cases inhibit 
proliferation, and many of the proliferative agents can act as chemoattractants (Munro & 
Cotran, 1988). The growth-regulatory molecules that can induce smooth muscle 
proliferation are generally not expressed in the normal artery, whereas they are 
upregulated in lesions of atherosclerosis. Chemotaxis is a critical event in the 
development o f the lesions of atherosclerosis. It is neccesary to bring leukocytes into the 
artery wall and, at some sites, smooth muscle cells from the media into the intima of the 
artery.
Although the nature of any immune response that is induced locally during atherogenesis 
is not understood, it is presumed that some cytokines, such as IL-1, TNFa, IFN7  and IL- 
2 together with the CSFs can also play a role as immunological mediators. In the 
process of atherogenesis, through cell-cell interaction, the release of one molecule can 
lead to expression of a second molecule in a target cell that can then either stimulate its 
neighbours in a paracrine way, or itself in an autocrine way. IL-1, TNFa or TGF/3 
released by activated lesion macrophages exposed to agonists, such as oxLDL, induce 
PDGF-AA gene expression and secretion by smooth muscle cells (Libby, et al, 1988). 
Endothelial cells in culture that are exposed to the agonist IL-1 express the gene for and 
secrete PDGF-BB (Raines, et al, 1989).
1.3.1.4 Cellular interactions
Endothelium
Knowledge accumulated over several decades has led to the formulation o f the response 
to injury hypothesis regarding the pathogenesis of atherosclerosis (Ross & Glomset,
1973; Ross & Harker, 1976). The different risk factors lead to endothelial dysfunction, 
which can elicit a series of cellular interactions that culminate in the lesions of
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Research on vascular endothelium has established endothelial cells as active cells which 
perform a variety of critical functions (Spittell, 1992; Munro & Cotran, 1988) including:
( 1) provision o f a nonthrombogenic surface as the endothelium linies the blood vessels in 
a continuous monolayer; (2 ) provision of a semipermeable barrier through which there is 
exchange and active transport of substances between blood and tissues, (3) maintenance 
of vascular tone by release o f small molecules such as NO, which accounts for the 
biological activity of endothelium-derived relaxing factor (EDRF), PGI2, and endothelin 
(ET) which modulate vasodilation or vasoconstriction, respectively; (4) formation and 
secretion of growth-regulatory molecules and cytokines; (5) ability to oxidize 
lipoproteins during the transgression process through endothelial cells. Changes in one 
or more o f these properties may represent the earliest manifestations of endothelial 
dysfunction.
Evidence has accumulated to suggest that oxLDL is a key component in endothelial 
injury (Andrews, et al, 1987; Leng, 1995). Once formed by the endothelium, oxLDL 
may directly injure the endothelium, decreasing the production of NO and PGI2 and 
thereby contributing to vasospasm and thrombosis, thus playing an initial role in the 
increased adherence and migration of monocytes and T lymphocytes into the 
subendothelial space (Wick, et al, 1995).
In atherosclerosis, the molecules mediating the attachment o f platelets and circulating 
leucocytes to altered endothelium and the subendothelial matrix are unknown, but 
intensive work in the area of cell adhesion has identified several new endothelial 
receptors which are candidates for this adhesive anchor. These include the intracellular 
adhesion molecules (ICAM), which interact with specific sites on neutrophils and 
lymphocytes, the vascular adhesion molecules (VAM), which recognises binding sites on
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lymphocytes, and the platelet-endothelial cellular adhesion molecules (PECAM), which is 
also expressed at high density on neutrophils and platelets. Besides facilitating leukocyte 
attachment, some receptors also appear to promote transendothelial migration of 
leukocytes. Thus, since platelets can attach to stimulated neutrophils and monocytes, 
platelets can be bound to the vascular wall indirectly - i.e., by adhering to leukocytes 
bound to the endothelium (Springer, 1990; Cybulsky & Gimbone, 1991; Ware &
Heistad, 1993). The cytokines IL-1 (produced by various cells) and TNF (produced by 
macrophages), and oxLDL can induce the formation of these adhesion molecules on 
endothelium (Zimmerman, et al, 1992; Ware & Heistad, 1993; Ross, 1993).
NO is synthesised from L-arginine by NO synthase (NOS) with reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) as cofactor (Figure 1-1). In the endothelial 
cells NOS can exist in either Ca++ / calmodulin dependent (caNOS) or Caf+ independent 
(ciNOS) isoforms. caNOS has been suggested to be constitutive and ciNOS the 
inducible isoform of NOS (Moncada, et al, 1991; Li, et al, 1991). ciNOS may combine 
with tetrahydrobiopterin (BH4) as a cofactor. Inducible nitric oxide synthase is 
expressed only after activation of cells with cytokines, such as TNFa, IFN- 7  or IL-1, and 
lipopolysaccharide (LPS) (Moncada, et al, 1991; Li, et al, 1991; Llibbs, 1991; 
Zimmenman, 1992; Vallance& Collier, 1994).
The formation of NO by endothelium can prevent platelet aggregation and can cause 
vasodilation (Figure 1-2) (Palmer, 1987; Radomski, et al, 1987 [l] [2] [3]; Ignaaro, 1988; 
Luscher, 1990). NO relaxes smooth muscle and inhibits platelet adhesion and 
aggregation by increasing the levels of cyclic guanosine monophosphate (cGMP). 
Vasomotor tone o f the artery appears to be controlled by the constant action o f NO 
(Ress, et al, 1989 [l] [2j; Vallance, et al, 1989; Panza, et al, 1990; Tolins, et al, 1990; 
Tolins & Shultz, 1994). Inhibition of formation o f NO or eicosanoids, such as PGI2, 
permit the opposing forces o f vasodilation, resulting from vasoconstrictors such as ET,
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L-NMMA
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L-arginine L-citrulline
1. The conversion of L-arginine to reactive nitrogen intermediates
NO synthesis is selectively catalysed by NO synthase and is competitively inhibited by L- 
arginine antagonists, L-NMMA (N^-monomethyl-L-arginine) or L-M^Arg (N^-nitro-L- 
arginine).
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PLATELET. cAMP cGMP
HEMOGLOBINTHROMBIN 
BRADYKININ 
SHEAR SRESS
EDRF-NO
Arachidonic aeidENDOTHELIAL
CELL L-Arginine
SMOOTH
MUSCLE EDRF-NO
cAMP J c G M P
Figure 1-2. Generation o f prostacyclin (PGI2), EDRF-nitric oxide in normal 
endothelial cells (Vane et al, 1990).
Stimulation of receptors on the cells by serotonin (5HT) or adenosine diphosphate (ADP) 
released from platelets or by thrombin, bradykinin, or shear stress, leads to the release of 
vasoactive mediators, Prostacyclin formed from arachidonic acid relaxes smooth muscle and 
inhibits aggregation of platelets by increasing levels of cyclic adenosine monophosphate 
(cAMP). EDRF-nitric oxide (NO) formed from L-arginine also relaxes smooth muscle and 
inhibits platlet aggregation and adhesion, by increasing levels o f cyclic guanosine 
monophosphate (cGMP). By increasing cAMP and cGMP simultaneously, prostacyclin and 
EDRF-nitric oxide synergistically inhibit platelet aggregation. Haemoglobin inactivates EDRF- 
nitric oxide.
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angiotensin II (A-II), or thromboxane A2 (TXA2) (Vane, et al, 1990).
The endothelium plays a critical role in maintaining the fluidity of blood as well as the 
patency of the blood vessels. Heparan sulphate, PGI2 and NO produced by endothelial 
cells are all antithrombotic (Vane, et al, 1990; Ware & Heistad, 1993) and endothelium 
can specifically bind factors that prevent coagulation (Rau, 1991; Spittell, 1992). In 
blood platelets, arachidonic acid is metabolised through a complex pathway to TXA2, 
which exerts an entirely opposing physiological effect on the cardiovascular system to 
PGI2. It has been suggested that the balance between these substances may have an 
important controling influence in thrombosis (Radomski, et al, 1987 [l]; [2], [3]). Careful 
histological studies of athromatous lesions in both human and animals have indicated that 
fibrin and platelets are important constituents of early lesions (Ross & Glomset, 1973). 
Any factor that predisposes towards platelet aggregation would have an important 
influence on the development of early atheromatous lesions.
PGI2 is generated mainly by the endothelium (Figure 1-3) and its synthesis can be 
stimulated by endothelial contact with activated leukocytes (Vane, et al, 1990). In vitro. 
human umbilical vein endothelial cells have been used to study the effects o f the 
interaction between human monocytes and endothelial cells on endothelial PGI2 
production. Hakkert and his colleagues (1992) have reported that direct cell-cell contact 
between purified monocytes and endothelial cells strongly enhanced PGI2 synthesis. 
Secretory products, such as IL-1, from monocytes and neutrophils and TNFa, from 
activated monocytes/macrophages, also enhanced endothelial PGI2 synthesis (Vane & 
Botting, 1995), although to a lesser extent than with monocytes that were in direct 
contact with endothelial cells. The explanation may be that monocytes also produce and 
secrete arachidonic acid metabolites by the cyclooxygenase pathway. Thromboxanes are 
the major products synthesized by monocytes via this route, whereas PGI2 is produced 
only in small amounts. It is possible that monocytes in close contact with endothelial
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Figur 1-3. Metabolic pathway showing formation of PGI2 and 
TXA, from arachidonic acid in endothelial cells
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cells enhance the endothelial PGI2 production by providing the endothelial cells with 
exogenous eicosanoids (Hakkert, et al, 1992).
Nitric oxide production by the endothelium may also be stimulated by peripheral blood 
cells. In vitro studies in the rat have shown that endothelial cells co-cultured with 
activated lymphocytes showed an increase in production of nitric oxide, this effect being 
dependant on cell-cell contact (Schuler, et al, 1995). As nitric oxide is known to inhibit 
leukocyte: endothelial cell interaction (Kuber, 1993), these may be local feedback control 
which regulates the adhesion of leukocytes to endothelial cells.
Platelets
The earliest and most consistent consequence of denuding endothelial injury is the 
adhesion of platelets to the subendothelial connective tissue followed by the platelet 
release reaction (Longenecker, 1985). The biologically important molecules released 
from platelets include /3-thromboglobulin, vasoconstrictive amines, arachidonic acid 
metabolites, and, o f most relevance to atherogenesis, mitogenic factors PDGF, TGFa 
and TGF(3 (Table 1-1). PDGF induces both migration and proliferation o f smooth 
muscle cells.
Platelets are excellent candidates as the initiators o f intimal plaque formation after 
denuding injury. In the human, it is highly likely that platelets are involved in early lesion 
formation in catheter-induced injury, in peri-anastomotic lesions o f vascular grafts, and in 
other traumatic vascular lesions (Ferrell, 1992).
Monocytes / macrophages. Macrophages are present in all stages o f atherosclerosis. The 
roles of the macrophages include: (1) action as an antigen-presenting cell to T 
lymphocytes, (2) action as a scavenger cell to remove antigenic materials, (3) production 
o f growth-regulatory molecules and cytokines. The macrophage is thus the principal
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inflammatory mediator of cells in the atheromatous plaque microenvironment.
LDL is a possible candidate antigen and may be taken up by the macrophages that 
transform into foam cells. Macrophages can oxidize LDL into oxLDL, which could set 
up a vicious cycle that could further exacerbate the atherogenic process (Leng, 1995). 
Macrophages also play a role in the fibroproliferative process by their capacity to form 
numerous growth factors, in particular PDGF (Ross, et al, 1990) as well as IL-1 and 
TNFg: (Table 1-1). PDGF exerts a mitogenic effect on mesenchymal cells and stimulates 
leukocyte migration, thus playing a role in sustaining an inflammatory / immune response 
(Wich, et al, 1995).
Smooth muscle. These cells respond to agents that induce either vasoconstriction, such 
as ET, A-II or vasodilation, such as PGE, PGI2 and NO when cells are in a contractile 
phenotype. They are capable o f expressing genes for a number of growth factors and 
cytokines, can respond to growth factors by expressing appropriate receptors, and can 
synthesize extracellular matrix. At sites of atherosclerosis, damaged smooth muscle cells 
may release FGF and in so doing could also stimulate neighbouring smooth muscle, the 
overlying endothelium, or vascular channels within the lesions. Their synthetic activity 
will determine the matrix content o f the lesion, which in turn could interact at their 
surface and modify their capacity to respond to various agonists. Thus the smooth 
muscle cell plays the critical role in the fibroproliferative component o f this disease 
process.
1.3.1.5 Immune responses
The involvement of immune reactions, at all stages o f atherosclerotic development 
(Libby & Llasson, 1991), has been neglected for many years in classical atherosclerosis 
research. It is now evident that T cells are among the earliest cells infiltrating the arterial
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intima in the initial stages of atherosclerosis. In the T-cell population, 70% were found 
to be CD4+, the remainder being CD8+, and the majority expressed major 
histocompatibility complex (MHC) class IIHLA-DR and IL-2 receptor (IL-2R), thus 
indicating an activated stage (Wick, et al, 1995).
The presence of T lymphocytes together with numerous activated macrophages suggests 
that not only is there an inflammatory reaction during the process of atherogenesis, but 
also that there may be an immunological reaction and that this may be related to a 
specific antigen (Ross, 1986; Munro & Cotran, 1988). Although it has not been possible 
thus far to identify such an antigen, autoantibodies have been found to oxLDL. 
Furthermore, clonal expansion o f lymphocytes does not appear to take place (Libby & 
Hasson, 1991). Whatever antigen the T cells that infiltrate the arterial intima are 
recognizing, it seems improbable that endothelial cells aberrantly expressing MHC class 
II antigens act as primary T-cell sensitization sites: HLA-DR, -DP and -DQ expression 
by endothelial cells was never observed without concomitant subendothelial 
accumulation of mononuclear cells capable of producing IFN-7 , pointing to MHC class 
II expression as a secondary phenomenon (van der Wal, et al, 1989). Thus, T-cell 
sensitization must occur at another site such as the regional lymph nodes. This 
suggestion is also supported by the demonstration o f increased serum levels o f neopterin, 
reflecting systemic activation o f macrophages by IFN- 7  (Tatzber, et al, 1991). In the 
studies on the immune system in the process of atherogenesis numerous questions remain 
to be answered.
1.3.2 Hypertensive vascular disease
Hypertension accelerates atherosclerosis (Chobanian et al, 1989) and the lesions have the 
same histological appearances and distribution as normotensive subjects with 
atherosclerosis (Haudenschill et al, 1979; Limas et al, 1982; ITuttner & Gabbiani, 1983;
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Chobanian et al, 1986). However, hypertension also causes thickening of the media of 
the muscular arteries (Spittell, 1992). This is the result o f hyperplasia o f smooth muscle 
cells and collagen deposition close to the internal elastic laminae. In contrast to 
artherosclerosis, which affects larger arteries, it is the smaller arteries and arterioles 
(vessels with an outside diameter of less than 1 0 0  ^m) which are especially affected in 
hypertension.
1.3.3 Diabetic vascular disease
Diabetic vascular disease is associated with damage involving both large and small 
vessels throughout the body. Patients with diabetes, particular juvenile - onset insulin- 
dependent diabetes, may develop three forms o f vascular disease:
• Atherosclerosis.
• Hypertensive vascular disease.
• Capillary micro-angiopathy. This is the most important and characteristic change in 
diabetes. The alterations are found throughout the systemic circulation and can be 
viewed directly in the retina. Small arterioles and capillaries are affected and there are 
both basement membrane thickening and intimal fibrosis.
1.4 C urrent pharmacological approaches to the treatm ent of peripheral arterial 
disease
Many elderly people with intermittent claudication may well not seek medical care, but 
for those who do, clinical medicine has little to offer, especially if symptoms are mild to 
moderate.
Recently clinical pharmacological approaches in the treatment of PVD mainly involves 
the management of thrombosis and administration o f vasodilators.
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1.4.1 Anticoagulants
Oral anticoagulants e. g. warfarine and dicoumarol, are used to prevent thrombus 
formation or the extension of an already existing thrombus in the slow-flow, low 
pressure venous side of the circulation, where the thrombus consists o f a fibrin web 
enmeshed with platelets and red cells. Oral anticoagulants are therefore widely used in 
the prevention and treatment of deep-vein thrombosis in the legs. However, 
anticoagulants are of less use in preventing thrombus formation in arteries, for in the 
high-pressure, high-velocity arterial system thrombi are composed mainly of platelets 
with little fibrin (the 'white' thrombus) and a coagulopathy due to deficiency of natural 
occuring anticoagulants (antithrombin III, protein C and protein S) producing arterial 
thrombosis seems very unlikely (Cooke, 1995). The serious adverse effect of 
anticoagulants is haemorrhage.
1.4.2 Thrombolytic agents
Thrombolytic agents, such as streptokinase, act by activating plasminogen to the 
proteolytic enzyme plasmin, which degrades fibrin and other procoagulant proteins 
including factors V and VIII and so digests thrombi. Streptokinase has only a limited 
success rate, with serious complications such as bleeding, hypotension and stroke 
(Lutomski, et al, 1995) and is not recommended (Housley, 1988).
1.4.3 Antiplatelet agents
By decreasing platelet aggregation, antiplatelet agents may inhibit thrombus formation on 
the arterial side of the circulation, where thrombi are formed by platelet aggregation and 
anticoagulants have little effect. Antiplatelet drugs have little effect in venous
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thromboembolism.
Aspirin irreversibly inhibits prostaglandin G / H synthase (cyclooxygenase) by acetylation 
of the hydroxyl group o f a single serine at its active site. Endothelial cells are nucleated 
and produce cyclooxygenase, regaining their ability to regenerate prostacyclin 
production in a few hours. However, non-nucleated platelets cannot produce 
cyclooxygenase, and thromboxane synthesis recovers only as new platelets enter the 
circulation. The life of a platelet is about 8  to 11 days. Thus, treatment with low dose 
aspirin leads to a cumulative inhibition o f thromboxaneA2 formation and allows 
endothelial cells to produce prostacyclin (Figure 1-3) by newly generated synthesised 
enzyme. Several administration methods and dosage forms of aspirin have been 
suggested so that the effects of aspirin on platelet cyclooxygenase will be optimised and 
those on endothelial cell (vasculature) cyclooxygenase will be minimised (Lutomski, et 
al, 1995).
An overview o f trials of antiplatelet treatment in patients with transient ischaemic attacks 
or minor ischaemic strokes (as in patients with unstable angina or myocardial infarction) 
showed that 15% fewer treated patients died and 30% fewer had non-fatal strokes or 
myocardial infarctions and that there is no evidence to suggest benefit in PVD 
(Lowe, 1990). Because atherosclerosis is a generalised disease and patients with PVD 
have an increased risk o f myocardial infarction and transient ischaemic attacks, 
physicians may consider using aspirin (Cooke. 1995).
Non-steroidal anti-inflammatory daigs (NSAIDs) are widely prescribed, but have the 
potential for serious side effects, particularly the risk o f gastric irritation and slight but 
persistent blood loss, especially in the elderly. The sudden onset o f exertional dyspnoea 
may be the first indication of side effects (British National Formulary, 1994).
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Prostacyclin (PGI2, epoprostenol) and its analogue iloprost are potent vasodilators and 
inhibit platelet aggregation by increasing cAMP in platelets and vascular smooth muscle 
cells. Intravenous prostacyclin and iloprost are already o f proven value in salvaging 
ischaemic limbs when surgery other than amputation may not be possible. These two 
drugs must be given by continuous intravenous (iv) infusion (Grant & Goa, 1992), which 
must be given continuously for at least 3 days or longer in the treatment of vascular 
diseases, including thromboangitis obliterans and Raynaud's phenomenon.and primary 
pulmonary hypertension (Belch et al, 1981, 1983; Szczeklik et al, 1979; Jones et al,
1987; Vane & Botting, 1995). Side-effects are dose dependent and include flushing, 
headache, gastrointestinal distress and hypotension, with bradycardia, pallor and 
sweating at higher doses.
Nitrate formulations have the active moiety o f nitric oxide (Feelisch, 1991). Nitric oxide 
induces relaxation of vascular smooth muscle cells and inhibition o f platelet aggregation 
by increasing intracellular cGMP. Nitrate formulations have an important role both for 
prophylactic use (taken before exertion) and for angina occurring during exercise or at 
rest. Nitrovasodilators are known to act in heart failure (Duprez & Clement, 1992) 
either by arteriolar dilatation which reduces both peripheral vascular resistance and left 
ventricular pressure at systole resulting in improved cardiac output, or by venous 
dilatation reducing cardiac pre-load. Nitrate formulations have no place in treating 
peripheral ischaemia from atherosclerosis, they have no effect on symptoms and may in 
theory be harmful because flow may be diverted to dilated unaffected vessels from the 
affected vessels ("steal" blood phenomenon). Adverse effects include flushing, headache 
and postural hypotension.
Slow channel calcium blockers, such as nifedipine reduce the frequency and severity o f
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attacks, even in organic change such as Raynaud’s phenomenon associated with systemic 
sclerosis and vasospasm. Side-effects include headache, flushing, dizziness, lethargy; 
also gravitational oedema, rash, nausea, increased frequency of micturition, eye pain, 
gum hyperplasia; depression and telangiectasia (British National Formulary, 1994).
Alpha adrenoceptor blockers such as prazosin and doxazosin may produce unacceptable 
hypotension. Beta adrenoceptor blockers, such as atenolol, which are usually used in 
treating hypertension, should be avoided because of their vasoconstrictive action on 
peripheral vessels due to unrestricted release of the peripheral sympathetic system 
(Cooke, 1995).
Giving up smoking may be of benefit in ameliorating progression o f disease and is 
essential in conservative management. This may be due to beneficial changes in 
haemostatic and rheological factors rather than regression o f atherosclerosis (Fowkes,
1990). Stopping smoking in conjuction with exercise, appropriate weight reduction and 
lowering of blood cholesterol (by diet or lipid lowering drugs, such as gemfibrozil, in 
those with levels of 8  mmol cholesterol /  L or over) may stablise the disease, enhance 
general health and may so improve claudication distance that the patient may become 
asymptomatic. The main effect of exercise may be to dilate collateral vessels and 
increase blood flow by reducing viscosity (Housley, 1988).
1.5 Alternative approaches to drug therapy
For decades many drugs have been used for the treatment o f vascular disease, but daig 
therapy has not successfully decreased the mortality and morbidity o f peripheral vascular 
disease.
Autohemotherapy, treatment of blood ex vivo followed by its re-injection, with blood
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treated with medical ozone alone or in combination with heat and ultraviolet light has 
been practised in parts o f Western Europe for many years (Rilling & Viebahn, 1987). By 
1986, no less than 340,000 treatments had been performed without any untoward effects 
(Bocci, 1994). A number o f claims have been made for such treatments, particularly an 
improvement in peripheral vascular disorders (Riva, et al, 1990). Immunological effects 
have been suggested by claims of benefit in viral diseases (Bassi, et al, 1982) and in some 
malignant tumours (Hernuss, 1975).
Regretfully, this form of autohaemotherapy has been carried out in an empirical fashion 
without appropriate controls, particularly in the treatment of viral diseases. The 
underlying mechanisms resulting in the clinical improvement in patients are not 
understood. However, there appears to be sufficient subjective anecdotal evidence to 
warrant scientific investigation, which is the purpose of this research.
As an introduction to the application o f ozone in medicine, the immune system effects of 
ozone will be reviewed. Because ozone may be used in combination with heat and 
ultraviolet irradiation, the effects o f these two stimuli on the human immune system will 
also be discussed.
1.5.1 The use of ozone in medicine
During the First World War, the healing o f wounds and fistulae with ozone and oxygen 
gas mixtures was reported sporadically, and a medical use was suggested.
Ozone can be formed by the action of UV light on oxygen. Conversely, the ozone 
molecule is capable of absorbing UV to produce diatomic oxygen once more. Ozone is 
the triatomic allotrope of oxygen and one o f several forms o f the oxygen atom which 
exist in nature. It is an extremely potent oxidant, unstable in an aqueous environment.
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Research on the effects of inhaled ozone has been intense. Ozone is highly toxic to 
pulmonary tissue and causes irreversible morphological damage which leads to interstitial 
fibrotic changes with associated decrements in pulmonary function when inhaled as an 
environmental pollutant (Hatch, et al, 1990). It has a broad spectrum of antimicrobial 
activity, killing bacteria, fungi, and viruses (Rilling & Viebahn, 1987; Wells, et al, 1991; 
Carpendale & Freeberg, 1991).
The powerful disinfectant property o f ozone gas has been used in medicine, the gas being 
administered at the surface using a pneumatic cuff or similar device. Medical ozone, a 
mixture o f ozone and oxygen, has been used in the treatment of various diseases, 
including the disinfection of open wounds and ulcers. Relief of pain has been noted in 
addition to its fungicidal, virucidal and bactericidal action. The resulting acceleration of 
healing has been attributed to an improvment of the oxygen supply to hypoxemic tissue 
areas (Dolphin & Walker, 1979).
For systemic diseases, such as circulatory disorders and viral infections, some form of 
invasive route of administration is required. To minimise the potential harmful side 
effects o f injecting ozone gas directly, treatment o f blood ex vivo followed by its re­
injection (autohaemotherapy) has been a route widely adopted in ozone therapy. Minor 
autohaemotherapy in which 5-10 ml of blood is treated with about 100 pg o f ozone and 
major autohaemotherapy in which 50-100 ml of blood is treated with about 2000 pg o f 
ozone are approaches that have been used (Rilling & Viebahn, 1987; Garber, et al, 1991; 
Romero, et al, 1993 [l] [2]).
There are a number o f publications, claiming benefit for autohaemotherapy with 
ozonized blood .
In 1993, Romero and his colleagues observed 72 non-diabetic patients with
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atherosclerosis obliterans, Fontaine stage II (intermittent claudication), treated by 
intravenous (major autohemotherapy) and intramuscular (minor autohemotherapy) 
injections. They claimed that there was an improvement in the ozone treated group in 
comparison with a control group treated by conventional means, the claudication 
distance in the treadmill test increased to 2.5 Km / hour (Romero, et al, 1993 [l]). 
Turczynski, et al (1991 f I ] [ 2 ] )  reported that patients with diabetes mellitus and coexisting 
symptoms of obliterative atherosclerosis of the lower limbs treated with ozonized blood 
administrated by major autohemotherapy had a similar improvement. In another small 
group of 15 patients with atherosclerosis obliterans of the lower limbs treated with 
ozonized blood autohemotherapy, Romero and his colleagues stated that there was a 
statistically significant decrease in amputation ratio (26.7 %) and surgery for patients 
with rest pain (13.3 %) in comparison with the control group (46.7 and 26.7 % 
respectively) (Romero, et al, 1993 [2]). Sroczynski et. al., observed 50 patients with 
atherosclerotic ischemia o f the lower extremities and 49 diabetic patients treated with 
ozonized blood using major (intravenous) autohemotherapy. The treatment showed a 
significant improvement in both groups manifested by an increase in ankle-brachial index, 
and a doubling of the intermittent claudication walking distance (Sroczynski et al, 1992). 
Kawalski, et. al. (1992) reported that 25 patients were given major autohemotherapy 
with ozonized blood pre- and post-rhinoplasty, resulting in a significant reduction in 
post-operative complications as compared to the control group.
Gierek et al (1992) reported on 206 patients with ophthalmologic disorders, such as 
inflammatory corneal ulcerations, optic neuritis and retinal pigment dystrophy that were 
treated by major autohemotherapy with ozonized blood. These patients had an 
improvement of visual acuity and in visual fields. Riva and his colleagues (1990) 
observed 20 patients affected by age-related degenerative maculopathy. The results have 
indicated that the majority of patients showed an improvement of their ocular condition 
confirmed by visual acuity and eye fluoroangiography after major autohemotherapy with
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ozonized blood.
Autohemotherapy with ozonized blood also has been successful used in treatment of 
acute and chronic viral diseases, such as herpes (healing of skin lesions and keratitis) and 
hepatitis and neoplasms (Rilling & Viebahn, 1987; Bassi et al, 1982).
1.5.2 The effects of ozone on the immune system
The potential effects of treating whole blood with ozone include the production o f a 
number of powerful reactive oxygen species, the peroxidation of phospholipids with the 
consequent disaiption of cell membranes and modification of specific receptors on cell 
membranes, leading finally to lymphocyte mitogenesis with possible induction and release 
of lymphokines (Bocci & Paulesu, 1990). It is known that several types of oxidants, 
such as periodate, hydrogen peroxide and galactose oxidase, could also trigger the 
synthesis and release o f interferon and other cytokines from monocytes and lymphocytes.
Hydrogen peroxide and its biosynthetic precursor superoxide anion (O2 ) stimulate a 
strong increase in expression and synthesis of interleukin-2 by accessory cell-depleted T- 
cell populations (Roth & Droge, 1989). Munakata and his colleagues have demonstrated 
that both exogenous and endogenous hydrogen peroxide released from activated 
macrophages induce the production of interferon and enhance natural killer (NK) cells 
activity. Both exogenous and endogenous hydrogen peroxide may be regarded as 
inducing IFN7  (Munakata et al, 1985).
Dianzani et al have shown that human lymphocyte cultures produce large amounts o f 
interferon after treatment with the enzyme galactose oxidase (Dianzani et al, 1979). A 
novel monokine MBF (macrophage-derived blastogenic factor) is secreted from human 
macrophages stimulated with galactose oxidase. This monokine stimulates resting T
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lymphocytes to produce IFN7  and to proliferate (Antonelli et al, 1988),
The oxidation of cell surface stnictures by mild oxidation with sodium periodate also 
induces marked polyclonal proliferation of peripheral blood mononuclear cells (PBMC) 
and causes the production o f IFN7  (Antonelli et al, 1988).
The specific effects of treating blood in vitro with oxygen containing small 
concentrations o f ozone include the stimulation of production of EFN7  (Bocci & Paulesu,
1990) and tumour necrosis factor-alpha (TNF-a) from human leukocytes (Paulesu et al,
1991). Recently it has been reported that oxygen / ozone induces the production of 
other cytokines, such as IL-l|8 , IL-2, IL-6 , IFN/J and GM-CSF, by PBMCs (Bocci, et al, 
1994).
The oxidation of galactose residues on cell surface staictures is considered a general 
feature of lymphocyte activation whatever the inducer (Antonelli et al, 1988; Dianzani et 
al, 1979). Cells may respond to extracellular stimuli by the de novo synthesis of 
proteins. Experimental evidence suggests that NF (nuclear factor)-kB is an oxidative 
stress-responsive transcription factor o f higher eukaryotic cells (Schreck et al, 1992). 
NF-kB can activate a great variety of genes involved in early defence reactions of higher 
organisms. The agents which can target NF-kB activation include the cytokines 
interleukin-1 and tumor necrosis factor, viruses, double-stranded RNA, endotoxins, 
phorbol esters, ultraviolet and ionizing irradiation and reactive oxygen intermediates 
(ROI), such as low concentrations of H20 2 (Schreck et al, 1992).
NF-kB is a member of a novel family o f transcription factors and is a multiprotein 
complex with 50kD (p50) and 65kD (p65) components. In nonstimulated cells, NF-kB 
resides in the cytoplasm in an inactive complex with the inhibitor IkB. Stimulation by 
reactive oxygen intermediates cause release of IkB and allows NF-kB to enter the
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nucleus and bind to DNA control elements thereby inducing the synthesis o f mRNA 
(Figure 1-4). NF-kB may provide an important model system to explore a potential role 
of oxidative stress in intracellular signalling processes.
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Figure 1-4. The activation of NF-kB.
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1.5,3 The effects of ultraviolet radiation on the immune system
The UV region of the electromagnetic spectrum is divided into three classes: UVA (320 
- 400 nm), UVB (290 - 320 nm) and UVC (200 - 290 nm). The shortest wavelengths 
have the highest energy. UVC has been termed germicidal radiation, since it is effective 
in killing single-celled organisms.
UV irradiation has profound immunomodulatory effects. It has been reported that UV 
irradiation has marked effects on the production of cytokines from mouse lymphocytes: 
the secretion o f IL-3, IL-6 , tumour necrosis factor (TNF) and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) is induced by UV irradiation (Pamphilon, et al,
1991).
Mirando and colleagues have demonstrated that monocytes irradiated in vitro with 
ultraviolet light efficiently inhibited the intracellular replication of mycobacterium avium 
intracellulare (MAI). Ultraviolet radiation augmented monocyte antimicrobial activity 
for MAI in a dose-dependent fashion (Mirando, et al, 1992). The inhibition o f MAI 
growth was thought to be mediated via a modulation of cell-mediated immunological 
function by UV exposure. UV radiation triggers the synthesis of TNF-alpha from 
monocytes.
However, comparing the absorption spectra o f biological molecules with the action 
spectra of ultraviolet radiation-induced events suggests that deoxyribonucleic acid 
(DNA) may be the target for UV light (McKenzie & Sauder, 1994). Suzuki and 
Watanabe (1992) have reported that there is an augmented gene expression o f HSP (heat 
shock protein) 72 in normal human cells after irradiation by ultraviolet light.
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The heat shock response is one o f the most universal reactions known and heat shock 
proteins (HSPs) are among the most conserved molecules in phylogeny. HSPs are 
produced when a prokaryotic or eukaryotic cell is confronted with a sudden increase in 
temperature (Kaufmann, 1990). When it was found that many insults other than heat can 
also induce HSP synthesis the term 'stress proteins' was introduced. In vitro after a short 
exposure (usually 2 0  minutes) to 41 °C - 43 °C, human alveolar macrophages are induced 
to synthesize 70 and 83 kDa HSPs, but inhibition of the synthesis is apparent after 
exposure to 37°C or 45 °C (Polla, 1988).
ft has become increasingly clear that HSPs can modify the function and destiny o f other 
proteins and thus play an important role in numerous physiological processes.
HSPs are grouped into families of different molecular sizes. Members o f a given family 
share several features in addition to size. In mammalian cells, HSP60 catalyses the 
folding of mitochondrial proteins. HSPs may accelerate the removal o f denatured 
proteins inside a cell. These features have sometimes been called 'house-keeping 
functions' o f HSPs. One of the best-studied examples of this is found in immunology: 
the heavy chain binding protein, Bip, which participates in the assembly of 
immunoglobulins belongs to the HSP70 family. Bip binds to the immunoglobulin heavy 
chain within the endoplasmic reticulum until association with the immunoglobulin light 
chain occurs, and thus prevents premature self assembly o f heavy chains. In the absence 
o f light chains, Bip remains permanently bound to the heavy chain, retaining it within the 
lumen of the endoplasmic reticulum. HSPs are involved in immunity and the immune 
system has adopted certain HSPs for its own particular purposes. Some HSP genes are 
localised within the major histocompatibility complex (MHC). Genes encoding HSP70 
have been mapped in the human MHC between the loci for complement components and
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tumour necrosis factor.
Stress can be induced by different stimuli including heat, ultraviolet irradiation, viral 
infection and oxygen metabolites, such as H20 2 (Polla, 1988; Kaufmann, 1990; Suznki & 
Watanabe, 1992).
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1.6 Conclusion
Peripheral vascular disease is responsible for considerable mortality and morbidity in 
heart attack and stroke, and is the principal cause o f gangrene and loss o f function of the 
extremities. Currently no successful treatment has been achieved for peripheral vascular 
diseases. The atherosclerosis process is the principal contributor to the pathogenesis of 
peripheral vascular disease. The process, in normal circumstances a protective response 
to insults to the endothelium and smooth muscle cells of the wall o f the artery, consists 
o f the formation of fibrofatty and fibrous lesions, preceded and accompanied by 
inflammation. With the progression of the process the artery concerned becomes narrow 
or occluded and this results in impairment of the blood supply. Many different cell types 
and a large number o f growth factors, cytokines, regulators of platelet aggregation and 
vasoregulatory molecules participate in this process. Adjusting the expression o f genes 
encoding these molecules and the targeting of specific cell types provides opportunities 
to develop new therapeutic agents to induce the regression of the lesions and, possibly, 
to prevent their formation. The elucidation of the roles of different cell types and the 
various molecules that are involved in atherogenesis provide an opportunity to 
investigate the mechanisms of HOU-autohaemotherapy.
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1.7 Aims of study
To determine the in vitro and in vivo biological changes occurring as a result o f the 
treatment of blood with heat, ozone / oxygen and ultraviolet light (HOU), and to provide 
a scientific explanation for the many claims made for autohaemotherapy in a number of 
human disorders and pathologies.
(1) To investigate the effect o f treatment of blood with HOU on blood platelet 
activity in vitro in order to gain an understanding of how such autohaemotherapy 
might resolve peripheral vascular disease.
(2) To investigate the effect o f treatment of blood with HOU on immune cells in 
peripheral blood in vivo in order to gain an understanding of how such 
autohaemotherapy might be beneficial in the treatment of viral diseases, 
immunodeficiencies and tumours.
(3) To investigate changes in levels of immune and haematological mediators in 
blood following treatment, in order to gain an understanding o f how 
autohaemotherapy might result in effects manifested throughout the body.
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The Effects of in vitro Treatment of Blood with 
Heat, Ozone/Oxygen and UV Irradiation on Biood Platelets
2.1 In troduction
In spite of the fact that autohaemotherapy with ozone- or HOU-treated blood has 
already been carried out with beneficial results in peripheral vascular diseases, the 
mechanism of action remains speculative and uncertain. There is increasing evidence 
that thrombosis is important in the development and progression of peripheral vascular 
disease (PVD) (Ross, 1993; Lowe, et al, 1994) and that platelets are one of the 
important constituents of thrombosis. The effect of treatment with HOU of blood from 
healthy volunteers and patients with PVD and diabetes in vitro on platelets and the 
mechanisms of the action were investigated in order to gain an understanding of how 
such autohaemotherapy might resolve peripheral vascular disease. In vitio data on the 
effect of this treatment on platelet function are currently lacking.
2.2 M ate ria ls  and  m ethods
The reagents and equipment used are listed in Appendix 4-3.
I  In vitro study in healthy volunteers
2.2.1 Blood sample collection
Venous blood (20 ml), taken from the healthy non-smoking volunteers, aged between 
20-50 years, was collected into tubes containing 3 .8  % sodium citrate anticoagulant in a 
ratio o f blood to anticoagulant of 9:1. None of the volunteers had taken any medication
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for at least 1 week prior to the investigation. The blood was divided into two 10 ml 
aliquots. One aliquot was treated with heat, ozone /  oxygen and ultraviolet (HOU) (see 
below), the other was used as an untreated control sample.
2.2.2 Treatment of blood samples
Blood was treated with different concentrations o f ozone using the Ozon-O-Med 
equipment (Appendix 2-1). In this system, blood is raised to and maintained at a 
temperature o f 42.5°C and is exposed to ultraviolet light at a wavelength o f 253.7 nm 
(Muller & Jentiens, 1990). Ozone in medical oxygen is bubbled through the blood at a 
oxygen flow rate o f about 0.12 L /  min for 3 mins. The concentration o f ozone is 
variable between 5 and 50 jug /  ml and is measured using an ozone monitor.
2.2.3 Reagents for the study of platelet aggregation
The reagents for the study o f platelet aggregation included ADP, collagen, thrombin, 
calcium ionophone A23187 and adrenaline. For the preparation o f these reagents see 
Appendix 4-3-3.
2.2.4 Platelet aggregation in HOU-treated whole blood
In order to investigate whether the HOU-treatment whole blood had an effect on 
platelet aggregation, platelet aggregation in HOU-treated whole blood was studied.
Platelet aggregation was measured by an end point turbidometric method (Bom, 1962).
To prepare platelet-rich-plasma (PRP), 10 ml aliquots o f blood sample (either HOU- 
treated or untreated control blood) was centrifuged at 200 xg for 15 mins at room
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temperature (18-25°C). The PRP was carefully removed using a plastic transfer 
pipette.
PRP (0.225 ml) was placed in an aggregometer cuvette and equilibrated to 37°C in the 
heating block o f the instrument. The speed o f the stirrer bar was 1,100 rpm. After 
stirring was commenced, 0.025 ml o f platelet aggregation agent was added at the final 
concentrations indicated in the results section. Light transmission through the plasma 
was monitored continuously on a chart recorder. The addition o f an aggregating agent 
results in the formation of increasingly larger platelet aggregates with a corresponding 
decrease in optical density. The change in optical density was recorded on the chart 
recorder. Each aggregation curve was observed for up to 3 minutes. Platelet 
aggregation in the HOU-treated samples was expressed as the percentage o f the 
aggregation in an untreated control samples for each individual experimental condition.
2.2.5 Washed platelet aggregation studies
In order to investigate whether HOU-treatment o f whole blood has a direct or an 
indirect effect on platelets via production o f the factors affecting platelet aggregation in 
whole blood, aggregation o f washed platelets was studied.
Blood (20 ml) was collected from each o f 5 normal healthy individuals. One 10 ml 
aliquot was treated with heat, ozone/oxygen and UV as described above, the other 10 
ml aliquot was used as an untreated control. PRP was prepared from both these 
samples. Platelets and PPP were prepared from the PRP by centrifugation at room 
temperature for 10 minutes at 1500 xg. The platelet poor plasma (PPP) was removed 
from the sedimented platelets using a plastic transfer pipette. The platelets were washed 
4 times in PBS by centrifuging for 10 mins at 1500 xg at room temperature and 
resuspended in PBS. Half o f the washed HOU-treated platelet (PLT[t]) suspension was
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added to an equal volume o f the HOU-treated PPP (PPP[t]) and tested directly for 
platelet aggregation as above. Half o f the washed untreated platelet (PLT[c]) 
suspension was added to an equal volume o f the untreated PPP (PPP[c]) and tested 
directly for platelet aggregation. The second aliquot o f washed HOU-treated platelets 
(PLT[t]) was added to untreated PPP (PPP[c]) and tested for platelet aggregation. The 
second aliquot o f the washed untreated platelets (PLT[cj) was added to HOU-treated 
PPP (PPP[t]) and tested for platelet aggregation.
2.2.6 Platelet aggregation in HOU-treated plasma
In order to investigate whether the inhibition o f platelet aggregation resulted from 
products o f HOU-treated blood cells, the effect o f HOU-treated plasma on the 
aggregation o f untreated platelets was investigated.
Blood (40 ml) was collected from each o f 4 individuals and divided into 2 x 10 ml and 
1 x 20 ml aliquots.
One 10 ml aliquot acted as the control and the other 10 ml aliquot was treated with 
HOU (ozone concentration 15 f ig  /  ml). They were tested for platelet aggregation as 
above.
The 20 ml aliqout was taken to prepare PRP by centrifugation at 200 xg for 15 mins at 
room temperature (18°C-25°C). The PRP was divided into two equal aliquots. These 
two aliquots o f PRP were centrifuged to separate PPP and platelets. One PPP aliquot 
was treated with HOU (ozone concentration 15 fig I ml) and the other acted as the 
untreated control. One platelet aliquot was re-introduced to the PPP aliquot treated 
with HOU. The other platelet aliquot was added to untreated PPP as a control. They
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were tested for platelet aggregation and the aggregation o f the platelets in untreated 
control PPP was used as a control
2.2.7 EDRF inhibitor - oxyhaemoglobin
The high affinity o f nitric oxide for the Fe2+ moiety o f oxyhaemoglobin was utilised to 
demonstrate whether the effect o f the HOU-treatment o f blood on platelet aggregation 
could be attributed to the released nitric oxide.
Oxyhaemoglobin reacts with NO to form a tightly bound complex:
NO + Hb40 8 ---------------- 3rHb4[ Fe2* ] 0 8
I
NO
Bovine haemoglobin (BHb) was dissolved in phosphate-buffered saline (PBS) to give a 
ImM /  L solution. As BHb contains both oxyhaemoglobin and a contaminating 
oxidized derivative methaemoglobin (metHb), the following purification procedure was 
employed. BHb was added to an 10M / L excess o f the reducing agent sodium 
dithionite (N a ^ O ^ . This was then purified by dialysis in a short length o f Visking 
tubing immersed in distilled water for 2 hours at 4°C with stirring and the final product 
was stored at -20°C in 100 gl aliquots (Martin, et al, 1985).
Oxy-Hb 0.025 ml o f a 10 pm /  L solution was added to 0.225 ml PRP prior to the 
addition o f platelet aggregatory agents. Platelet aggregation in the presence o f this 
inhibitor o f NO activity was compared with that in its absence.
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2.2.8 Blood platelet and RBC counts and H b measurement
Blood platelet counts were performed on whole blood (untreated control blood and 
HOU-treated blood), using a Coulter counter loaned by the Department of 
Haematology, Northern General Hospital, Sheffield, UK.
2.2.9 N itrite and n itrate  measurements
NO is unstable and decomposes rapidly in biological solutions to form mixtures of the 
stable derivatives, nitrite (N 02) and nitrate (N 03). Tolins and Shultz (1994) have 
demonstrated that serum and urine levels o f N 0 2 and N 0 3 can be utilised as markers o f 
endogenous NO activity.
PPP was prepared from either control or HOU-treated blood immediately after 
treatment by centrifugation at 1,500 xg and 4 °C for 15 minutes and stored at -20 T o r  
below and the analysis was carried out as soon as possible.
The principle o f the measurement o f nitrite and nitrate is based on that fact the nitrate in 
a sample is reduced by a cadmium catalyst to nitrite, which reacts with the Griess 
reagent to form a purple azo dye. For the details o f the preparation o f the reagents and 
procedure see Appendix 2-3.
2.2.10 6-keto prostaglandin-Fl-alpha measurements
2.2.10.1 Specimen collection and storage
Venous blood was collected from healthy volunteers and treated using the Ozon-O-Med 
device as above. Indomethacin was added to the blood immediately a f t e r  t r e a t m e n t  t o
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inhibit the subsequent metabolism o f arachidonic acid to prostaglandins. PPP was 
prepared in the same way as for analysing NO and the plasma sample stored at -70 °C 
until assay.
2.2.10.2 Extraction of 6-keto-prostaglandin Fla
Solid phase extraction procedures result in a high recovery and clean plasma extract. In 
this experiment, Amprep C2, 100 mg minicolumn were employed. For the method of 
extraction o f 6-keto-prostaglandin F la see Appendix 2-4.
2.2.10.3 Radioimmunoassay
The concentration o f 6-keto prostaglandin-Fl-alpha in the extraxted sample was 
measured using a commercially available radioimmunoassasy kit. The 6-keto- 
prostaglandin-Fl-alpha is the stable metabolite of prostacyclin and is a measure of 
prostacyclin concentration (Siess & Dray, 1982). For the assay principle and procedure 
see Appendix 2-5 and Appendix 2-6.
2.2.11 Platelet-derived growth factor (PDGF) measurement
20 ml venous blood from two healthy non-smoking volunteers was collected into 
EDTA. The blood was divided into two 10 ml aliquots. One aliquot was treated with 
HOU, the other was used as an untreated control. PRP was prepared from the control 
or treated blood, then 100 p\ PBS, ADP (0.01 mM / L), collagen (0.1 mg / ml) or 
epirephrine (0.01 mM / L) were added to 900 p\ o f control PRP or treated PRP. After 
incubation for 1 hour to maximise the release o f PDGF, the PRP containing PBS or 
platelet agonist were centrifuged at room temperature for 10 minutes at 1500 xg, the
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PPP was removed from the sedimented platelets and the plasma stored at -70°C prior to 
analysis.
20 ml venous blood from six healthy non-smoking volunteers was collected into 
EDTA. The blood was divided into two 10 ml aliquots. One aliquot was treated with 
HOU, the other was used as an untreated control. PPP was prepared from control and 
treated blood by centrifugation at room temperature for 10 minutes at 1500 xg and 
stored at -70 °C prior to analysis.
The concentration o f PDGF in plasma was measured using a commercially available 
radioimmunoassasy kit (Amersham International UK). The principle and procedure o f 
the assay are similar to those o f the commercial 6-keto-prostaglandin-Fl-alpha assay. 
PDGF can be measured in the range 1.56 to 200 fmol / tube ( 46.8 - 6000 pg /  tube ).
II In vitro study in patients with PVD and diabetes
2.2.1 Patients
Fourteen patients with vascular disease only, 11 male, 3 female, aged between 50-60 
years and 8 patients with diabetes, 5 male, 3 female, aged between 45-60 years were 
recruited for the study. These latter were a heterogeneous group and included patients 
with diabetes complicated by vascular disease and leg ulcer. All patients were from the 
in-patient and out-patient department o f vascular disease at the Royal United Hospital, 
Bath.
The diagnosis o f peripheral vascular disease was based on a typical history and clinical 
examination confirmed by angiography. All had limb pain at rest, limb oedema, change 
o f skin pigmentation, desquamation, eczema and cyanosis; and some o f them had skin
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ulcers. The diagnosis of diabetes was also based on typical history and clinical 
examination confirmed by an increase in a level o f glucose in blood and urine. Some o f 
the diabetic patients were taking insulin or oral hypoglycaemic agents.
2.2.2 Treatment of blood samples
Blood (20 ml) was collected from each patient into tubes containing 3.8 % sodium 
citrate anticoagulant in a ratio o f blood to anticoagulant o f 9:1 and the 10 ml o f the 
anticoagulated blood was placed into the reaction container o f the Ozon-O-Med 
machine (Appendix 2-1). Blood was treated as described above, using an ozone 
concentration o f 15 pg /  ml in combination with a temperature o f 42.5 °C and UV 
irradiation. The other 10 ml blood was used as an untreated control sample.
PRP and PPP from either the HOU-treated or control untreated sample were prepared 
for studying platelet aggregation and the measurement o f 6-keto prostaglandin ¥loi as
described above.
2.2.3 Platelet aggregation in HOU-treated whole blood
Platelet aggregation was studied using the agonists ADP, thrombin and calcium 
ionophore A23187 in platelet rich plasma (PRP). Platelet aggregation in the treated 
samples was expressed as percentage o f the aggregation in the control samples for each 
individual experimental condition.
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2.2.4 6-keto-prostaglandin Fla measurements
The method o f extraction o f 6-keto-prostaglandin F la are detailed in Appendix 2-4.
The concentration o f 6-keto-prostaglandin Fla in plasma was measured using a 
commercially available ELISA kit. For the priciple o f the assay see Appendix 4-4.
m . Statistical analysis
Statistical comparisons were made using the Student's t test for paired samples, 
comparing treated sample with their corresponding controls. P  < 0.05 (two tailed) was 
taken as significant. All values are expressed as the mean ± sd.
2.3. Results
I In vitro study on blood from healthy volunteers
2.3.1 Blood platelet, RBC counts and Hb measurement
Following treatment o f 10 ml whole blood with 5-50 /zg/ml o f ozone in oxygen at an 
oxygen flow rate of 0.12 L / min for 3 mins at 42.5 °C (total mass o f ozone reacted 1.8 -
18.0 mg) and exposure to heat and UV light, there was an apparent overall increase in 
the platelet count to 186.5% ± 107.9% (range 65.5 - 461.5%, P  < 0.01) o f the control 
value in the 15 individuals investigated. This suggests that, under the conditions used in 
these experiments, the treatment o f whole blood with heat, ozone / oxygen and 
ultraviolet irradiation does not destroy the blood platelets. A possible cause o f this 
increase in platelet counts may be disaggregation o f small platelet clumps present in the 
circulation by a de-aggregatory stimulus resulting from the blood treatment or from a 
blood sampling artifact.
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Following treatment o f 10 ml whole blood with 5-50 pgJvoX o f ozone in oxygen at an 
oxygen flow rate o f 0.12 L / min for 3 mins at 42.5 °C (total mass o f ozone reacted 1.8 -
18.0 mg) and exposure to heat and UV light, there was no decrease in the RBC count 
(control 4.12 ± 0.81 x 1012/L , treated blood 4.35 ± 0.54 x 1012 /L , n =  16 ) and no 
significant increase in the Hb (control 12.6 ± 2.07 g / dL, treated blood 13.2 ± 1.47 g / 
dL, n = 16). This suggests that, under the conditions used in these experiments, the 
treatment o f whole blood does not cause a significant haemolysis compared with the 
control blood samples, indicating that the treatment regime had an insignificant effect on 
erythrocyte integrity.
2.3.2 Platelet aggregation in the plasma from HOU-treated whole blood
Platelets from blood treated with 5-50 pg /  ml ozone as above showed a reduction in 
their ability to aggregate in response to ADP (0.001-0.05 mmol / L final concentrations, 
Figure 2-1). The overall inhibition o f aggregation was 47.5% =fc 28.6% (n=14, P <
0.001). The inhibition was variable between individuals, ranging from 2.6 - 91%. There 
was no significant difference between the inhibitory effects on blood taken from males 
and females (inhibition o f aggregation in males 40.8% ± 27.7%, n = 8, inhibition o f 
aggregation in females 56.3% ± 29.8%, n = 6).
This inhibitory effect o f HOU-treatment was dependent on the concentration o f ADP 
between 0.001 mmol /  L and 0.05 mmol / L, showing a higher level o f inhibition o f 
platelet aggregation at lower concentrations o f ADP (Table 2-1). The inhibitory effect 
at final concentration 0.001 mmol / L ADP was significantly (P < 0.05) greater than at 
final concentration 0.05 mmol /  L o f this agonist (Table 2-1). However, this 
relationship was not observed at higher ADP concentrations.
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Table 2-1. The inhibition of platelet aggregation in response to ADP by treatment of 
blood in vitro with HOU-treatment (ozone concentration 5-50 pg /  ml).
ADP final 
concentration 
(mmol / L)
Inhibition o f 
aggregation 
Mean (%)
Inhibition o f 
aggregation 
Sd ( % )
Number o f 
observations p*
0.001 65.3 23.4 8 0.001
0.005 53.3 29.4 5 0.02
0.01 42.7 31.9 10 0.01
0.05 32.0** 29.1 8 0.02
* - compared to the untreated control sample.
** - significantly different from 0.001 mmol/L ADP, P < 0.05.
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Figure 2-1. Platelet aggregation induced by different concentrations o f ADP in 
untreated control and HOU-treated blood obtained from vU normal, 
healthy volunteer. The inhibition of the platelet aggregation in the 
blood treated with HOU is dependent on the concentration o f ADP, 
greater inhibition was displayed at lower ADP concentrations 
(concentration o f ozone in oxygen: 25 pg / mL).
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Whole blood treated with 5 - 35 pg /  ml ozone in the presence o f heat and UV also 
showed a high level o f inhibition o f platelet aggregation using collagen as the platelet 
agonist (Table 2-2).
Whole blood treated with 5 - 40 pg /  ml ozone, heat and UV showed a higher level o f 
inhibition o f aggregation (up to 94.2% ± 5.3%, P < 0.001, n = 5) using the calcium 
ionophore A23187 as platelet agonist (Table 2-3).
With thrombin as the inducer o f platelet aggregation, platelets from whole blood treated 
with 5 - 40 fig /  ml ozone, heat and UV also showed an inhibition o f aggregation (Table 
2-4).
A reduction in the concentration o f ozone in the oxygen bubbled through the blood 
sample resulted in a reduction in the effect o f treatment on the inhibition o f platelet 
aggregation in two o f the four individuals investigated. This difference was significant 
in the responses o f the same individual to the treatment, although the overall mean 
values o f the four individuals investigated were not significantly different (Table 2-5) 
(Figure 2-2).
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Table 2-2. The inhibition o f platelet aggregation in response to collagen 
by HOU-treatment (ozone 5 - 35 pg /  ml).
Collagen final 
concentration 
(mg / mL)
Inhibition o f 
aggregation 
Mean (%)
Inhibition of 
aggregation 
Sd ( % )
Number of 
observations p*
0.02 79.2 24.9 4 0.01
0.1 66.7 37.5 5 0.02
1.0 73.4 16.3 4 0.01
* - compared to the untreated control sample.
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Table 2-3. The inhibition o f platelet aggregation in response to calcium 
ionophore A23187 by HOU-treatment (ozone 5 - 40 jug / ml).
Calcium ionophore 
A23187 final 
concentration (pg/mL)
Inhibition o f 
aggregation 
Mean (%)
Inhibition o f 
aggregation 
Sd ( % )
Number of 
observations p*
0.5 60.7 35.8 5 0.02
1.0 43.1 47.8 6 NS
5.0 94.2 5.3 5 0.001
10.0 62.6 36.9 5 0.02
* - compared to the untreated control sample. 
NS - no significant difference.
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Table 2-4. Inhibition o f platelet aggregation in response to thrombin 
by HOU-treatment (ozone 5 - 40 pg /  ml).
Thrombin final 
concentration 
(u / mL)
Inhibition of 
aggregation 
Mean (%)
Inhibition o f 
aggregation 
Sd ( % )
Number o f 
Observations p*
0.1 52.7 37.1 5 0.05
0.5 68.2 17.7 6 0.001
* - compared to the untreated control sample.
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Table 2-5. The comparison o f the inhibition o f platelet aggregation by ADP in blood 
HOU-treatment in different concentrations o f ozone.
SUBJECT 5 pg i ml ozone 25 pg / ml ozone 50 pg / ml ozone
Male 1 15.5 53.9 65.6*
Male 2 8.7 11.2 24.7 **
Female 1 87.3 91.6 93.9
Female 2 42.3 69.2 39.4
Mean (n=4) 38.5 56.6 55.9
Sd 35.7 33.9 30.5
* - significant different from ozone 5 ug / ml at P  < 0.01
** - significant different from ozone 5 ug / ml at P < 0.02
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Figure 2-2. Platelet aggregation after blood treated with different ozone 
concentration 5, 25, 50 jig / ml in the present of heat and UV.
< 5 1  >
Chapter 2 The Effects o f  in vitro Treatment o f  Blood with HOU on Blood Platelets
2.3.3 The aggregation of washed platelets in the plasma 
from HOU-treated whole blood
The washed untreated control platelets (PLT[c]) were added to the washed HOU- 
treated PPP (PPP[t]) (ozone 15 pg/ml) and the untreated control PPP (PPP[c]) 
respectively. There was a reduction of PLT[c] aggregation ability in the PPP[t] 
compared to in the PPP[c] using ADP, thrombin and calcium ionophore A23187 as the 
platelet agonists (for the concentrations o f these three platelet agonist see Appendix 2- 
6). The height of the aggregation curve of PLT [c] in PPP [c] was 43.3 mm ± 6.2 mm, 
and the height o f the aggregation curve o f PLT [c] in PPP [t] was 23.7 mm ±13.8  mm,
P < 0.02, n = 5 (Figure 2-3 A, B). For the platelet aggregation of the 5 individuals see 
Appendix 2-6.
The washed HOU-treated platelets (PLT[t]) (ozone 15 pg/ml) were added to the 
PPP[c] and the PPP[t] respectively. The aggregation ability o f the PLT[t] showed a 
reduction in the PPP[t] compared to in the PPP[c] using ADP, thrombin and calcium 
ionophore A23187 as the platelet agonists (for the concentrations o f these three platelet 
agonist see Appendix 2-6). The height o f the aggregation curve o f PLT [t] in PPP [c] 
was 40.2 mm ±11.7  mm, and the height o f the aggregation curve o f PLT [t] in PPP [t] 
was 27.6 mm ± 12.3 mm, P < 0.05, n = 5 (Figure 2-3 C, D). For the platelet 
aggregation o f 5 individuls see Appendix 2-6. There were no significant difference 
either between A and C or between B and D.
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PLT[c] in PPP[c] PLT[c] in PPP[t] PLT[t] in PPP[c] PLT [t] in PPP[t]
PLT[c] - washed untreated control platelets 
PLT[t] - washed HOU-treated platelets 
PPP[c] - untreated control plasma 
PPP[t] -HOU-treated plasma.
Figure 2-3. Comparation of aggregation of washed platelet from control and HOU- 
treated blood induced by the platelet agonists.
P < 0.02, when A compared with B.
P < 0.05, when C compared with D.
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2.3.4 Platelet aggregation in HOU-treated plasma
Table 2-6 shows the comparison between HOU-treatment o f whole blood and HOU- 
treatment o f plasma in the inhibition o f platelet aggregation. All four individuals 
demonstrated significant inhibitions o f platelet aggregation in HOU-treated whole 
blood, P < 0.05, 0.01, 0.05 and 0.02 respectably. Treatment o f plasma with HOU, by 
contrast, did not result in the significant inhibition o f platelet aggregation.
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2.3.5 The effect of oxyhaemoglobin on inhibition of platelet aggregation
Oxyhaemoglobin was added after the blood was HOU-treated and before aggregation 
was investigated. The inhibitory effect of platelet aggregation by HOU-treatment 
decreased when the oxyhaemoglobin was added to PRP from HOU-treated blood 
compared to the equivalent volume o f phosphate-buffered saline (0.025 ml) to the PRP 
(Figure 2-4). The inhibition o f platelet aggregation in response to ADP without oxy-Hb 
was 63.1% ± 36.9%, and 34.5% ± 38.7% with oxy-Hb, P  <0.05, n = 4. The inhibition 
o f platelet aggregation in response to thrombin without oxy-Hb was 64.5% ± 32.9%, 
and 41.4% ± 39.1% with Oxy-Hb, P < 0.05, n = 6 (Figure 2-5).
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Figure 2-4. platelet aggregation after blood treated with HOU in the present and 
absent of oxyhaemoglobin.
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Figure 2-5. The reversal by oxyhaemoglobin of the inhibition of platelet
aggregation following treatment of blood with oxygen / ozone, heat 
and UV irradiation.
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2.3.6 Nitrite and nitrate measurement
Ozone, heat and UV treatment of whole blood resulted in an increase in the 
concentration o f nitrite plus nitrate (69.6 pM ± 36.9 pM) compared to the 
corresponding untreated control sample (51.15 pM ± 27.1 pM), P < 0.05, n = 10 
(Figure 2-6). When plasma was treated with Ozon-O-Med rather than the blood 
containing the cellular components, no increase in nitrite could be detected, suggesting 
that the increase in nitrite is derived from blood cells.
2.3.7 6-keto-PGFia measurement
The concentration o f 6-keto prostaglandin-Fia was 47.4 pg / ml ± 15.6 pg /  ml in the 
post-treatment samples and 24.5 pg /  ml ± 9.30 pg /  ml in the pre-treatment samples (n 
= 12). This difference was significant at P < 0.001 (Figure 2-7).
The concentration o f 6-keto-PGFla following treatment o f blood with UV light only 
was not significantly different from the pre-treatment sample (14.30 pg / ml ±  3.9 pg / 
ml with UV, control 12.9 ± 1.6, n = 4)
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Figure 2-6. The changes of the concentration of nitrate plus nitrite in plasma.
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Figure 2-7. The changes of the concentration of 6-keto prostaglandin-Fla in 
plasma following treatment of whole blood with HOU.
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2.3.8 Platelet-derived growth factor (PDGF)
Table 2-7 shows the concentrations o f PDGF in plasma after PRP from untreated 
control and HOU-treated whole blood was exposed to platelet aggregating agents. In 
this experiment, the amount o f PDGF released by platelets from treated whole blood did 
not show any significant difference compared with the control sample.
Table 2-8 showed concentrations o f PDGF in plasma from control untreated and treated 
whole blood. The levels o f PDGF in the treated whole blood did not show any 
significant difference compared with the control sample.
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Table 2-8. Comparison o f the concentrations o f PDGF in control and
HOU-treated blood samples (ozone 50 pg/ ml) (fmol / tube).
Subject No Control Treatment
1 14.30 9.27
2 11.20 34.63
3 15.86 49.53
4 15.57 48.63
5 6.1 7.30
6 10.3 6.40
Mean 
(n = 6)
12.22 25.96
Sd 3.77 20.75
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II In vitro study in patients with PVD and diabetes
2.3.1 Platelet aggregation
After 10 ml o f whole blood was treated with 15 pg /  ml ozone in the presence of heat 
and UV irradiation, either in the patients with vascular disease or in the patients with 
diabetes, platelets showed a reduction in their ability to aggregate in response to ADP, 
thrombin and calcium ionophore A 23187 (Table 2-9 and Table 2-10).
In blood collected from the patients with vascular disease, after treatment with HOU in 
vitro, there was a significant inhibition of platelet aggregation in response to calcium 
ionophore A 23187 at final concentrations o f 10 p g  /  mL and 5.0 p g  /  mL, 77.3 % ± 
32.4 % (n = 12, P < 0.001) and 56.0 % ± 39.4 % (n = 12, P < 0.001) respectively, 
when compared to the control samples. With thrombin at final concentrations o f 1 u / 
mL and 0.5 u /  mL as platelet agonist, the inhibition o f aggregation was 79.3 % ± 27.0 
% (n = 10, P < 0.001) and 83.8 % ± 18.1 % (n = 8, P < 0.001) respectively when 
compared to the control samples. With final a concentration o f 10 pM  /  L ADP as the 
inducer o f platelet aggregation, the inhibition o f aggregation showed a higher level 94.0 
% ± 9.4 % (n = 6, P < 0.001) when compared to the control samples (Table 2-9).
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Table 2-9. Inhibition o f platelet aggregation in vitro in the vascular disease patients
group after ex vivo treatment of blood using HOU.
Platelet agonist and 
final concentration
Calcium-ionophore-A 23187 
lOjttg/ml 5 pg /ml
Thrombin 
1 u / ml 0.5 u / ml
ADP
10mM /L
Mean o f inhibition of 
platelet aggregation (%)
77.3 56.0 79.3 83.8 94.0
Sd (%) 32.4 39.4 27.0 18.1 9.4
n 12 12 10 8 6
p* < 0.001 < 0.001 <0.001 < 0.001 < 0.001
* - comparing with the corresponding untreated control sample.
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In blood collected from the diabetic patients, after blood was treated with HOU in vitro. 
there was a significant inhibition o f platelet aggregation in response to calcium 
ionophore A 23187 at final concentrations o f 10 pg /ml and 5.0 pg /  ml, 55.9 % ± 30.9 
% (n = 8, P  < 0.002) and 68.8 % ± 35.6 % (n = 7, P < 0.01) respectively, when 
compared to the control samples. With thrombin at final concentrations o f 1 u /  mL and 
0.1 u / mL as agonist, the inhibition o f aggregation was 50.8 % ± 33.2 % (n = 8, P < 
0.01) and 47.9 % ± 37.3 % (n = 8, P  < 0.01) respectively, when compared to the 
control samples. With final a concentration o f 10 pM  /  L ADP as the inducer o f platelet 
aggregation, the inhibition o f aggregation was 43.6 % ± 30.4 % (n = 6, P < 0.02) when 
compared to the control samples (Table 2-10).
Neither in the patients with vascular disease nor the diabetic patients, were there 
significant differences in the inhibition o f platelet aggregation between the two different 
final concentrations (10 pg /  mL and 5 pg I mL) of calcium-ionophore-A 23187 
investigated. Likewise, there were also no significant differences in the inhibition o f 
platelet aggregation at the two different final concentrations 1 u /  mL and 0.5 u /  mL of 
thrombin used.
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Table 2-10. Inhibition o f platelet aggregation in vitro in the group o f diabetic patients 
after ex vivo treatment of blood using HOU.
Platelet agonist and final 
concentration
Calcium-ionophore-A 23187 
10 /xg /ml 5 p g  /ml
Thrombin 
1 u  0.5 u
ADP 
10 p M  /  L
Mean o f inhibition of 
platelet aggregation (%)
55.9 68.8 50.8 47.9 43.6
Sd (%) 30.9 35.6 33.2 37.3 30.4
n 8 7 8 8 6
p* < 0.002 <0.01 <0.01 <0.01 <0.02
* - comparing with untreated control sample.
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2.3.2 6-keto-prostagIandin F la
Table 2-11 shows that 6-keto-prostaglandin F la levels in the plasma o f 14 patients with 
vascular disease, measured by an enzyme-linked immunosorbent assay, were 42.76 ±
24.6 pg /mL in control untreated samples and 119.82 ± 99.46 pg /  ml after HOU- 
treatment. This increase was significant (P < 0.02).
Table 2-12 shows that in the eight diabetic patients, the concentration o f 6-keto- 
prostaglandin F la in the plasma was 27.75 ± 9,99 pg /mL in the control untreated 
samples and 53 ± 18.38 pg /  mL after treatment samples . This increase was significant 
(P < 0.05).
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Table 2-11. The concentration o f 6-keto-PGFla (pg / ml) in blood plasma from 
patients with vascular disease before and after the ex vivo treatment o f whole blood 
using HOU.
Patients Control sample Treated sample
1 39.36 233.0
2 48.3 361.3
3 22.56 266.6
4 108.3 137.6
5 11.7 34.5
6 23 57
7 30 94
8 29 120
9 52 31
10 56 70
11 44 43.5
12 19.5 41
13 67 96
14 48 92
Mean 42.76 119.82*
Sd 24.6 99.46
* P  < 0.02 compared to the control
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Table 2-12. The concentration o f 6-keto-PGFla (pg /  ml) in blood plasma from
patients with diabetes before and after the ex vivo treatment of whole 
blood using HOU.
Patients Control sample Treated sample
1 16.5 62.0
2 30.5 45.0
3 38.0 33.0
4 44.0 49.0
5 26.0 49.0
6 15.0 44.0
7 29.5 48.0
8 22.5 94.0
Mean 27.75 53.0*
Sd 10.0 18.38
* P < 0.05 compared to the control
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III. Comparisons of the inhibition of platelet aggregation and the levels of 6-keto- 
prostaglandin F lo, in the healthy volunteers and patients with PVD and
diabetes
Results from normal healthy volunteers were compared with these from the two patient 
groups. However, this comparison was not totally appropriate as they were of a lower 
age range (20-50 years) than the patients.
Figure 2-8 shows the comparisons of inhibition of platelet aggregation in vitro in three 
groups (normal individuals, vascular disease and diabetic patients) after HOU-treatment 
of blood with the Ozon-O-Med device. A significantly greater inhibition of platelet 
aggregation was apparent in the vascular disease patients group compared to the normal 
controls when 10 jumol / L ADP was used as the platelet agonist (P < 0.002). When the 
vascular disease patient group was compared with the diabetic patient group, 
significantly greater inhibition of platelet aggregation were apparent in the vascular 
disease patient group when using 0.5 u /mL thrombin (P < 0.05) and 10 pmo\ / L ADP 
(P <0.01) as platelet agonists. Platelet from the diabetic and the healthy volunteers 
showed no difference in their response to ex vivo HOU treatment.
Figure 2-9 shows the comparisons of 6-keto-prostaglandin F la concentrations before
and after in vitro blood HOU-treatment in normal, vascular disease patients and 
diabetics. The levels of 6-keto-prostaglandin F lo; were significantly higher in treated
vascular patients' blood than in treated blood from diabetics or the healthy volunteers {P 
< 0.05). The levels of 6-keto-prostaglandin F la in untreated blood is not significantly
different in these three groups.
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Figure 2-8. Comparisons in the inhibition of platelet aggregation in vitro after ex vivo 
HOU-treatment of blood from normals, vascular disease patients and 
diabetics
100
90 
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70 
60 -i- 
50 - -  
40 -I- 
30 
20 + -  
10 4-  
0
□ Normal individuals
□ Diabetic patients 
S  Vascular patients
PO.Q1**
P<0.002*
Calcium-ionophron- Thrombin 0.5 u/ml ADP 10uM/L
A23187 10 ug I ml
n =  5 8 12 6 8 8 10 6 6
* - compared to normal individuals;
** - compared to the diabetic patients.
NS - no significant difference.
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Figure 2-9. Comparisons of 6-keto-prostaglandin F la concentrations before and after
in vitro blood HOU-treatment in normal, vascular disease patients and 
diabetics.
□ Control 
H Treated sample
Normal individuals Vascular patients Diabetic patients
P* <0.001 <0.02 <0.05
n = 12 14 8
* control sample comparing with the corresponding treated sample.
** comparing with normal individuals' HOU-treated samples.
*** comparing with diabetic patients' HOU-treated samples.
NS no significant difference P > 0.05.
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2-4 Discussion
There are three basic pathways of platelet aggregation: the release of ADP, the 
liberation and metabolism o f arachidonate, and the synthesis of platelet-aggregating 
factor (PAF), all o f which are interlinked. ADP causes a chain of events involving 
phosphatidyl inositol metabolism, leading to the exposure o f fibrinogen binding sites on 
the platelet membrane and aggregation. Collagen causes platelet aggregation through a 
pathway dependent on prostaglandin biosynthesis. This induces arachidonic acid 
mobilisation from the membrane, followed by conversion to thromboxane A2, which is a 
potent stimulator o f platelet aggregation, causing ADP release and calcium flux. Similar 
considerations apply to thrombin. Adrenaline acts synergistically with other reagents 
(The British Society for Haematology BCSH Haemostasis & Thrombosis Task Force, 
1988). A third pathway of platelet activation has been suggested to be the formation o f 
PAF, although its site o f synthesis and catabolism and its mechanism o f stimulation o f 
platelets are unknown. PAF aggregates rabbit platelets in the subnanomolar 
concentration range, and human platelets at 10 times higher concentrations. Rabbit 
platelets also form larger amounts of PAF upon stimulation by thrombin, although the 
formation o f PAF by human platelets is less easily detected (Longenecker, 1985). Each 
one o f these pathways generates compounds which act as intercellular mediators to 
propagate the rapid activation o f all the platelets. It is currently thought that the 
mechanism o f stimulation by endogenous pathways is through a common intercellular 
trigger, possibly calcium (Longenecker, 1985).
The experimental results of these in vitro studies showed that platelet aggregation was 
inhibited when whole blood was treated with heat, ozone /  oxygen and ultraviolet using 
the Ozon-O-Med device. The inhibition o f the platelet aggregation response shows a 
decrease in the height and the slope o f the aggregation curve. The inhibition o f platelet 
aggregation might result from the direct effect of HOU-treatment on platelets or by the
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production o f inhibitors o f platelet aggregation produced by the HOU-treatment of 
whole blood cells or plasma.
A higher concentration o f ADP (0.05 mmol / L) resulted in a lower inhibitory effect (32 
% ± 29.1 %) on platelet aggregation than lower concentrations o f ADP (0.001 mmol /
L, inhibition 65.3 % ± 23.4 %, n = 8, P  < 0.05), which suggests that this observed 
inhibition is reversible (Table 2-1). This reversible inhibition may be explained as the 
higher agonist concentrations partially overcoming the inhibitory effect of heat, oxygen / 
ozone and ultraviolet by hyperstimulating the platelets. That this inhibition is reversible 
indicates that the function o f platelet aggregation is not damaged by HOU-treatment.
The results from studies using washed platelets also indicated that the observed 
inhibition o f platelet aggregation by HOU-treatment was not due to direct platelet 
damage - platelets isolated from treated blood maintained their ability to aggregate in 
the absence o f plasma from treated blood.
The inhibition o f aggregation o f treated platelets also occurs in response to collagen, 
thrombin and the calcium ionophore A 23187. These results suggest that the inhibition 
o f platelet aggregetion by HOU-treatment may act via a decrease in the calcium flux 
into platelets.
HOU-treatment of blood resulted in an apparent increase in total blood platelet count (P 
< 0.01). This is probably due to disaggregation o f small platelet clumps present in the 
circulation by the de-aggregatory stimulus resulting from the blood treatment.
The results from the studies on washed platelet aggregation indicated that some 
inhibitors in the plasma are derived from treated whole blood. A comparison o f platelet 
aggregation in the plasma from HOU-treated whole blood with plasma treated directly 
with HOU demonstrated a significant inhibition o f platelet aggregation in HOU-treated
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whole blood but not in HOU-treated plasma. This suggests that the inhibitors may be 
produced by the blood cells and not directly by the effects of either heat, UV light or 
ozone on plasma.
Nitric oxide plays a role in the inhibition o f platelet adhesion and aggregation by the 
stimulation o f soluble guanylate cyclase and inducing a rise in intracellular levels of 
cyclic GMP in platelets (Synder & Bredt, 1992). Nitric oxide also acts upon vascular 
smooth muscle via a similar pathway causing relaxation and vasodilation.
In the HOU-treated whole blood there was a significant increase in the concentration o f 
nitric oxide, as measured by its stable metabolites nitrite plus nitrate. Evidence that the 
inhibition o f the platelet aggregation may be partly caused by NO increase is indicated 
by the reversal by oxyhaemoglobin in the inhibition o f platelet aggregation. 
Oxyhaemoglobin inhibits NO by chemically binding (Synder & Bredt, 1992; Salvimini et 
al, 1990; Ignarro [l], 1989; Sarrel, et al, 1990). NO is a small and lipophilic molecule.
It rapidly permeates the biological membrane barrier. Oxyhemoglobin cannot penetrate 
platelets, so the reversing effect must be due to removal o f NO from the extracellular 
medium to create a concentration gradient which then results in a reduced NO 
concentration inside the platelets (Ignarro, 1990).
Prostacyclin inhibits platelet aggregation and induces vasodilatation by stimulating 
adenylate cyclase and inducing an elevation in intracellular levels of cyclic AMP in 
vascular smooth muscles and platelets (Moncada & Vane, 1979; Vane & Botting,
1995). cAMP is thought to regulate calcium levels by promoting its uptake into the 
dense tubular system. cGMP regulates calcium levels by inhibiting calcium influx and 
mobilization from intracellular stores. Therefore the final common result is a reduction 
in calcium availability (Radomski et al, 1990).
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Monocytes produce small amounts of PGI2 by the cyclooxygenase pathway and IL-1 
can enhance monocyte PGI2 synthesis (Hakkert, et al, 1992). The results (Figure 2-7) 
showed that there was an increase in the concentrations o f prostacyclin, as measured by 
its stable metabolites 6-keto PGFla, in the HOU-treated blood. Furthermore, higher 
levels o f 6-keto PGFla were found in plasma prepared from HOU-treated blood o f 
vascular disease patients (Figure 2-9) - correlating with an increased platelet inhibiting 
effect o f treatment on blood from these patients (Figure 2-8). The increase in 
prostacyclin may be explained that UV, ozone/oxygen and IL-1 released by monocytes 
and neutrophils from HOU-treated blood, induce the synthesis of cycloxygenase by 
trigging NF-kB in monocytes.
PDGF was originally identified as a product of platelets and is a specific protein of 
platelets. It is present in the alpha-granules and represents the major mitogenic 
constituent o f serum (Heldin, et al 1985, Ross, et al 1986). It is released from platelets 
upon exposure to ADP, thrombin and collagen and may be part of the repair response to 
thrombolytic injury (Ross, et al 1986 ). Measurement of the blood platelet alpha- 
granule component platelet-derived growth factor in plasma from HOU-treated and 
untreated blood revealed no significant difference, indicating that this treatment did not 
affect the platelet release reaction or disrupt the integrity of the platelet.
The results from the in vitro studies on the vascular and diabetic patients also show the 
inhibition o f platelet aggregation in response to ADP, thrombin and calcium ionophore 
A23187 and the significant increases in prostacyclin levels, as measured by its stable 
metabolites 6-keto PGFla, after blood treated with HOU.
In summary, these in vitro results suggest that HOU-treatment of whole blood using the 
Ozon-O-Med device can inhibit platelet aggregation. This treatment does not damage 
platelets. The inhibition o f platelet aggregation is probably due to the increases in the
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synthesis o f prostacyclin and nitric oxide by leucocytes activated by HOU. These 
observations provide a basis supporting the empirical observation o f improvements in 
peripheral vascular disease following Ozon-O-Med and similar ozone-based treatments.
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CHAPTER 3
Safety of Minor Autohaemotherapy with 
Blood Treated with Heat, Oxygen/Ozone and UV Irradiation
3.1 Introduction
Any new drug or device needs to have proven safety and efficacy before translating into 
a medical therapy. There are a number o f ways o f checking safety, the most basic 
approach is by the observations o f clinical symptoms, signs and objective laboratory 
results from a clinical trial involving a small number o f volunteers treated with the new 
drug or device.
For over 3 decades approximately 380,000 patients had been treated with ozonized 
blood autohaemotherapy (Jacobs, 1982) or HOU-autohaemotherapy in Western 
Germany. However, the application o f ozone therapy and HOU-therapy remains 
unproved because o f insufficient objective laboratory results forjudging adverse effects.
Objectives
The aim o f this study was to assess the effect of HOU-minor autohaemotherapy, in 
which 10 ml o f blood is treated with oxygen containing ozone at a concentration o f 15 p 
g /  ml at an elevated temperature (42.5 °C) and in the presence UV irradiation, using the 
'Ozon-O-Med' device and then injected to the donor intramuscularly
The following investigations were performed on healthy volunteers after a course o f 
HOU-treatment.
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(a) Side effects on clinical examination
(b) Standard haematological parameters in peripheral venous blood: haemoglobin (Hb), 
white blood cell (WBC) count, differential WBC, platelet count, red blood cell (RBC) 
count, RBC indices (Hct - haematocrit, MCV - mean corpuscular volume, MCH - mean 
corpuscular haemoglobin).
(c) Standard clinical biochemistry parameters in peripheral venous blood: urea, sodium 
(Na+), potassium (K+), bicarbonate, creatinine, total protein, albumin, bilirubin, alkaline 
phosphatase (Aik. phos), gamma-glutamyltransferase (Gamma G. T. ), aspartate 
transaminase (AST) and lactate dehydrogenase (LDH).
(d) Urinary dipstick tests.
3.2 Methods
3.2.1 Subjects
19 healthy, non-smoking volunteers aged 20-30 years were recruited in the study. 15 
volunteers were male and 4 were female. All were judged to be healthy on the basis of a 
medical history, physical examination, urinary dipstick tests and clinical biochemistry 
results (urea, Na+, K+, bicarbonate, creatinine, total protein, albumin, bilirubin, Aik. 
phos, Gamma G. T., AST and LD) and haematology results (Hb, WBC count, 
differential, platelet count, RBC count and RBC indices, which includ Hct, MCV,
MCH).
Five o f the 19 subjects were allocated to a control group. These 5 male volunteers were
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given a sham treatment by intramuscular re-injection o f their own untreated blood. The 
treated volunteers (10 male, 4 female) were re-injected with their own blood after 
exposure to the heat, oxygen / ozone and UV irradiation stimuli. Subjects were 
randomly allocated to the control or treatment group and treated in a double blind 
fashion, i.e. neither the volunteer, the clinician administering the treatment, nor the 
individual carrying out the laboratory studies were aware o f what treatment was used in 
any particular case.
The subject No 13. in the HOU-treated group showed a blood urea o f 7.5 mmol /  L 
which is outside the quoted normal range prior to the HOU-treatment, but clinically, 
there was no apparent cause for this increased value.
Volunteers were asked to avoid drugs known to affect platelet function (The British 
Society for Haematology BCSH Haemostasis and Thrombosis Task Force, 1988), 
including: aspirin, beta-blockers, antihistamines, tricyclic antidepressants, NSAIDs, 
corticosteroids and antibiotics, through the study and for two weeks beforehand.
The study was approved by the medical research ethics committee o f Bassetlaw Hospital 
and Community Health Service (Barrowby House, Highland Grove, Worksop, 
Nottinghamshire, United Kingdom, S 81 OJN) and all subjects gave their written 
informed consent to participate in the study.
3.2.2 Exclusions
The contraindications for ozone therapy include acute alcohol intoxication, recent 
myocardial infarction, haemorrhage, hyperthyroidism and thrombocytopenia (Rilling & 
Viebahn, 1987). Individual with a previous history o f anaphylaxis were excluded, as
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were pregnant or lactating females.
3.2.3 Trial design and statistical analysis
By taking blood samples prior to the minor autohaemotherapy treatment regime, each of 
the individuals acted as their own control. Before / after treatment changes were 
measured (see Table 3-1). Results were expressed as mean ± sd. Statistical evaluation 
was performed using the student's t test for paired samples with P < 0.05 as the minimum 
level o f significance.
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Table 3-1. Proocal for autohaemotherapy and blood sampling
Day bleed
vol
Blood tested for: 
re-inject biochemistry haematology 
vol
activity of immune cell mediators 
(PGI9, NO, IFN-gamma and IL-2)*
Mon 40 ml 10ml 10 ml 10ml 10 ml
Wed 20 ml 10 ml 10 ml
Fri 20 ml 10 ml 10 ml
Mon 20 ml 10 ml 10 ml
Wed 10 ml 10 ml
Wed(+2h)** 30 ml 10 ml 10 ml 10 ml
Fri 10 ml 10 ml
1 week later 10 ml 10 ml
* Details given in Chapter 4.
**30 ml blood were collected 2 hours after the injection o f HOU-treated or sham-treated 
blood
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3.2.4 Methodology
The reagents and equipment used are specified in Appendix 4-4.
Blood (10 ml) was collected into sodium citrate anticoagulant, pharmaceutical grade for 
injection (from Quarzlampenfabrik, Dr Muller, Gmbh, Essen, Germany) (2.0 ml o f a 3.13 
% solution, final blood citrate concentration 0.018 mol/L) and 10 ml of the 
anticoagulated blood was placed into the reaction vessel o f the Ozon-O-Med equipment 
(Appendix 2-1). After connecting the thermocouple and gas inlet tube to the machine, a 
standard three minutes treatment cycle was initiated, using a pre-set ozone concentration 
o f 15 pg /  ml. The medical grade oxygen was converted to ozone by silent electrical 
discharge at ambient temperature, and the mixture o f oxygen and ozone was then 
bubbled through the sample for 3 min. The temperature of the blood was raised to 42.5° 
C and the blood was also exposed to UVC irradiation, at a wavelength o f 253.7 nm and 
a dose of 6.0 mJ / cm2, during this treatment. After treatment, the blood was withdrawn 
into a syringe, then mixed with 2 ml o f a local anaesthetic procaine (Wo), pharmaceutical 
grade (from Quarzlampenfabrik, Dr Muller, Gmbh, Essen, Germany) and injected 
intramuscularly into the gluteal muscle (Appendix 2-2).
A disposable sterile pack is provided for each treatment, containing a syringe, sodium 
citrate, reaction vessel, gas inlet tube and thermocouple (Appendix 2-2). Each sterile 
pack is used once only, to exclude cross-contamination o f blood during treatment in the 
Ozon-O-Med equipment.
This procedure was carried out 5 times over a 2 week period. Control subjects had 
blood withdrawn, anticoagulated as above but the blood was not treated with ultraviolet 
light, heat and oxygen / ozone. The untreated blood was reinjected intramuscularly after
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mixing with 2 ml procaine (1%).
3.2.5 Clinical monitoring of individuals
All individuals were kept under observation for 60 minutes after each treatment as a 
precaution against an anaphylactic reaction. Blood pressure was taken immediately 
before and 1 hour after each minor autohaemotherapy treatment.
Any adverse events noted at the time o f treatment or reported later by any individual 
were recorded and, if necessary, further evaluated and followed up.
3.2.6 Urine test
Before each treatment and at the second day after the final treatment, urine was tested 
for blood, bilirubin, protein (albumin is indicated with greater sensitivity than other 
proteins), ketones, ascorbic acid, glucose and pH using a Maxi Screen Combi 6A (from 
Cambrige Selfcare Diagnostics limited, UK) test strip with vitamin C alert.
3.2.7 Laboratoiy studies
A standard haematology screen (Hb, WBC count, differential, platelet count, RBC count 
and RBC indices, which included Hct, MCV, MCH) and clinical biochemistry profile 
(urea, Na+, K+, bicarbonate, creatinine, total protein, albumin, bilirubin, Aik. phos, 
Gamma G. T., AST and LD) was carried out before and after the course o f treatment at 
the Department of Haematology and Clinical Chemistry at the Victoria Hospital, 
Worksop.
< 92  >
C h a p t e r  3  S a f e t y  o f  M i n o r  A  u t o h a e m o t h e r a p y  w i t h  B l o o d  T r e a t e d  w i t h  H O  U
3.3 Results
3.3.1 Clinical monitoring
All 19 subjects (14 HOU-treated and 5 control subjects) were monitored within 1 hour 
o f receiving each treatment for their immediate general reaction. In neither the control 
nor the HOU-treated groups after injection did any individual complain o f specific 
symptoms such as fever, headache and malaise. There was no swelling, redness or 
tenderness in the local areas o f the injection. There were no acute allergic reactions. 
After treatment, the following symptoms were investigated: pruritis, change of taste, 
fever, buccal ulceration, purpura, epitaxis, bleeding (e.g. gum), bruising, diarrhoea, 
uricaria, eczema, dyspnea and chest pain. No individual complaimed o f any o f the 
above. Blood pressure and pulse were normal before and 1 hour after each minor 
autohaemotherapy treatment. There were no significant changes in blood pressure or 
pulse rate either in the control or the HOU-treated groups (Table 3-2 and 3-3).
3.3.2 Urine test
No abnormalities were observed.
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Table 3-2. Changes in the blood presure and pulse o f pre-treatment and post-final 
treatment in the HOU treated group.
Pre-treatment Post-final treatment
Subject No Blood presure 
(systolic/diastolic)
Pulse 
( /m in)
Blood presure 
(systolic/ diastolic)
Pulse 
( /  min)
1 9 3 /6 5 56 112 /70 57
2 120 / 80 100 1 00 /70 82
3 1 10 /70 60 130 /70 60
4 119/93 61 103/63 59
5 8 0 /7 0 46 8 0 /6 0 50
6 101 /57 61 120 / 70 65
7 127/91 100 116 /90 75
8 133 /87 87 111/61 76
9 122 / 70 58 149 / 57 57
10 125 /80 64 123 / 73 48
11 120 /80 62 100 /70 82
12 100 /70 69 122 /  90 84
13 130 /80 70 127 / 76 70
14 133/71 73 117 /69 82
mean* 115/76 69 115/71 68
sd 1 6 /1 0 16 1 6 /1 0 13
* No significant changes in blood pressure or pulse rate.
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Table 3-3. Changes in the blood presure and pulse o f pre-treatment and post-final 
treatment in the control group.
Pre-treatment Post-fina treatment
Subject No Blood presure Pulse Blood presure Pulse
(systolic/diastolic) ( /  min) (systolic/diastolic) ( /  min)
1 129 / 100 62 109/91 55
2 123/75 53 126 / 85 61
3 122 /  77 50 119/65 62
4 118/73 61 112 /66 47
5 120 /69 60 110 /70 60
Mean* 122 /79 57 115/75 57
Sd 4 /1 2 5 7 /1 2 6
* No significant changes in blood pressure or pulse rate.
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3.3.3 Haematology screen
Table 3-4 and Table 3-5 summarise the results of measurements of haematological 
parameters in the HOU-treated and control groups. All parameters were within the 
quoted normal range for all individuals both before and after treatment (see Appendix 3- 
1 for comprehensive data).
There was a significant increase in lymphocyte counts after HOU-treatment in treated 
group (P < 0.01, n = 14), but still all within quoted normal range. There was no 
significant difference in lymphocyte counts when compared to the control group. No 
significant changes were observed in the other parameters.
3.3.4 Biochemistry screen
Table 3-6 and Table 3-7 summarise the results of measurements of clinical biochemistry 
profiles in the control and HOU-treated group. Appendix 3-2 show the results of clinical 
biochemistry screen for all individuals (in the HOU-treated and control group) both 
before and after treatment. One subject (N ol3) in the HOU-treated group, had a pre­
treatment blood urea concentration (7.5 mmol /  L) above normal. This returned to 
within normal limits (5.4 mmol / L) following treatment. Except for this individual, all 
results were within the quoted normal range for all individuals both before and after 
treatment.
In conclusion, there was no evidence that the HOU treatment in this small group was 
associated with any adverse reactions or any abnormality in biological function.
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Table 3-4. Haematological parameters in HOU-treated group ( n = 14 )
Haematological Pre-treatment After-treatment Normal range
parameter Mean Sd Mean Sd
Haemoglobin g /d l 14.42 1.10 13.99 0.97 F 11.5-16.5
M 13.0-18.0
White blood cells 10 9 /L 6.15 1.66 6.65 1.70 4.0 - 12.0
Platelet i o 9 / l 258.85 45.61 252.14 38.06 150 - 400
Hct L / L 0.417 0.032 0.406 0.029 F 0.37 - 0.47
M 0.49 - 0.54
Red blood cells 10 12 /L 4.78 0.42 4.64 0.34 F 3 .8 -5 .8
M 4 .5 -6 .5
MCV fl (femtoliters) 87.42 2.91 87.52 3.52 7 8 -9 8
MHC Pg 30.22 1.33 30.17 1.41 2 7 -3 2
Neutrophils 10 9 / L 3.42 1.59 3.83 1.63 2.0 - 7.5
Eosinophils i o 9 / l 0.21 0.14 0.20 0.14 0.1 -0 .4
Basophils i o 9 / l 0.038 0.05 0.025 0.046 0 - 0.1
Lymphocytes i o 9 / l 1.88 0.49 2.10* 0.46 1 .5 -4 .0
Monocytes i o 9 / l 0.61 0.24 0.52 0.21 0.2 - 0.8
* P < 0.01 compared to pre-treatment.
Hct Hematocrit
MCV Mean Corpuscular Volume
MCH Mean Corpuscular Hemoglobin
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Table 3-5. Haematological parameters in control untreated group (n = 5)
Haematological Pre-treatment After-treatment Normal range
parameter Mean Sd Mean Sd
Haemoglobin g / d l 14.80 0.62 14.38 0.52 F 11.5-16.5
M 13.0-18.0
White blood cells 1 0 9 / L 6.80 1.45 7.28 1.25 4.0 - 12.0
Platelet i o 9 / l 271.40 30.94 261.20 43.57 150 - 400
Hct L / L 0.429 0.013 0.410 0.015 F 0.37 - 0.47
M 0.49 - 0.54
Red blood cells 10 12 /L 4.78 0.16 4.48 0 .2 1 F 3 .8 -5 .8
M 4.5 - 6.5
MCV fl (femtoliters) 90.84 1.90 91.46 2.65 7 8 - 9 8
MCH Pg 31.34 0.63 32.06 1.14 2 7 - 3 2
Neutrophils 1 0 9 / L 3.64 1.25 4.10 1.04 2.0 - 7.5
Eosinophils i o 9 / l 0.30 0.18 0.32 0.14 0.1 -0.4
Basophils i o 9 / l 0 . 0 2 0.04 0.08 0.08 0 - 0 . 1
Lymphocytes i o 9 / l 2.26 0.32 2 . 2 0 0.30 1.5-4.0
Monocytes i o 9 / l 0 . 6 0.27 0.58 0.14 0 . 2  - 0 . 8
Hct Hematocrit
MCV Mean Corpuscular Volume
MCH Mean Corpuscular Hemoglobin
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Table 3-6. Biochemistry parameters in HOU treated group (n = 14)
Biochemistry
parameter
Pre-treatment 
Mean Sd
After-treatment 
Mean Sd
Normal range
Urea mmol /L 4.49 1 . 2 2 4.70 0.95 2.5-6 .5
Sodium mmol /L 140.71 1.26 141.78 1.25 135 - 145
Potassium mmol /L 4.10 0 . 2 0 4.20 0.37 3.5-  5.0
Bicarbonate mmol /  L 29.14 3.46 30.92 3.19 2 2 - 3 2
Creatinine umol / L 87.71 8.51 95.25 7.68 45 - 120
Total Protein g / L 74.64 4.81 73.38 2.75 6 0 - 8 8
Albumin g / L 46.92 2.23 46.69 2.28 3 5 - 5 0
Bilirubin g / L 12.64 5.58 12.61 7.61 3 - 2 1
Alk.Phos u / L 184.42 51.91 170.23 44.60 80 - 300
Gamma G. T. u /L 15 9.55 13.30 7.02 7 - 5 0
AST u / L 19.14 4.80 17.46 4.29 0 - 4 0
LD u / L 285.78 35.41 280 39.39 230 - 460
Alk.Phos Alkaline phosphase 
Gamma G. T. Gamma-Glutamyltransferase 
AST Aspartate transaminase 
LD Lactate Dehydrogenase
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Table 3-7. Biochemistry parameters in control untreated group ( n = 5 )
Biochemistry
parameter
Pre-treatment 
Mean Sd
After-treatment 
Mean Sd
Normal range
Urea mmol /L 4.80 1 .1 1 4.32 0 . 6 6 2.5 - 6.5
Sodium mmol /L 140.20 1.09 142.60 2.70 135 - 145
Potassium mmol /L 4.12 0.30 4.38 0.19 3.5-5 .0
Bicarbonate mmol / L 29.00 3.53 32.40 3.50 2 2 - 3 2
Creatinine umol /  L 85.33 5.13 95.00 14.67 45 - 120
Total Protein g / L 72.60 3.36 71.00 3.00 6 0 - 8 8
Albumin g / L 46.80 1.92 46.40 1.14 3 5 - 5 0
Bilirubin g / L 11.80 5.35 8 . 2 0 4.26 3 - 2 1
Alk.Phos u / L 161.80 34.16 151.00 26.59 80 - 300
Gamma G. T. u / L 23.80 19.38 21.60 16.56 7 - 5 0
AST u / L 16.60 3.43 16.20 2.58 0 - 4 0
LD u / L 282.60 55.13 267.60 41.64 230 - 460
Alk.Phos Alkaline phosphase 
Gamma G. T. Gamma-Glutamyltransferase 
AST Aspartate transaminase 
LD Lactate Dehydrogenase
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3-4 Discussion
All haematological and biochemical parameters were in normal ranges, suggesting that 
HOU-treatment with ozone 15 jug/ml does not induce a hepatic or renal dysfunction .
The results o f this investigation support currently published data on the safety of HOU- 
autohaemotherapy (Viehausen, 1988; Garber et al, 1991).
In 1988, Dr Med. Gunther Viehausen observed 50 subjects aged 50-60 years treated 
with Ozon-O-Med equipment. His procedure was carried out 6  times over 3 weeks. 
Clinical and laboratory chemical examinations were carried out prior to and six weeks 
after treatment. One case of chronic progressive hepatitis and six cases o f diabetes 
mellitus were diagnosed during the pre-treatment assessment o f these subjects. The 
other 43 were normal healthy subjects. Subjectively, patients reported that they felt 
better during treatment, and that afterwards they felt stronger and slept better. No 
adverse effects were detected in tests of target organ system, such as the liver and 
kidney. In some cases abnormal laboratory parameters prior to HOU-therapy, 
normalised or showed reducing abnormalities after Ozon-O-Med treatment.
Garber et al (1991) performed a pilot study o f minor autohaemotherapy with HOU- 
treated blood in 18 patients with HIV. The treatment was carried out three times per 
week for 8  weeks followed by 4-weeks observational follow-up. No significant bruising 
occurred and there were no incidences o f abscess or other localised complications. All 
haematological and biochemical parameters were stable. The treatment did not cause 
haemolysis, hepatic or renal dysfunction in these patients. Again, the treatment was well 
tolerated.
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Bocci and his colleagues were unable to find any toxic effects of ozonized blood 
autohaemotherapy in a recent study (1994) o f 4 normal volunteers.
These data clearly show that HOU treated blood used intramuscularly is remarkably free 
o f adverse effects, extending the small amount of published information.
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CHAPTER 4
The Effects of Minor Autohaemotherapy with 
Blood Treated with Heat, Oxygen/Ozone and UV Irradiation
4.1 Introduction
Endothelial dysfunction plays a critical role in peripheral vascular disease (Vane, et al, 
1990; Rau, 1991; Ware & Heistad, 1993; Ross, 1993). Many in vitro and in vivo 
experiments have demonstrated that a deficiency in the release of nitric oxide and 
prostacyclin by endothelial cells contributes to vascular disease (Radomski, et al, 1987 
[3]; Willis, et al, 1986; Vallance, et al, 1989; Panza, et al, 1990; Tolins & Shultz, 1994; 
Chester, et al, 1990).
Initial studies in vitro (Chapter 2) have demonstrated that, following whole blood treated 
with a mixture of oxygen and ozone, heat and UV irradiation, there is a decrease in 
platelet aggregation to various agonists and evidence of an increase in the levels of 
prostacyclin and nitric oxide. While these findings in vitro provide some scientific 
validity for the anecdotal claims of efficacy in peripheral vascular disease following 
Ozon-O-Med and similar ozone-based treatments, it does not explain how the 
administration of a small volume o f treated blood (lOmL) can have the profound 
systemic activity suggested by these clinical observations. In order to attempt to explain 
this, further work on minor autohaemotherapy with the HOU-treated blood was 
performed.
The claimed benefits for ozone-therapy have already been outlined in Chapter 1. The 
therapeutic benefit in various fungal, viral diseases and tumours appears unlikely to be 
due to a direct viricidal properties of ozone, because ozone and peroxides decompose
< 103 >
C h a p t e r  4  T h e  E f f e c t s  o f  M i n o r  A u t o h a e m o t h e r a p y  w i t h  B l o o d  T r e a t e d  w i t h  H O U
very rapidly and the small ( 1 0  ml) blood sample only represents a minimal fraction o f the 
internal milieu. Many studies have discovered that, in vitro, appropriate concentrations 
o f ozone can activate monocytes and lymphocytes, and induce the release of an array o f 
cytokines such as IL-1/3, IL-2, EL-6 , TNFa, EFN/3, EFN7  and GM-CSF (Bocci & 
Paulesu, 1990; Paulesu, et al, 1991; Bocci, et al, 1994). With these discoveries in vitro. 
a reasonable hypothesis has been proposed: ozone may act mainly via the stimulation of 
monocytes and lymphocytes as an inducer o f release o f cytokines (EFNs, Lis, TNFa, 
CSF). These cytokines in turn may stimulate an array of immune functions such as 
activation o f macrophages and neutrophils, enhanced expression o f major 
histocompatibility complex class I and II antigens on infected cells, monocytes and 
lymphocytes, thus leading to an activation o f the host’s immune system (Bocci, 1992; 
1994). If  this hypotheses was shown to be true, it could provided a rational basis for 
understanding the mechanisms o f action o f autohaemotherapy with blood exposed to 
ozone ex vivo in peripheral vascular disease, viral diseases and neoplasms.
Objectives
The aims of this study were to assess the effects of minor autohaemotherapy with blood 
treated with heat, oxygen / ozone and UV irradiation on:
(a) The concentrations o f certain mediators o f platelet aggregation in the plasma 
prepared from peripheral venous blood from treated volunteers.
(b) The activation status o f peripheral blood immune cells from treated volunteers.
(c) The cytokine levels in the plasma prepared from peripheral venous blood from 
treated volunteers.
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4.2 Materials and methods
The reagents and equipment used are listed in Appendix 4-3-1 and 4-3-2.
4.2.1 Subjects
This study was performed on the nineteen subjects as already mentioned in Chapter 3. 
They were healthy, non-smoking volunteers within the age range 20-30 years o f age.
For two weeks beforehand and during the study the subjects did not taken any drugs. O f 
the 19 individuals, a control group o f 5 individuals (male) were given a sham treatment 
by intramuscular re-injection of their own untreated blood. The treatment group o f 14 
individuals (10 male, 4 female) were re-injected with their own blood after exposure to 
the heat, oxygen /  ozone and UV irradiation stimuli. For treatment protocol see Table 3- 
1 in Chapter 3.
4.2.2 Samples
Blood samples were collected at intervals throughout the study as indicated in the 
protocol given in Table 3-1. In order to assess the expressions o f certain molecules 
which are characteristic of activated mononuclear cells, peripheral mononuclear cells 
(PBMCs) were isolated and slides were prepared for microscopy using alkaline 
phosphatase/anti-alkaline phosphatase (APAAP) immunoenzymatic staining. Plasma 
was prepared for measurements o f nitrite plus nitrate, 6 -keto-PGFla IFN7  and IL-2 .
1 year after the minor autohaemotherapy, the concentration o f 6 -keto-PGFla was 
measured in plasma samples from HOU-treated or the sham treated subjects.
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4.2.3 Preparation of mononuclear cells
Mononuclear cells were isolated from whole blood by density gradient centrifugation on 
Histopaque 1077 (Appendix 4-1) and were washed 3 times with DMEM. The cell pellet 
was then resuspended in DMEM (1 x 10 6 cells / ml) and 10 p\ aliquots was placed in 
individual wells o f a multispot slide and left to air dry. Slides were stored at -20 °C in 
aluminium foil until required.
4.2.4 Alkaline phosphatase/anti-alkaline phosphatase (APAAP)
APAAP immunoenzymatic staining method was employed to assess the expression of 
certain molecules on PBMCs. For the priciple of APAAP immuno-enzymatic staining 
see Appendix 4-2-1. The APAAP immuno-enzymatic staining procedure is described in 
detail in Appendix 4-2-2. The monoclonal mouse antibodies used in this study are 
shown in Table 4-1. The percentage of positive expression of each specific antigen on 
PBMCs was calculated from the ratio o f the number o f positive cells to the number o f 
PBMC (CD45 positive cells) per high power field (see Figure 4-1).
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Table 4-1. Monoclonal mouse antibodies detected at leucocyte antigens.
MAb (Antigen) Source Specificity
HLe-1 (CD45) Becton-Dickinson 
Oxford, UK.
Reacts strongly with all 
leucocytes.
HLA-DR (CR3/43) Dako, Denmark. Identifies HLA-DR molecules o f 
the major histocompatibility 
complex (MHC class II) 
activated macrophage / 
monocytes and some B cells.
IL-2R (CD25) Dako, Denmark. Identifies interleukin-2 (ACT-1) 
receptor on activated T 
lymphocytes.
Macrophage (Ber-Mac3) Dako, Denmark. Identifies activated monocytes.
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F igure 4-1. Photomicrographs of APAAP stained peripheral blood mononuclear cells 
(magnification = xlOOO)
(a)Peripheral blood mononuclear cells (PBMCs) stained by CD45
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(b) CD25 staining activated T lymphocytes in PBMCs before HOU-autohaemotherapy
(c) CD25 staining activated T lymphocytes in PBMCs after HOU-autohaemotherapy
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♦  ",
(d) HLA-DR staining activated mononuclear cells in PBMCs before HOU-autohaemotherapy
*
% * ■ *
(e) HLA-DR staining activated mononuclear cells in PBMCs after HOU-autohaemotherapy
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(f) Ber-Mac3 staining activated monocytes in peripheral blood before HOU-autohaemotherapy
A .
(g) Ber-Mac3 staining activated monocytes in peripheral blood after HOU-autohaemotherapy
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4.2.5 Nitrite and nitrate measurement
The preparation of plasma, the method of reduction from nitrate to nitrite and the 
measurement o f nitrite using the Griess reagent are described at Appendix 2-3.
4.2.6 EIA for 6-keto-prostaglandin Fla
The sample preparation and method of extraction of 6 -keto-prostaglandin F la  are 
detailed in Chapter 2 and Appendix 2-4. The concentration o f 6 -Keto-prostaglandin-Fl- 
alpha in plasma was measured using a commercially available ELISA kit. For the 
priciple of the assay see Appendix 4-3.
4.2.7 ELISA assay for IFN-gamma and IL-2
The concentration o f IFN-gamma in plasma was measured using a commercially 
available ELISA kit (Endogen Inc, 45 ID street, Boston, MA, USA). This kits detects a 
minimum level o f 5 pg / mL o f biologically active interferon-gamma. Expected IFN- 
gamma values in most healthy individuals are less than 10 pg / mL.
The levels o f IL-2 in plasma was also measured by an ELISA method (T Cell Diagnostic, 
Inc, 38 Sidney Street, Cambridge, MA02139)
4.2.8 Statistical analysis
Results are expressed as mean ± sd. The paired student's t-test was used to compare 
pre and post-treatment values. A P value of = or < 0.05 was taken as significant.
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4.3 Results
4.3.1 Expression of molecules (surface markers) on PBMCs
4.3.1.1 Expression of CD25 on PBMCs
Table 4-2 shows the expression o f CD25 measured by the APAAP method on the 
PBMCs of healthy volunteers following a course o f autohaemotherapy with HOU- 
treated homologous blood. There was a gradually increase in the proportion o f PBMCs 
expressing CD25 after the first three treatments. There was a statistically significant 
increase after each treatment, when compared to the proportion o f PBMCs expressing 
CD25 before treatment. After 5 injections (the complete course o f autohaemotherapy), 
there was a significant mean increase in the proportion o f PBMCs expressing CD25, P < 
0.001, n = 14. One week after the last treatment, the proportion o f PBMCs expressing 
CD25 was still more than that before this treatment, P < 0.05, n = 6 . Table 4-3 shows 
that no change occured in the control group. In Figure 4-2 a comparison between the 
treated and control groups shows a statistically significant increase in the proportion o f 
PBMCs expressing CD25 after the second, third, fourth injection HOU-treated 
homologous blood and post-treatment mean {P < 0.05, < 0.02, < 0.05 and < 0 . 0 1  
respectively).
< 113  >
C h a p t e r  4  T h e  E f f e c t s  o f  M i n o r  A  u t o h a e m o t h e r a p y  w i t h  B l o o d  T r e a t e d  w i t h  H O  U
Table 4-2. The expression of CD25 on peripheral blood mononuclear cells (as a 
percentage o f CD45 positive cells) in normal healthy volunteers treated 
with antologous blood exposed to HOU stimuli.
Subject
No
Pre-treatment
(Baseline)
Post-1st 
treatment
Post-2nd
treatment
Post-3rd
treatment
Post-4th
treatment
Post-5th
treatment
Post treatment 
Mean (n=5)
1 week post 
treatment
1 17 26 34 55 58 30 46.6 57
2 13 75 39 21 58 74 53.4
3 29 69 72 27 100 45 62.6
4 40 42 60 72 56 88 63.6 59
5 50 96 89 87 85 71 85.6 72
6 34 32 58 40 31 40 40.2 35
7 48 45 46 76 45 52 52.8
8 50 53 77 63 56 82 66..2
9 51 50 50 64 47 58 53.8
10 47 51 41 46 36 38 42.4
11 30 79 62 80 52 36 61.8 61
12 47 48 48 53 57 71 55.4 53
13 31 43 45 45 55 48 47.2
14 40 42 46 60 43 45 47.2
Mean 37.64 53.64 54.79 56.36 55.64 55.57 55.20 56.17
Sd 12.41 19.36 15.79 19.36 17.97 18.51 12.26 12.17
N 14 14 14 14 14 14 14 6
p * <0.05 < 0.002 <0.01 <0.02 <0.01 <0.001 <0.05
P* values are calculated in comparison to the pre-treatment baseline.
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Table 4-3. The expression o f CD25 on peripheral blood mononuclear cells (as a 
percentage of CD45 positive cells) in a control group of normal 
volunteers reinjected with their own untreated blood.
Subject
No
Pre-treatment
(Baseline)
Post-1 St 
treatment
Post-2nd
treatment
Post-3rd
treatment
Post-4th
treatment
Post-5th
treatment
Post reatment 
mean (n=5 )
1 week post 
treatment
1 22 73 31 17 45 57 44.6
2 25 39 35 30 21 34 31.8
3 60 49 46 44 40 34 42.6 43
4 47 42 25 32 46 35 36.0 45
5 48 32 52 28 18 32 32.4 29
Mean 40.40 47.00 37.80 30.20 34.00 38.40 37.48 39.00
Sd 16.29 15.76 11.03 9.65 13.47 10.45 5.86 8.72
N 5 5 5 5 5 5 5 3
p* NS NS NS NS NS NS NS
P* values are calculated in comparison to the pre-treatment baseline. 
NS: No significant difference at P > 0.05.
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Figure 4-2. Comparisons of CD25 expression on peripheral blood mononuclear cells 
(as a percentage of CD45 positive cells) in the HOU-treated and the 
control group of normal volunteers.
□ HOU-treated group §  Control group
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40
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10
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Pre- Post-1 st Post-2nd Post-3rd Post-4th Post-5th Post 1 week
treatment treatment treatment treatment treatment treatment treatment post
mean treatment
P values are calculated in comparison to the control group. 
NS No statistically significant changes at P  > 0.05.
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4.3.1.2 Expression of HLA-DR on PBMCs
Table 4-4 shows the expression of HLA-DR assessed by the APAAP method on the 
PBMCs of healthy volunteers after autohaemotherapy with HOU-treated homologous 
blood. There was a gradual increase in the proportion o f PBMCs expressing HLA-DR 
after the first three treatments. There was also a statistically significant increase after 
every treatment, when compared to the proportion o f PBMCs expressing HLA-DR 
before treatment. After completing 5 treatments, there was a significant mean increase in 
the proportion o f PBMCs expressing HLA-DR, P < 0.001, n = 14. One week after the 
last treatment, the proportion o f PBMCs expressing HLA-DR was not significantly 
different from before this treatment (P > 0.05, n= 6 ). Table 4-5 shows that there were 
no significant changes in the control group. A comparison o f the treated and control 
group in Figure 4-3 shows that there was a significant increases in the proportion of 
PBMCs expressing HLA-DR after every treatment and post treatment mean, P  < 0.05, < 
0.01, < 0.05, < 0.05, 0.02 and < 0.002 respectively.
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Table 4-4. The expression of HLA-DR on peripheral blood mononuclear cells (as a 
percentage of CD45 positive cells) in normal healthy volunteers treated 
with antologous blood exposed to HOU stimuli.
Subject
No
Pre4reatment
(Baseline)
Post-lst
treatment
Post-2nd
treatment
Post-3rd
treatment
Post-4th
treatment
Post-5th
treatment
Post treatment 
mean (n=5)
1 week post 
treatment
1 34 34 45 54 50 49 46.4 39
2 16 37 33 35 55 82 48.4
3 49 61 52 52 96 49 62.0
4 25 42 35 75 54 91 59.4 60
5 26 57 76 92 39 62 65.2 79
6 48 44 71 35 53 75 55.6 46
7 41 44 45 70 55 65 55.8
8 28 21 52 37 28 60 39.6
9 46 53 73 56 54 62 59.6
10 39 37 48 36 40 47 41.6
11 40 67 52 70 40 47 55.2 68
12 45 48 52 59 61 60 56.0 44
13 39 37 48 36 40 47 41.6
14 41 50 63 63 54 54 56.8
Mean 36.93 45.14 53.21 54.86 51.36 60.71 52.70 56.00
Sd 9.83 12.03 13.18 17.82 15.75 13.81 8.50 15.63
N 14 14 14 14 14 14 14 6
p * <0.05 <0.001 <0.01 <0.01 < 0.001 < 0.001 NS
P* values are calculated in comparison to the pre-treatment baseline. 
NS: No significant difference at P > 0.05.
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Table 4-5. The expression o f HLA-DR on peripheral blood mononuclear cells (as a 
percentage of CD45 positive cells) in a control group of normal 
volunteers reinjected with their own untreated blood.
Subject
No
Pre-treatment
(Baseline)
Post-1 St 
treatment
Post-2nd
treatment
Post-3rd
treatment
Post-4th
treatment
Post-5th
treatment
Post treatment 
mean (n=5)
1 week post 
treatment
1 33 30 37 39 47 56 41.8
2 28 36 30 33 33 47 35.8
3 55 33 43 51 35 40 40.4 31
4 20 15 19 17 14 24 17.8 29
5 39 44 42 32 31 41 38.0 42
Mean 35.00 31.60 34.20 34.40 32.00 41.60 34.76 34.0
Sd 13.17 10.64 9.93 12.32 11.83 11.72 9.75 7.0
N 5 5 5 5 5 5 5 3
p* NS NS NS NS NS NS NS
P* values are calculated in comparison to the pre-treatment baseline. 
NS: No significant difference at P  > 0.05.
< 119  >
Chapter 4 The Effects o f Minor Autohaemotherapy with Blood Treated with HOJJ
Figure 4-3. Comparisons of HLA-DR expression on peripheral blood mononuclear 
cells (as a percentage of CD45 positive cells) in the HOU-treated and the 
control group of normal volunteers.
□ HOU-treated group S Control group
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treatment treatment treatment treatment treatment treatment treatment post
mean treatment
P values are calculated in comparison to the control group. 
NS No statistically significant changes at P > 0.05.
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4.3.1.3 Expression of Ber-M ac3 on PBMCs
Table 4-6 shows the expression o f Ber-Mac3 measured by the APAAP method on the 
PBMCs of healthy volunteers following a course o f autohaemotherapy with HOU- 
treated homologous blood. There was a statistically significant increases after the first 
and second treatments (P < 0.05 and < 0 . 0 1  respectly), when compared to the 
proportion o f PBMCs expressing Ber-Mac3 before treatment. After completing 5 
treatments, there was a significant mean increase in the proportion o f PBMCs expressing 
Ber-Mac3, P < 0.01, n = 14. One week after the last treatment, the proportion o f 
PBMCs expressing Ber-Mac3 was not significantly different from the proportion of 
PBMCs expressing Ber-Mac3 before treatment (P > 0.05, n = 6 ). Table 4-7 shows that 
there were no statistically significant changes in the control group. In Figure 4-4 a 
comparison of the treated and control groups showed a significant difference in the 
proportion o f PBMCs expressing Ber-Mac3 after the second treatment (P < 0.05, n=14).
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Table 4-6. The expression o f Ber-Mac 3 on peripheral blood mononuclear cells (as a 
percentage of CD45 positive cells) in normal healthy volunteers treated 
with antologous blood exposed to HOU stimuli.
Subject
No
Pre-treatment
(Baseline)
Post-lst
treatment
Post-2nd
treatment
Post-3rd
treatment
Post-4th
treatment
Post-5th
treatment
Post treatment 
mean (n=5)
1 w eek post 
treatment
1 41 37 52 25 34 47 39.0 26
2 19 31 37 32 34 18 30.4
3 39 39 44 46 61 47 47.4
4 39 42 55 60 33 65 51.0 29
5 19 40 47 34 37 16 34.8 32
6 46 49 52 35 38 25 39.8 29
7 30 30 35 34 37 46 36.6
8 38 36 45 34 45 44 40.8
9 38 42 37 40 32 40 38.2
10 30 28 47 38 27 34 34.8
11 34 58 35 44 44 40 44.2 40
12 37 48 47 31 56 70 50.4 44
13 29 38 58 69 32 47 48.8
14 33 29 28 35 35 26 30.6
Mean 33.71 39.07 44.21 39.86 38.93 40.36 40.49 33.33
Sd 7.80 8.51 8.72 11.81 9.56 15.79 6.94 7.09
N 14 14 14 14 14 14 14 6
p * <0.05 <0.002 NS NS NS <0.01 NS
P* values are calculated in comparison to the pre-treatment baseline. 
NS: No significant difference at P > 0.05
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Table 4-7. The expression o f Ber-Mac 3 on peripheral blood mononuclear cells (as a 
percentage of CD45 positive cells) in a control group o f normal 
volunteers reinjected with their own untreated blood.
Subject
No
Pre-treatment
(Baseline)
Post-1 St 
treatment
Post-2nd
treatment
Post-3rd
treatment
Post-4th
treatment
Post-5th
treatment
Post treatment 
mean (n=5)
1 w eek post 
treatment
1 29 21 25 27 26 31 26.0
2 30 27 36 41 49 43 39.2
3 35 76 38 33 54 68 53.8 48
4 19 21 36 29 39 64 37.8 28
5 38 20 38 36 23 22 27.8 22
Mean 30.20 33.00 34.60 33.20 38.20 45.60 36.92 32.67
Sd 7.26 24.20 5.46 5.59 13.66 20.11 11.11 13.61
N 5 5 5 5 5 5 5 3
p* NS NS NS NS NS NS NS
P* values are calculated in comparison to the pre-treatment baseline. 
NS: No significant difference at P > 0.05.
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Figure 4-4. Comparisons o f Ber-Mac 3 expression on peripheral blood mononuclear 
cells (as a percentage of CD45 positive cells) in the HOU-treated and 
the control group o f normal volunteers.
□ HOU-treated group g  Control group
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P  values are calculated in comparison to the control group. 
NS No statistically significant changes at P > 0.05.
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4.3.2 6-keto-prostaglandin F la
Table 4-8 shows the 6 -keto-prostaglandin F la levels in plasma before, during and after a 
course o f HOU-treatment. There were significant increase in 6 -keto-prostaglandin F la 
concentrations after the first, the second and the fifth HOU-treatment compared with 
pre-treatment levels (P < 0.05, n = 14). After completling 5 treatments, there was a 
statistically significant mean increase in 6 -keto-prostaglandin F la concentrations, P < 
0.02, n = 14. One week after the last treatment, 6 -keto-prostaglandin F la levels were 
not significantly increased compared to those measured before treatment (P > 0.05, n = 
6 ). One year after the last treatment, the 6 -keto-prostaglandin Fla levels in the HOU- 
treated group showed a level not different from pre-treatment level (n = 13, pre- 
treatment: 27.6 pg / mL, 1 year later: 27.8 pg /  mL). Table 4-9 shows that no change 
occured in the control group. In Figure 4-5 a comparison between the treated and 
control groups showed no significant differences in 6 -keto-prostaglandin F la 
concentrations. Although one week after the last treatment, the mean o f 6 -keto- 
prostaglandin F la levels in HOU-treated group were much higher than that in control 
group, this did not reach a statistical significance probably as a result of too small a 
number o f observations.
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Table 4-8. 6 -keto-prostaglandin F la concentrations (pg / mL) in the plasma from 
normal healthy volunteers treated with antologous blood exposed 
to HOU stimuli.
Subject
No
Pre-treatment
(Baseline)
Post-1st 
treatmen
Post-2nd
treatment
Post-3rd
treatment
Post-4th
treatment
Post-5th
treatment
Post treatment 
mean (n=5)
1 w eek post 
treatment
1 year post 
treatment
1 55.25 t  68.35 58.20 59.80 101.80 51.35 67.90 31.18 27.00
2 16.28 12.93 14.24 17.16 24.00 25.01 18.67 31.00
3 7.21 17.94 18.35 42.31 20.23 24.26 24.62 28.00
4 16.75 34.00 17.25 51.00 49.00 60.00 42.25 59.00 10.50
5 17.15 44.43 30.80 25.79 4.17 37.00 28.44 21.98 42.50
6 53.75 56.60 72.00 44.65 88.50 68.75 66.10 63.15 21.50
7 23.42 34.69 31.79 15.33 24.51 54.60 32.18 23.00
8 30.69 27.70 23.55 38.40 34.64 26.71 30.20 22.00
9 44.12 33.01 38.62 29.69 12.33 21.90 27.11 22.00
10 16.06 25.52 20.03 29.42 22.07 15.11 22.43 19.00
11 10.25 13.22 17.42 13.12 37.50 11.23 18.50 79.05 35.00
12 42.97 82.75 42.72 107.00 68.22 56.24 71.39 131.40 47.00
13 24.63 24.08 33.04 15.92 10.58 23.50 21.42 33.00
14 14.76 17.69 18.35 27.20 47.58 36.69 29.50
Mean 26.66 35.21 31.17 36.91 38.94 36.60 35.76 64.29 27.81
Sd 16.06 21.06 17.03 24.67 29.42 18.37 18.76 39.08 9.92
N 14 14 14 14 14 14 14 6 13
p * < 0.05 < 0 .05 NS NS < 0.05 < 0 .02 NS NS
P* values are calculated in comparison to the pre-treatment baseline.
NS: No significant difference at P > 0.05.
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Table 4-9. 6 -keto-prostaglandin F la concentration (pg / mL) in the plasma from 
control group o f normal volunteers reinjected with their own untreated 
blood.
Subject
No
Pre-treatment
(Baseline)
Post-lst
treatment
Post-2nd
treatment
Post-3rd
treatment
Post-4th
treatment
Post-5th
treatment
Post treatment 
mean (n=5)
1 week post 
treatment
1 year post 
treatment
1 25.00 96.00 22.00 37.00 30.30 15.00 40.06 27.00
2 28.00 17.00 40.00 35.60 36.50 27.00 31.22 14.50
3 30.70 35.00 10.50 34.00 31.00 29.00 27.90 27.50 65.00
4 52.50 62.50 25.25 18.00 49.00 37.00 38.35 29.50 18.50
5 29.00 26.50 42.00 30.00 10.30 10.30 23.82 31.00 21.50
Mean 33.04 47.40 27.95 30.92 31.42 23.66 32.27 29.33 29.30
Sd 11.07 32.03 13.13 7.68 13.99 10.85 6.88 1.76 20.47
N 5 5 5 5 5 5 5 3 5
p * NS NS NS NS NS NS NS NS
P* values are calculated in comparison to the pre-treatment baseline. 
NS: No significant difference at P > 0.05.
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Figure 4-5. Comparisons of the concentration of 6-keto PGFla in the plasma from 
HOU-treated and the control groups of normal volunteers.
□ HOU-treated group El control group
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There were no statistically significant differences at P > 0.05.
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4.3.3 IFN-gamma and IL-2
Table 4-10 shows the plasma levels of IFNy in 10 healthy volunteers after 
autohaemotherapy with HOU-treated homologous blood. IFN-y was not detectable in 
most of the samples.
Table 4-11 shows the plasma levels of EFNy in 3 healthy volunteers in the control group. 
None o f the samples had detectable levels of IFN-gamma.
The plasma levels o f IL-2 was measured in 10 healthy volunteers after autohaemotherapy 
with HOU-treated homologous blood and 3 healthy volunteers in the control group. IL- 
2  was not detectable in most o f the samples (not shown).
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Table 4-10. IFN-gamma concentration (pg / mL) in the serum from the normal 
healthy volunteers treated with antologous blood exposed to HOU 
stimuli.
Subject
No
Pre-treatment
(Baseline)
Post-1 st 
treatment
Post-2nd
treatment
Post-3rd
treatment
Post-4th
treatment
Post-5th
treatment
1 week post 
treatment
2 <5.0 <5.0 <5.0 <5.0 <5.0 <5.0
3 <5.0 <5.0 <5.0 <5.0 <5.0 <5.0
5 5.55 <5.0 8.35 5.3 <5.0 <5.0 <5.0
7 <5.0 <5.0 <5.0 <5.0 <5.0 <5.0
8 <5.0 <5.0 <5.0 <5.0 5.6 <5.0
9 <5.0 <5.0 <5.0 <5.0 5.2 <5.0
10 <5.0 <5.0 <5.0 <5.0 <5.0 <5.0
11 <5.0 <5.0 <5.0 <5.0 <5.0 <5.0 <5.0
13 <5.0 <5.0 <5.0 <5.0 <5.0 <5.0 <5.0
14 6.0 <5.0 <5.0 7.6 <5.0 <5.0
N 10 10 10 10 10 10 3
Table 4-11 . IFN-gamma concentration (pg / mL) in serum from the control group o f 
normal volunteers re-injected with their own untreated blood.
Subject
No
Pre-treatment
(Baseline)
Post-1 St 
treatment
Post-2nd
treatment
Post-3rd
treatment
Post-4th
treatment
Post-5tli
treatment
1 <5.0 <5.0 <5.0 <5.0 <5.0 <5.0
2 <5.0 <5.0 <5.0 <5.0 <5.0 <5.0
5 <5.0 <5.0 <5.0 <5.0 <5.0 <5.0
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4.3.4 Nitrite plus nitrate
Table 4-12 shows the nitrite plus nitrate concentrations in the plasma from healthy 
volunteers following a course o f autohaemotherapy with HOU-treated homologous 
blood. There were no significant differences in the nitrite plus nitrate concentrations 
after treatment, when compared to the nitrite plus nitrate concentrations before 
treatment. Table 4-13 shows the nitrite plus nitrate concentrations in the plasma from 
healthy volunteers of the control group. There were also no significant differences in the 
nitrite plus nitrate concentrations. A comparison bewteen the HOU-treated and control 
groups showed no significant difference in the nitrite plus nitrate concentrations (Figure 
4-6).
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Table 4-12. Nitrite plus nitrate concentration (as (jM nitrite / mL) in the plasma from 
normal healthy volunteers treated with antologous blood exposed to 
HOU stimuli.
Subject
No
Pre-treatment
(Baseline)
Post-1st 
treatment
Post-2nd
treatment
Post-3rd
treatment
Post-4th
treatment
Post-5th
treatment
Post treatment 
mean (n=5)
1 week post 
treatment
1 47.0 45.0 38.0 61.0 66.0 48.0 51.60 66.0
2 34.5 23.0 14.75 33.0 36.0 34.5 28.25
3 72.0 40.0 56.0 56.0 55.0 37.0 48.80
4 62.5 54.0 54.0 84.0 70.0 61.0 64.60 66.0
5 74.0 84.0 84.0 73.0 96.0 80.0 83.40 52.0
6 47.0 42.0 33.0 56.0 42.0 35.0 41.60 33.0
7 58.0 64.0 43.0 35.0 37.0 22.0 40.20
8 39.0 35.0 31.0 23.0 34..0 25.0 29.60
9 70.0 32.0 16.0 29.0 34.0 41.0 30.40
10 62.0 27.0 45.0 58.0 45.0 60.0 47.00
11 78.0 96.0 100.0 82.0 92.0 78.0 89.60 72.0
12 66.0 70.0 45.0 23.0 48.0 47.0 46.60 60.0
13 36.0 41.0 22.0 37.0 25.0 56.0 36.20
14 34.0 34.0 66.0 58.0 60.0 60.0 55.60
Mean 55.71 49.07 46.27 50.57 52.86 48.89 49.53 58.17
Sd 15.78 21.85 24.56 20.77 21.74 17.89 18.77 14.06
N 14 14 14 14 14 14 14 6
p * NS NS NS NS NS NS NS
P* values are calculated in comparison to the pre-treatment baseline. 
NS: No significant difference at P > 0.05.
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Table 4-13. Nitrite plus nitrate concentration (as pM nitrite /  mL) in the plasma from 
a control group o f normal healthy volunteers reinjected with their own 
untreated blood
Subject
No
Pre-treatment
(Baseline)
Post-lst
treatment
Post-2nd
treatment
Post-3rd
treatment
Post-4th
treatment
Post-5th
treatment
Post treatment 
mean (n=5)
1 week post 
treatment
1 35.0 33.0 21.0 34.0 43.0 18.0 29.80
2 26.0 18.0 30.0 42.0 39.0 31.0 32.00
3 40.0 61.0 38.0 38.0 46.0 66.0 49.80 110.0
4 40.0 46.0 56.0 54.0 62.5 68.0 57.30 60.0
5 34.5 27.0 26.0 30.0 29.0 23.0 27.00 31.0
Mean 35.10 37.00 34.20 39.60 43.90 41.20 39.18 67.00
Sd 5.73 16.84 13.68 9.21 12.22 24.01 13.50 39.96
N 5 5 5 5 5 5 5 3
p * NS NS NS NS NS NS NS
P* values are calculated in comparison to the pre-treatment baseline. 
NS: No significant difference at P > 0.05.
< 133 >
Nitr
ic 
oxid
e 
con
cen
trat
ion
 (u
M/m
l)
Chapter 4 The EJfects o f  Minor Autohaemotherapy with Blood Treated with HOU
Figure 4-6. Comparisons o f the concentration of nitric oxide in the plasma from 
HOU-treated and control groups of normal volunteers.
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There were no statistically significant differences at P > 0.05.
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4.4 Discussion
The gene of the human major histocompatibility complex (MHC) Class II consists of 
some subregions: HLA-DP, -DQ and -DR, containing a minimum of one alpha and one 
beta chain. All HLA Class II gene subregion products show a similar biochemical 
structure. DAKO-HLA -DR, CR3 /  43 is a mouse monoclonal antibody that reacts with 
the beta-chain o f all products o f the gene subregions DP, DQ and DR. In peripheral 
blood DAKO-HLA -DR, CR3 / 43 stains activated mononuclear cells. Their expression 
by and the accompanying activation o f macrophages is highly dependant on the release 
of IFNy from activated T cells (Unanue, 1992; Basham & Merigan, 1983; Vivelizier, et 
al, 1984; McNicholas, et al, 1982). MHC complex Class II antigen expression is also 
commonly induced by TNFa, GM-CSF, IL-4, bacterial lipopolysaccharide (LPS) 
(Bendtzen et al 1988; Schwamberger et al, 1989; Phillips et al, 1990; Watanabe & Jacob, 
1991), reactive oxygen species (ROS) and reactive nitrogen intermediates (RNI) (Hibbs, 
et al, 1988; Liew & Cox, 1991). The results presented above show that 
autohaemotherapy with HOU-treated blood enhances the expression o f HLA-DR on 
lymphocytes and monocytes as measured by APAAP method. This may be due to the 
fact that after HOU-autohaemotherapy, upon blood reinjection, PBMCs activated ex 
vivo by HOU can stimulate other PBMCs to release cytokines including IFN7 , TNFa, 
GM-CSF and reactive nitrogen intermediates (RNI).
IL-2R is a multi-subunit system consisting o f a 55 kD a-subunit (also known in the 
human as Tac antigen) and 70 kD /3-subunit. Whereas the /3-subunit is expressed on 
resting T cells, the a-subunit expression must be induced by mitogenic stimulation or EL- 
2 stimulation, i.e. the a-subunit is strongly expressed on activated T cells (Greene, et al, 
1986; Morgan et al, 1976). The mouse mAb DAKO-CD25, ACT-1 reacts with the a- 
subunit of IL-2R. In this in vivo trial, the result shows that after autohaemotherapy with
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HOU-treated blood there was an increase in the expression o f IL-2R on T lymphocytes 
as measured by the APAAP method. This suggests that upon HOU-treated blood 
reinjection, ex vivo activated T cells may activate the other peripheral blood T cells via 
EL-2 release and these activated T cells may release more IL-2 to stimulate more T cells 
to activate.
Ber-Mac3. is a 140 KD glycoprotein and expressed in high density on lipopolysaccharide 
or IFN- 7  stimulated monocytes (Backe et al, 1991). The results presented in this 
investigation show that autohaemotherapy with blood exposured to HOU enhances the 
expression o f Ber-Mac3 on monocytes. This implies that after HOU-autohaemotherapy, 
T cells can be activated and may release IFN- 7  to activate peripheral blood monocytes.
The above observation o f the expression o f some activation markers on PBMCs suggest 
that autohemotherapy with HOU-treated blood may modify cytokine levels.
Recently, a study of leukocyte-endothelial cell interactions suggested that many agonists, 
such as the cytokines IFN7 , TNFor, IL-1 and IL-2 secreted from activated leukocytes, as 
well as lipopolysaccharide (LPS), can activate the endothelial cells and stimulate nitric 
oxide synthesis (Li, et al, 1991; Zimmerman, et al, 1992). NO is synthesised from L- 
arginine by NO synthase (NOS) and in the endothelial cells, there are two types o f NOS, 
calcium dependent (caNOS) and calcium independent (ciNOS) isoforms, the former is 
constitutive and the latter is an inducible isoform of NOS (Moncada, et al, 1991).
However, in this in vivo study the levels o f IL- 2  and IFN- 7  in the peripheral blood 
circulation were mostly undetectable and there was no significant increase in the levels of 
nitric oxide after autohaemotherapy with blood treated with HOU. This could be 
because, upon reinjection, the fractions o f PBMCs activated by heat, ozone and
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ultraviolet, home in on lymphoid microenvironments, such as spleen, bone marrow and 
lymph nodes and non-lymphoid microenvironments and there begin to release cytokines 
and nitric oxide that interact with either stationary cells or by PBMCs in transit. The 
current evidence is tending toward the view that in physiological conditions cytokines 
and nitric oxide are usually made as autocrine and paracrine factors secreted into a 
limited space between interacting cells, and any small amounts reaching the circulation 
do not disturb homoeostasis (Jacob, 1989; Bocci, 1988; Liew & Cox, 1991). For each 
reinjection o f PBMC in the small 10 ml HOU-treated blood this only represents a 
minimal fraction o f the whole PBMC population o f the internal milieu. Therefore, unless 
a far larger number o f cells is involved, the spillovers o f cytokine and NO in the 
circulation appear unlikely but, even if it occurs to a small extent, dilution in the plasma 
pool and rapid turnover would prevent a significant increase (Bocci, 1988).
Furthermore, levels o f nitrate and nitrite in blood can be affected by a number o f factors 
including dietary intake and renal clearance. Thus, these measurements are at best an 
imprecise reflection o f nitric oxide production.
The above in vivo results in which little or no IFN7  and IL-2 could be detected in the 
peripheral circulation of treated or control volunteers are compatible with those o f 
Bocci, et al. Bocci and his colleagues (1994) demonstrated that after a single or five 
consecutive autohaemotherapy treatments with ozonized blood, there was a lack o f 
circulating IL-1/3, IL-2, IL-6 , TNFa, IFN/3, IFN7  and GM-CSF, but there was an 
increase in the levels of Mx protein, a marker o f cell activation, in blood. The expression 
o f Mx protein in PBMC is induced by IFNa and is a fairly long-lasting process in 
comparison to the turnover of cytokines (Bocci, et al, 1994).
The above results show that in a group o f young health volunteers, treatment by
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reinjection o f HOU-treated blood produces a significant rise in prostacyclin as measured 
as its stable metabolite 6 -keto-PGFlcr The primary site of prostacyclin synthesis is the
endothelium o f blood vessels (Vane & Botting, 1995). The generation o f prostacyclin by 
endothelial cells can be stimulated by contact with activated leukocytes (Vane, et al; 
1990). Hakkert and his colleagues (1992) have reported that direct cell-cell contact 
between purified monocytes and endothelial cells strongly enhanced PGI2 synthesis by 
endothelial cells. Secretory products, such as IL-1, from monocytes and neutrophils, 
also increase the level and the expression o f cyclooxygenase mRNA in endothelial cells 
and enhance endothelial PGI2 synthesis, although to a lesser extent than with monocytes 
that were in direct contact with endothelial cells. Monocytes produce and secrete 
arachidonic acid metabolites by the cyclooxygenase pathway (Hakkert, et al, 1992). 
Thromboxanes are the major products synthesized by monocytes via this route, whereas 
PGI2 is produced only in small amounts. It is possible that monocytes in close contact 
with endothelial cells enhance the endothelial PGI2 production by providing the 
endothelial cells with exogenous eicosanoids (Hakkert, et al, 1992).
In conclusion it appears that autohaemotherapy with HOU-treated blood in normal 
subjects leads to a very mild process o f activation o f the immune system, without 
apparent side effects because of a lack of leakage o f cytokines into the general 
circulation. Possibly by the interaction between endothelial cells and activated 
leukocytes or by cytokines secreted by activated leukocytes, the endothelium o f blood 
vessels becomes activated and then increases in the synthesis o f prostacyclin or nitric 
oxide. Prostacyclin and nitric oxide are known to dilate blood vessels (Moncada &
Vane, 1979; Palmer, et al, 1988; Stuehr, et al, 1989) and inhibit platelet aggregation 
(Radomski et al, 1987 [l] [2] [3]). Such increases o f prostacyclin and nitric oxide would 
therefore offer a dual beneficial effect in the treatment of vascular disease.
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The results from this in vivo study provide the first objective evidence and support the 
subjective anecdotal observation o f clinical benefits in peripheral vascular disease 
following ozone/oxygen autohaemotherapy or HOU autohaemotherapy.
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Summary and Conclusions
Atherosclerosis and its complications, such as myocardial infarction, stroke and 
peripheral vascular disease, remain major causes o f morbidity and mortality in the 
Western World (Munro & Cotran, 1988; Fowkes, 1988; Office o f Population Censuses 
& Surveys, 1991). At the present time there is no widely accepted successful drug 
treatment (Lowe, 1990; Lutomski, et al, 1995) for atherosclerosis. Atheroslerosis is the 
commonest and most important vascular disease (Fowkes, 1990; Leng, 1995). With the 
recent advance in cellular immunology, atherosclerosis has been recognised as an 
immunologically mediated disease (Wick, et al, 1995). The lesions o f atherosclerosis 
result from an excessive, inflammatory-fibroproliferative response to various forms o f 
insult to the endothelium o f the artery wall. A large number o f growth factors, cytokines 
and vasoregulatory molecules participate in this process (Ross, 1993).
Although ozone is toxic to pulmonary tissue when inhaled as an environmental pollutant 
(Hatch, et al, 1990), the insufflation o f blood with oxygen containing low levels o f ozone 
gas alone, or in the presence o f heat and UV, and re-injection into the donor 
(ozone/oxygen autohaemotherapy or HOU-autohaemotherapy) has been used for a long 
time in continental Europe for the treatment o f a variety of diseases, and in particular o f 
peripheral vascular disease (Rilling & Viebahn, 1987; Gierek, et al, 1992; Romero, et al, 
1993 [l] [2]). In Germany, for example, approximately 380,000 patients have been 
treated.
The claims for the beneficial effects have already been outlined in Chapter 1. Currently 
these studies have provided an explanation o f the some mechanisms o f the action o f 
HOU-autohaemotherapy.
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This study has investigated the effect of the treatment o f blood ex vivo with HOU on the 
platelets in vitro. The results show that either in the healthy volunteers or in patients 
with PVD and / or diabetes, there is a significant inhibition o f platelet aggregation in 
response to various agonists (ADP, thrombin and the calcium ionophore A23187) when 
whole blood is treated with HOU. That inhibition o f platelet aggregation does not result 
from the disruption o f the integrity o f the platelets is indicated by the evidence that 
platelets isolated from treated blood aggregated normally in platelet poor plasma isolated 
from untreated blood. Furthermore, there were no significant differences in the levels of 
PDGF, present in platelet a-granules, observed between the HOU-treated blood and the 
untreated blood.
NF (nuclear factor)-kB is thought to be an oxidative stress-responsive transcription 
factor o f eukaryotic cells and can activate a great variety of genes involved in defence 
reactions (Schreck et al, 1992). NF-kB activation can also be induced by UV irradiation. 
In vitro HOU treatment of blood may activate NF-kB in the leucocyte populations, 
resulting in the upregulation o f cytokine synthesis. Many in vitro experiments have 
proved that ozone induces peripheral blood mononuclear cells (PBMCs) to release 
cytokines, including IFN/3, IFN7 , TNFa, IL-1/3, IL-2, IL- 6  and GM-CSF (Bocci & 
Paulesu, 1990; Paulesu, et al, 1991; Bocci, et al, 1994).
It has been reported that IFN7 , TNFa, EL-1 and IL-2, can stimulate monocytes and 
neutrophils to produce NO by upregulating nitric oxide synthase, which exists as an 
inducible isoform in these cells (Salvemini et al, 1989; Liew & Cox, 1991; Moncada & 
Palmer, 1991; Vallance & Collier, 1994; Ding, et al, 1988; Hibbs, et al, 1987; 1992; 
McCall, et al, 1990; Stuehr, et al, 1985; 1989; Wright, et al, 1989). In the in vitro HOU- 
treated whole blood there was a significant increase in the concentration o f nitric oxide, 
as measured by its stable metabolites nitrite plus nitrate.
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Many results indicate that nitric oxide plays a role in the inhibition o f platelet aggregation 
and in vasodilation, by the stimulation o f soluble guanylate cyclase and the induction o f a 
rise in the intracellular levels of cyclic GMP in platelets and vascular smooth muscle cells 
(Ignarro, et al, 1987; Ignarro, 1990; Synder & Bredt, 1992; Moncada, et al, 1989; 
Marietta, et al, 1988). NO has also been observed to inhibit mitogenesis and the 
proliferation o f cultured rat vascular smooth muscle cells (Garg & Hassid, 1989).
Evidence that the observed inhibition o f platelet aggregation in HOU-treated blood is at 
least in part caused by an increase in NO levels is provided by the reversal of the 
inhibition in the presence of oxyhaemoglobin, an NO inhibitor (Synder & Bredt, 1992; 
Salvimini et al, 1990; Ignarro, 1989 [l]; Sarrel, et al, 1990).
Recent research has indicated that monocytes can produce PGI2 in small amounts by the
cyclooxygenase pathway and that IL-1, secreted from activated monocytes and
neutrophils, can enhance monocyte PGI2 synthesis (Hakkert, et al, 1992). In this in vitro
study the results showed an increase in the concentrations of prostacyclin, as measured 
by its stable metabolites 6 -keto PG F ia , in the HOU-treated blood. The explanation for
the increase in prostacyclin may be that the UV, ozone/oxygen and IL-1 released by the 
activated PBMC and neutrophils by HOU induce the synthesis of cycloxygenase by 
activating NF-kB.
Prostacyclin has been shown to inhibit platelet aggregation and induce vasodilatation by 
stimulating adenylate cyclase and inducing an elevation in intracellular levels of cyclic 
AMP in vascular smooth muscles and platelets (Radomski et al (2) (3), 1987; Moncada & 
Vane, 1979; Vane & Botting, 1995).
It is possible that activated monocytes and T lymphocytes in blood treated with HOU in 
vitro. after reinjection in the donor, may activate other peripheral leukocytes via
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autocrine and paracrine effects and release IFNy and IL-2. This is supported by in vivo 
results of the enhancement of the expression o f the activation markers EL-2R, HLA-DR 
and Ber-Mac3 on PBMCs after autohemotherapy with HOU-treated blood.
The primary sites of prostacyclin (PGI2) synthesis are the endothelium o f blood vessels 
(Ross, 1993; Vane & Botting, 1995). The generation of prostacyclin by endothelial cells 
can be stimulated by contact with activated leukocytes (Vane, et al; 1990). Hakkert et al 
have demonstrated that in vitro direct cell-cell contact between monocytes and 
endothelial cells strongly enhances PGI2 synthesis by the endothelial cells via the 
monocytes providing the endothelial cells with exogenous eicosanoids. Secretory 
products, such as IL-1, from monocytes and neutrophils, also increase the expression o f 
cyclooxygenase mRNA in endothelial cells and enhances endothelial PGI2 synthesis 
(Hakkert, et al, 1992). In the in vivo HOU studies the results show that after HOU- 
autohaemotherapy there is a significant increase in prostacyclin measured as its stable 
metabolite 6-keto-PGFla, perhaps reflecting such an interaction between activated
monocytes and the endothelium.
It has been discovered that in the endothelial cells there are two types o f nitric oxide 
synthase, calcium dependent (caNOS) and calcium independent (ciNOS) isoforms, the 
former is constitutive and the latter is an inducible isoform of NOS (Moncada, et al,
1991; Marsden, et al, 1993). Many agonists, such as IFNy, TNFa, IL-1 and 
lipopolysaccharide (LPS), can activate the endothelial cells and stimulate nitric oxide 
synthesis (Li, et al, 1991; Zimmenman, et al, 1992). In this in vivo study the 
enhancement of the expression o f IL-2R, HLA-DR and Ber-Mac3 on PBMC after 
autohaemotherapy with HOU-treated blood suggests an increase in activation o f T 
lymphocytes, which may release IFNy. This would potentially enhance nitric oxide 
synthesis via stimulating inducible isoform o f NOS in endothelial cells.
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Overall, it appears that in normal subjects autohaemotherapy with HOU-treated blood 
leads to a very mild activation o f the immune system. By an interaction between 
endothelial cells and activated leukocytes, or by the effect of cytokines secreted by 
activated leukocytes on endothelial cells, there is an increase in the synthesis of 
prostacyclin and / or nitric oxide by the endothelium. Prostacyclin and nitric oxide are 
known to dilate blood vessels (Moncada & Vane, 1979) and inhibit platelet aggregation 
(Radomski et al, 1987 [l] [2] [3]). So the increases of prostacyclin and nitric oxide might 
offer a dual beneficial effect in the treatment o f vascular disease.
It has been stated that endothelial dysfunction plays a critical role in peripheral vascular 
disease (Vane, et al, 1990; Rau, 1991; Ware & Heistad, 1993; Ross, 1993). There is 
much evidence that a deficiency in the release of nitric oxide and prostacyclin by 
endothelial cells contributes to vascular disease (Rees, et al, 1989 [l] [2]; Vallance, et al, 
1989; Panza, et al, 1990; Tolins & Shultz, 1994). I f  autohaemotherapy with HOU- 
treated blood did result in the upregulation o f endotheliual production o f vasodilators 
such as PGI2 and NO, the therapy could be a major advance in the treatment of a number 
o f vascular disease.
There were no apparent adverse effects o f this treatment observed in these healthy 
volunteers as monitored by clinical symptoms, signs, urinary test, standard haematology 
screen and clinical chemical profile.
These observations provide objective evidence and support the subjective anecdotal 
observations o f the clinical benefits of HOU-autohaemotherapy and similar ozone / 
oxygen autohaemotherapy in the treatment of peripheral vascular disease.
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Future Research
With the recent increase in knowledge o f the underlying mechanisms o f vascular disease 
and immunology, it has been possible to further evaluate autohaemotherapy with HOU- 
treated blood within the molecular biological, immunological and clinical areas. It is 
apparent that such an approach is necessary, in order for this treatment to become 
accepted by those responsible for treating patients.
1. Extension o f the studies in vitro
To optimise the conditions o f HOU stimulation, it is necessary to investigate the effects 
of time, temperature and ozone concentration. There may be different effects on the 
inhibition o f platelet aggregation and on molecular marker expression on PBMCs, which 
can be more accurately estimated by flow cytometry than by the visual microscopic 
method used here. It has been reported that ozone at high concentrations can be noxious 
to cell components, for example, increasing the ozone concentration may produce a 
consistent increase of hemolysis due to a decrease in reduced glutathione, which 
maintains RBC membranes in a stable state (Bocci, et al, 1993 [2]) and a reduced 
production o f IFN and IL-2 in conjunction with reduced PBMC respiration (Bocci & 
Paulesu, 1990; Bocci, et al, 1993 [l]). It is necessary to standardise the ozonization 
procedure in order to yield the maximal therapeutic effects with minimal damage to the 
cells.
In order to understand the process more fully, the identification of these populations o f 
blood cells which are stimulated by this technique need to be determined in greater detail.
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The results of this research so far indicate that there is a potential rationale for the 
application o f HOU-autohaemotherapy in the area o f occlusive vascular diseases (from 
critical limb to heart, brain and retinal ischaemia). This conclusion is derived from the 
observation, both in vitro and in vivo. o f the increased production o f prostacyclin and 
nitric oxide which are known to be inhibitors o f blood vessel constriction and blood 
platelet aggregation and, which therefore improve blood flow.
It would be necessary to cany out clinical trials in patients with vascular disease and this 
study so far has provided data on the safety of the procedure. In future clinical trials in 
patients the clinical improvement should be assessed by strict clinical criteria relating to 
objective measurements and not limited to subjective assessments. The results o f a 
double-blind, randomised control trial are also required in order to exclude a 
spontaneous remission and /  or a placebo effect.
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2-1. OZON-O-M ED machine
D strtx-iof to* Canada
M E D O Z O N  C A N A D A , INC.OakviB*. Ont. (416) 827-5255
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Appendices
D isposab le  blood-hand ling  kit (from BASF) for u se  with th e  
O ZO N -O -M E D  m ach ine.
2-2. O Z O N -O -M E D  treatm en t process
P a tien t’s  blood is draw n. Blood and anti-coagulant are placed in the OZON-O-MED
reaction tank.
Blood is ozonized , irrad ia ted and  h ea ted  inside th e  
O ZO N -O -M E D  m ach ine.
R e-in jec tion of blood in to pa tien t.
<  A - 2 >
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2-3. Procedure for measurement of nitrite and nitrate
A reduction column was constructed from Teflon tubing threaded with a 1-meter length 
of 1-mm diameter cadmium wire. The column was prepared for use by washing with 10 
ml quantities of 1 N  HC1, distilled water, 2% copper sulphate solution, and distilled 
water in that sequence at about 2 0  ml per minute.
The Griess reagent consists o f 1 part 0.1% naphthylethylene diamine dihydrochloride in 
distilled water plus 1 part 1% aminobenzenesulfonaminde in 5% concentrated H3P 0 4, the 
2  parts being mixed together within 1 2  hours o f use and kept chilled.
A 5% aqueous N U C l adjusted to PH 9.0 with sodium borate was made and stored 
refrigerated for up to several months.
PPP was deproteinized before analysis as follows. To 250 p\ o f PPP was added 50 p\ 
35% sulfosalicyclic acid. Treated PPP was mixed by vortexing every 5 min and allowed 
to react for 30 min at room temperature. The treated samples were then centrifuged at 
1 0 ,0 0 0  xg for 15 min.
A series o f standard sodium nitrate solution was prepared. To two hundred microliters 
of the supernatant or standard nitrate solution was added 300 pi o f 5% aqueous NH4C1 
buffer and 60 p\ 5% NaOH and the mixture was passed through the cadmium column .
Nitrate in a sample is reduced by the cadmium column to [N 02]“ which reacts with the 
Griess reagent to form a purple azo dye. Nitrite in the sample needs no reduction. The 
colour o f the product is developed at 60° C in a water bath, then cooled to 0°C, and its 
absorbance at 546 nm measured with a spectrophotometer (Green et al, 1982). The 
concentration o f nitrite plus nitrate in PPP can be read off the standard curve o f [N 03]".
< A-3 >
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2-4. Ex traction of 6 -keto-prostaglandin F la
Solid phase extraction with Amprep C2, 100 mg minicolumn ( Amersham codes RPN 
1903) was employed.
1) To condition the column
1) Rinse an Amprep C2 1 0 0  mg minicolumn with 2  ml methanol,
ii) Rinse the column with 2 ml distilled water.
Note: Do not allow the sorbent in the column to dry.
2 ) Sample treatment
Acidify 1 ml o f plasma with 100 p\ of 2 M /L  citric acid and apply to the column.
3) Remove interferences
i) Rinse the column with 5.0 ml distilled water.
ii) Rinse with 5.0 ml 10% ethanol.
iii) Rinse with 5.0 ml hexane or petroleum ether 30°C-40 °C
4) Elution
Pass 5.0 ml methy formate through the column and collect the eluate.
The sample can be dried under nitrogen, reconstituted in assay buffer and assayed 
directly.
< A -4>
A p p e n d i c e s
2-5. Radioimmunoassay for 6-keto prostag!andin-Fla
2-5-1. Principle of the radioimmunoassay for 6-keto prostag!andin-Fla
The concentration o f 6 -Keto prostaglandin-Fl-alpha in the extraxted sample was 
measured using a commercially available radioimmunoassasy kit (Amersham 
International UK).
The assay is based on the competition between unlabelled 6 -keto-prostaglandin F la and a 
fixed quantity of a high specific activity 6 -keto-prostaglandin F la [I125] iodotyrosine 
methyl ester tracer compound for binding to an antibody for 6 -keto-prostaglandin F la. 
With fixed amounts of antibody and radioactive ligand, the amount o f radioactive ligand 
bound by the antibody will be inversely proportional to the concentration o f added non­
radioactive ligand.
The antibody bound 6 -keto-prostaglandin F la is then reacted with Amerlex-M second 
antibody bound to magnetisable polymer particles. Separation of the antibody bound 
fraction is effected by centrifugation o f the Amerlex-M suspension and decantation o f the 
supernatant.
Measurement of the radioactivity in the pellet enables the amount of labelled
Free
[125I] 6 -keto-prostaglandin F la
Bound
[125I] 6 -keto-prostaglandin F la-antibody
+ an tibody^
6 -keto-prostaglandin F la 6 -keto-prostaglandin F la-antibody
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6 -keto-prostaglandin F la in the bound fraction to be calculated. The concentration of
unlabelled 6 -keto-prostaglandin F la in the sample is then determined by interpolation
from a standard curve. This provides a rapid, simple and sensitive method for the
determination o f 6 -keto-prostaglandin F la in vitro over the range 3-400 pg /  tube.
2-5-2. Procedure of the radioimmunoassay for 6-keto-prostaglandin Fla
(1) Prepare all reagents and standards as the instructions.
(2) Equilibrate all reagents to room temperature, and mix before use.
(3) Label polypropylene tube in duplicate for total count tube (TC), non-specific 
binding tubes (NSB), zero standard tube (B0), standards and samples.
(4) Pipette 300 pi of assay buffer into the zero standard tubes( B0).
(5) Pipette 400 p\ o f assay buffer into the non-specific binding tubes(NSB).
(6 ) Pipette 200 p\ of assay buffer into all standard and sample tubes.
(7) Pipette 100 p\ o f each diluted standard into the appropriatedly labelled tubes and
vortex mix.
(8 ) Pipette 100 p\ o f each sample, in duplicate, into the appropriatedly labelled tubes 
and vortex mix.
(9) Pipette 100 p\ of [125I] 6 -keto-prostaglandin F la into all tubes and vortex mix.
(11) Pipette 100 p\ of antiserum into all tubes except the non-specific binding
tubes(NSB).
(12) Vortex mix all tubes thoroughly for 2-5 seconds and incubate overnight (between 
15 and 18 hours) at 2°C-8°C.
(13) Gently shake and swirl the bottle containing Amerlex-M second antibody reagent 
(blue-green) to ensure a homogenous suspension. Then add 500 pi to each tube 
except the TC.
< A -6>
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(14) Vortex mix all tubes thoroughly and incubate for 10 minutes at room temperature 
(15°C-30°C).
(15) Seperate the antibody bound fraction by centrifugation for 10 minutes at 1500 g, 
then aspirate the supernatant liquids.
(16) Determine the radioactivity present in each tube by counting for at least 
60 seconds in a gamma scintillation counter.
< A-7 >
A p p e n d i c e s
2-6. Height (mm) of washed platelet aggregation in HOU-treated whole blood in 
5 individuals
(1) The first individual
Reagents PPP[c] + 
PLT [c]
PPP[c] + 
PLT [t]
PPP[t] + 
PLT [t]
PPP[t] + 
PLT [c]
ADP (juM /  L)
1 0 0 6 6 130 1 1 0 50
50 30 50 6 6
25 25 58 30 25
1 0 19 13 15 1 0
Thrombin (u / ml)
1 0 1 1 0 160 145 1 0 0
5 40 49 39 19
Calcium 
ionophore 
A23187 ( f i g  /  ml) 
1 0 0
28
19
30
2 0
25
5
24
5
50
2 0 2 1 19 1 0
5
Mean 39.7 59 43.8 27.7
Sd 30.3 51.7 49.5 30.5
< A -8>
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(2) The second individual
Reagents PPP[c] + 
PLT [c]
PPP[c] + 
PLT [t]
PPP[t] + 
PLT [t]
PPP[t] + 
PLT [c]
ADP (pM  /  L)
1 0 0 65 45 33 5
50 1 2 0 52 52 33
25 2 0 30 45 25
1 0 15 40 38 1 0
Thrombin (u / ml)
1 0 62 55 38 49
5 130 70 35 1 0
Calcium
ionophore A23187 
0 xg/m l)
1 0 0
1 0
1 0
33
1 0
15
7
40
.1 0
50
8 1 0 0 1 0
5
Mean 48.9 38.3 29.2 21.3
Sd 48.4 2 0 .1 17.7 16
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(3) The third individual
Reagents PPP[c] + 
PLT [c]
PPP[c] + 
PLT [t]
PPP[t] + 
PLT [t]
PPP[t] + 
PLT [c]
A D P (^ M /L )
100 55 20 4 4
50 25 45 12 15
25 15 42 5 5
10 20 15 5 8
Thrombin (u / ml) 
10 135 135 16 12
5 65 35 35 14
Calcium ionophore 
A23187 fcig/m l) 
100 43 25 25 27
50 10 30 26 9
5 27 20 18 12
Mean 43.9 40.8 16.2 11.8
Sd 38.8 36.8 10.9 6.9
< A-10>
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(4) The fourth individual
Reagents PPP[c] + 
PLT [c]
PPP[c] + 
PLT [t]
PPP[t] + 
PLT [t]
PPP[t] + 
PLT [c]
ADP O M /L )
100 45 13 5 10
50 20 15 5 5
25 8 18 4 8
10 14 14 5 5
Thrombin (u /  ml)
10 120 120 25 15
5 37 37 33 20
Calcium 
ionophore 
A23187 (/ig /m l) 
100
25
12
4
16
20
30
14
20
50
30 9 5 15
5
Mean 34.6 27.3 14.7 12.4
Sd 34.2 35.9 12.2 5.8
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(5) The fifth individual
Reagents PPP[c] + 
PLT [c]
PPP[c] + 
PLT [t]
PPP[t] + 
PLT [t]
PPP[t] + 
PLT [c]
ADP (p ,M  /  L)
100 70 42 88 57
50 55 42 44 49
25 67 42 29 42
10 42 33 10 45
Thrombin (u / ml)
10 80 80 47 67
5 59 53 48 86
Calcium ionophore 
A23187 0xg/m l) 
100 38 8 10 22
50 10 0 20 26
5 22 19 12 14
Mean 49.2 35.4 34.2 45.3
Sd 23.1 24.3 25.6 22.9
< A -12>
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Summary: The comparison of height of platelet aggregation (mm)
A B C D
Subject PLTfcl in PPP [cl PLTfcl in PPP [tl PLTftl in PPP [cl PLTftl in PPP [tl
1 43.9 11.8 40.8 16.2
2 49.2 45.3 35.4 34.2
3 34.6 12.4 27.3 14.7
4 39.7 27.7 59.0 43.8
5 48.9 21.3 38.3 29.2
Mean 43.3 23.7 40.2 27.6
Sd 6.2 13.8 11.7 12.3
PLT[c] - washed control platelets; PLT[t] - washed treated platelets. 
PPP[c] - control plasma; PPP[t] - treated plasma.
P < 0.02, when A compared with B.
P < 0.05, when C compared with D.
NS, when A compared with C, and when B compared with D
< A-13 >
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3-1. Clinical Haematological Parameters
HAEMOGLOBIN (Normal range : F 11.5-16.5 g/dL; M 13.0-18.0 g/dL)
HOU-treated group
Subject No Pre-treatment Post-treatment
1 F 12.2 12.7
2 F 13.7 12.8
3 M 15.4 14.8
4 M 15.2 13.5
5 F 14.6 14.4
6 M 16.2 15.9
7 M 13.8 14.3
8 M 14.4 13.9
9 M 14.8 14.2
10 F 13.0 12.3
11 M 14.6 15.2
12 M 15.9 13.9
13 M 13.5 14.1
14 M 14.6 13.9
Mean 14.42 13.99
Sd 1.10 0.97
Control group
Subject No Pre-treatment Post-treatment
1 M 14.0 13.6
2 M 15.3 14.9
3 M 14.4 14.6
4 M 15.5 14.7
5 M 14.8 14.1
Mean 14.80 14.38
Sd 0.62 0.52
< A -14>
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WHITE BLOOD CELLS (Normal range : 4.0-12.0 x 10 9 / L>
HOU-treated group
Subject No_____________ Pre-treatment______________Post-treatment
1 7.2 8.3
2 8.5 9.9
3 9.8 6.8
4 5.4 6.0
5 5.1 5.7
6 5.0 5.3
7 5.0 5.9
8 7.5 7.5
9 5.3 5.4
10 7.7 10.1
11 4.3 5.3
12 4.7 5.6
13 5.6 6.5
14 5.1 4.8
Mean 6.15 6.65
Sd 1.66 1.70
Control group
Subject No Pre-treatment Post-treatment
1 5.5 6.0
2 9.3 7.8
3 6.3 9.2
4 6.5 6.7
5 6.4 6.7
Mean 6.80 7.28
Sd 1.45 1.25
< A-15 >
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PLATELET (Normal ranee : 150-400 x 10 9 / L>
HOU-treated group
Subiect No Pre-treatment Post-treatment
1 287 325
2 284 253
3 206 201
4 263 259
5 324 276
6 251 251
7 266 262
8 359 316
9 205 207
10 264 275
11 219 231
12 229 205
13 204 223
14 263 246
Mean 258.85 252.14
Sd 45.61 38.06
Control group
Subject No Pre-treatment Post-treatment
1 233 225
2 274 254
3 317 317
4 277 294
5 256 216
Mean 271.40 261.20
Sd 30.94 43.57
< A-16>
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Hct (Normal range : F 0.37-0.47 L / L; M 0.49-0.54 L / L)
HOU-treated group
Subject No__________________ Pre-treatment_______________Post-treatment
1 F 0.350 0.355
2 F 0.398 0.365
3 M 0.447 0.426
4 M 0.432 0.397
5 F 0.413 0.424
6 M 0.466 0.461
7 M 0.400 0.409
8 M 0.436 0.406
9 M 0.434 0.415
10 F 0.377 0.359
11 M 0.407 0.432
12 M 0.463 0.410
13 M 0.398 0.419
14 M 0.424 0.410
Mean 0.417 0.406
Sd 0.032 0.029
Control group
Subject No Pre-treatment Post-treatment
1 M 0.416 0.390
2 M 0.443 0.418
3 M 0.417 0.409
4 M 0.443 0.431
5 M 0.429 0.404
Mean 0.429 0.410
Sd 0.013 0.015
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RED BLOOD CELLS (Normal range : F 3.8-5.8 x 1 0 ^  / L; M 4.5-6.5 xlO ^  / L)
HOU-treated group
Subiect No Pre-treatment Post-treatment
1 F 3.95 3.98
2 F 4.76 4.38
3 M 5.12 4.90
4 M 4.72 4.31
5 F 4.66 4.76
6 M 5.31 5.27
7 M 4.31 4.34
8 M 5.08 4.70
9 M 5.10 4.96
10 F 4.45 4.27
11 M 4.57 4.79
12 M 5.49 4.89
13 M 4.39 4.59
14 M 5.02 4.87
Mean 4.78 4.64
Sd 0.42 0.34
Control group
Subiect No Pre-treatment Post-treatment
1 M 4.52 4.16
2 M 4.74 4.41
3 M 4.96 4.62
4 M 4.88 4.73
5 M 4.80 4.51
Mean 4.78 4.48
Sd 0.16 0.21
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MCV (Normal range : 78-98 fl)
HOU-treated group
Subiect No____________Pre-treatment______________ Post-treatment
1 88.5 89.2
2 83.6 83.2
3 87.2 87.0
4 91.6 91.9
5 88.5 89.1
6 87.7 87.4
7 92.8 94.2
8 85.7 86.3
9 85.1 83.7
10 84.8 84.0
11 89.1 90.1
12 84.2 83.8
13 90.6 91.2
14 84.5 84.2
Mean 87.42 87.52
Sd 2.91 3.52
Control group
Subiect No Pre-treatment Post-treatment
1 92.0 93.6
2 93.4 94.7
3 88.8 88.5
4 90.7 91.1
5 89.3 89.4
Mean
Sd
90.84
1.90
91.46
2.65
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MCH (Normal range : 27-32 pg)
HOU-treated group
Subiect No____________ Pre-treatment____________ Post-treatment
1 30.9 32.0
2 28.7 29.2
3 30.1 30.3
4 32.1 31.2
5 31.4 30.2
6 30.5 30.1
7 32.1 33.0
8 28.3 29.6
9 29.0 28.7
10 29.3 28.8
11 31.9 31.7
12 29.0 28.4
13 30.8 30.7
14 29.1 28.6
Mean 30.22 30.17
Sd 1.33 1.41
Control group
Subiect No Pre-treatment Post-treatment
1 31.1 32.6
2 32.2 33.8
3 30.8 31.6
4 31.8 31.0
5 30.8 31.3
Mean
Sd
31.34
0.63
32.06
1.14
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RPW (Normal range : 11.0-16.0)
HOU-treated group
Subiect No______________ Pre-treatment_______________ Post-treatment
1 12.7 12.9
2 12.3 12.4
3 11.7 12.1
4 1 2 .2 1 1 .8
5 1 2 .2 12.1
6 1 2 .0 11.9
7 12.3 1 2 .6
8 1 2 .2 12.5
9 12.3 12.3
10 1 2 .6 1 2 .6
11 1 2 .0 11.7
12 1 2 .0 1 2 .2
13 1 2 .6 12 .8
14 12.7 1 2 .6
Mean 12.27 12.32
Sd 0.29 0.37
Control group
Subiect No Pre-treatment Post-treatment
1 12.7 1 2 .8
2 12.1 12.1
n0 12.7 12.4
4 12.1 12.4
5 12.3 1 2 .6
Mean
Sd
12.38
0.30
12.46
0.26
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NEUTROPHILS (Normal range : 2.0-7.5 x 109 / L)
HOU-treated group
Subiect No_____________Pre-treatment_____________Post-treatment
1 4.4 5.2
2 5.8 7.2
3 7.2 4.2
4 2 .8 3.0
5 1.8 2 .2
6 2 .1 2.3
7 3.1 3.5
8 3.8 4.2
9 3.1 3.3
10 4.6 6 .8
11 1.8 2 .6
12 2.9 3.2
13 2.5 4.2
14 2 .0 1.8
Mean 3.42 3.83
Sd 1.59 1.63
Control group
Subiect No Pre-treatment Post-treatment
1 2.3 3.1
2 5.7 4.3
3 3.5 5.8
4 3.5 3.6
5 3.2 3.7
Mean 3.64 4.10
Sd 1.25 1.04
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EOSINOPHILS (Normal range : 0.1-0.4 x 10 9 / L)
HOU-treated group
Subiect No________________Pre-treatment_____________ Post-treatment
1 0.1 0 .1
2 0.1 0 .1
3 0.1 0 .1
4 0.5 0.4
5 0.3 0.3
6 0.3 0.4
7 0.1 0.1
8 0.4 0.4
9 0 .2 0 .1
10 0 .2 0 .1
11 0 .1 0 .2
12 0.4 0.4
13 0 .2 0 .2
14 0 .0 0 .0
Mean 0 .21 0 .2 0
Sd 0.14 0.14
Control group
Subiect No Pre-treatment Post-treatment
1 0.1 0.1
2 0 .6 0.4
3 0 .2 0.3
4 0.3 0.3
5 0.3 0.5
Mean 0.30 0.32
Sd 0.18 0.14
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BASOPHILS (Normal ranee : 0 - 0.1 x 10 9  /L)
HOU-treated group
Subiect No Pre-treatment Post-treatment
1 0 .0 0 .0
2 0 .0 ND
n:> 0 .0 ND
4 0 .0 0 .0
5 0.1 0 .0
6 0 .0 0 .1
7 0.1 ND
8 ND 0 .0
9 0.1 ND
10 0 .0 ND
11 0.1 0.1
12 0 .0 0 .0
13 0 .0 ND
14 0.1 0 .0
Mean 0.04 0.03
Sd 0.05 0.05
Control group
Subiect No Pre-treatment Post-treatment
1 0 .0 0 .2
2 0.1 0.1
3 0 .0 0 .1
4 0 .0 0 .0
5 0 .0 0 .0
Mean 0 .0 2 0.08
Sd 0.04 0.08
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LYMPHOCYTES (Normal range : 1.5 - 4.0 x 10 9 / L)
HOU-treated group
Subiect No____________ Pre-treatment________________Post-treatment
1 2.1 2.4
2 2 .0 2 .6
3 2 .0 2.4
4 1.5 2 .0
5 2.5 2.5
6 1.8 1.8
7 1.4 1.8
8 2 .0 2 .2
9 1.3 1.4
10 2.5 2 .8
11 1.6 1.7
12 0.9 1.3
13 2.3 2 .0
14 2.5 2 .6
Mean 1 .88 2 .1 0
Sd 0.49 0.46
Control group
Subject No Pre-treatment Post-treatment
1 2.3 2.1
2 2 .8 2.4
3 2 .0 2.4
4 2 .2 2.4
5 2 .0 1.7
Mean 2.26 2 .2 0
Sd 0.32 0.30
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MONOCYTES (Normal ranee : 0.2 - 0.8 x 10 9  / L)
HOU-treated group
Subiect No Pre-treatment Post-treatment
1 0 .6 0 .6
2 0 .6 ND
3 0.5 0.1
4 0 .6 0 .6
5 0.5 0.7
6 0 .8 0.7
7 0.4 0.5
8 1.4 0.7
9 0 .6 0 .6
10 0.4 0.4
11 0 .6 0.7
12 0.5 0.7
13 0 .6 0.1
14 0.5 0.4
Mean 0.61 0.52
Sd 0.24 0 .2 1
Control group
Subiect No Pre-treatment Post-treatment
1 0 .8 0.5
2 0 .2 0 .6
3 0 .6 0 .6
4 0.5 0.4
5 0.9 0 .8
Mean 0 .6 0.58
Sd 0.27 0.14
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3-2. Clinical Biochem istry Param eters 
UREA (Normal range : 2.5-6.5 mmol / L)
HOU-treated group
Subiect No Pre-treatment Post-treatment
1 4.8 5.4
2 3.7 5.4
3 2 .8 5.0
4 5.0 5.9
5 4.7 3.7
6 4.5 3.5
7 3.4 5.3
8 4.5 4.6
9 5.0 5.8
10 3.3 3.6
11 4.6 3.0
12 3.2 5.2
13 7.5 5.4
14 5.9 4.0
Mean 4.49 4.70
Sd 1 .2 2 0.95
Control group
Subiect No Pre-treatment Post-treatment
1 6 .0 4.2
2 5.9 5.5
3 4.6 4.0
4 3.6 3.9
5 3.9 4.0
Mean 4.80 4.32
Sd 1.11 0 .6 6
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SODIUM (Normal range : 135-145 mmol / L)
HOU-treated group
Subiect No___________________ Pre-treatmen________________Post-treatment
1 140 142
2 139 141
3 141 144
4 141 143
5 141 142
6 139 143
7 141 142
8 139 142
9 140 141
10 141 139
11 141 142
12 141 140
13 143 142
14 143 142
Mean 140.71 141.78
Sd 1.26 1.25
Control group
Subiect No Pre-treatmen Post-treatment
1 140 140
2 140 141
3 139 141
4 142 145
5 140 146
Mean 140.20 142.60
Sd 1.09 2.70
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POTASSIUM (Normal range : 3.5-5.0 mmol / L)
HOU-treated group
Subiect No_____________Pre-treatment___________ Post-treatment
1 4.6 4.5
2 4.0 4.2
3 3.9 4.2
4 4.3 4.4
5 4.0 3.5
6 4.2 4.2
7 4.0 5.0
8 3.9 4.5
9 4.1 4.5
10 3.9 4.3
11 4.4 3.8
12 4.1 3.9
13 4.0 4.0
14 4.0 3.9
Mean 4.10 4.20
Sd 0 .2 0 0.37
Control group
Subiect No Pre-treatment Post-treatment
1 3.6 4.3
2 4.2 4.6
3 4.2 4.4
4 4.4 4.1
5 4.2 4.5
Mean 4.12 4.38
Sd 0.30 0.19
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BICARBONATE (Normal range : 22-32 mmol / L)
HOU-treated group
Subiect No_____________Pre-treatment___________ Post-treatment
1 32 34
2 27 28
3 30 30
4 34 31
5 25 29
6 31 30
7 26 37
8 25 37
9 28 28
10 26 26
11 29 31
12 36 32
13 32 30
14 27 30
Mean 29.14 30.92
Sd 3.46 3.19
Control group
Subiect No Pre-treatment Post-treatment
1 27 36
2 25 36
3 28 29
4 34 29
5 31 32
Mean 29.00 32.40
Sd 3.53 3.50
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CREATININE (Normal ranee : 45-120 junol / L)
HOU-treated group
Subiect No Pre-treatment Post-treatment
1 79 90
2 93 89
3 10 0 101
4 92 99
5 ND ND
6 75 85
7 ND 96
8 ND 109
9 ND ND
10 ND ND
11 ND ND
12 88 93
13 87 ND
14 ND ND
Mean 87.71 95.25
Sd 8.51 7.68
Control group
Subiect No Pre-treatment Post-treatment
1 ND ND
2 ND 115
3 84 88
4 91 96
5 81 81
Mean 85.33 95.00
Sd 5.13 14.67
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TOTAL PROTEIN (Normal range : 60-88 g / L)
HOU-treated group
Subiect No_________________ Pre-treatment____________ Post-treatment
1 6 8 73
2 77 74
3 72 69
4 75 6 8
5 78 77
6 71 72
7 69 75
8 76 72
9 77 76
10 81 73
11 71 75
12 80 73
13 6 8 ND
14 82 77
Mean 74.64 73.38
Sd 4.81 2.75
Control group
Subiect No Pre-treatment Post-treatment
1 72 70
2 69 67
3 77 74
4 70 70
5 75 74
Mean 72.60 71.00
Sd 3.36 3.00
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ALBUMIN (Normal ranee:
HOU-treated group
Subiect No
 35-50 g / L )  
Pre-treatment Post-treatment
1 43 46
2 47 44
3 46 44
4 49 46
5 47 46
6 49 48
7 44 51
8 47 47
9 46 46
10 48 ' 44
11 47 51
12 51 47
13 44 NB
14 49 47
Mean 46.92 46.69
Sd 2.23 2.28
Control group
Subiect No Pre-treatment Post-treatment
1 46 47
2 45 45
3 50 48
4 46 46
5 47 46
Mean 46.80 46.40
Sd 1.92 1.14
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HOU-treated group
Subiect No Pre-treatment Post- treatment
1 9 12
2 11 9
3 9 7
4 25 18
5 11 12
6 2 2 32
7 10 8
8 10 3
9 2 0 2 0
10 10 6
11 14 8
12 11 13
13 7 ND
14 8 16
Mean 12.64 12.61
Sd 5.58 7.61
Control group
Subiect No Pre-treatment Post- treatment
1 16 13
2 17 6
3 4 2
4 13 10
5 9 10
Mean 11.80 8 .2 0
Sd 5.35 4.26
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ALK.PHOS (Normal range : 80-300 u / L)
HOU-treated group
Subiect No____________Pre-treatment___________ Post-treatment
1 144 173
2 185 163
3 165 148
4 146 140
5 203 205
6 260 245
7 109 108
8 137 132
9 223 236
10 229 227
11 130 130
12 190 137
13 289 NB
14 172 169
Mean 184.42 170.2
Sd 51.91 44.6'
Control Group
Subiect No Pre-treatment Post-treatment
1 128 1 2 2
2 158 145
3 162 153
4 143 141
5 218 194
Mean 161.80 151.0
Sd 34.16 26.5!
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GAMMA G.T.(Normal range : 7-50 u / L)
HOU-treated group
Subject No_______________ Pre-treatment_______________Post-treatment
1 8 8
2 17 19
3 21 15
4 13 13
5 9 10
6 12 10
7 8 8
8 9 9
9 8 9
10 9 10
11 13 15
12 13 13
13 41 ND
1 4______________________ 29__________________________ 34
Mean 15.00 13.30
Sd 9.55 7.02
Control group
Subiect No________________ Pre-treatment_______________Post-treatment
1 11 10
2 22 21
3 57 50
4 9 10
 5_______________________ 20__________________________ 17
Mean 23.80 21.60
Sd 19.38 16.56
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AST (Normal range : 0-40 u / L)
HOU-treated group
Subiect No_______________ Pre-treatment Post-treatment
1 14 18
2 2 0 19
3 2 0 18
4 19 16
5 2 0 18
6 23 18
7 15 18
8 12 12
9 19 19
10 15 13
11 21 12
12 18 17
13 32 ND
14 2 0 29
Mean 19.14 17.46
Sd 4.80 4.29
Control group
Subiect No 
1 
2
3
4
 5_________
Mean
Sd
Pre-treatment
16
20
15
12
20
16.60
3.43
Post-treatment
15
19
14
14
 19
16.20
2.58
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LP (Normal range : 230-460 u / L)
HOU-treated group
Subject No_____________ Pre-treatment____________Post-treatment
1 285 290
2 263 282
3 323 261
4 277 295
5 253 234
6 365 291
7 269 270
8 244 237
9 315 353
10 249 238
11 280 237
12 334 309
13 273 NB
14 271 343
Mean 285.78 280.00
Sd 35.41 39.39
Control group
Subiect No Pre-treatment Post-treatment
1 276 247
2 318 264
3 232 2 2 2
4 230 271
5 357 334
Mean 282.60 267.60
Sd 55.13 41.64
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4-1. Isolation of mononuclear cells from peripheral blood
In general, methods for the isolation o f mononuclear cells from circulating blood and 
bone marrow have employed mixtures o f polysaccharide and radiopaque contrast 
medium (Boyum, 1968). Histopaque 1077 from Sigma is a solution o f polysucrose and 
sodium diatrizoate, with a density of 1.077. This medium facilitates rapid recovery o f 
viable mononuclear cells from small volumes o f blood. This procedure is suitable for 
studying cell -mediated lympholysis and for human lymphocyte antigen (HLA) typing.
(1) 3.0 ml HISTOPAQUE-1077 are carefully layered over 3.0 mL anticoagulated 
venous blood in a 15 mL centrifuge tube.
(2) Centrifuge at 400 xg for exactly 30 minutes at room temperature. Centrifugation 
at lower temperatures, such as 4°C may result in cell clumping and poor recovery. 
During centrifugation, erythrocytes and granulocytes are aggregated by 
polysucrose and sediment; whereas, lymphocytes and other mononuclear cells 
remain at the plasma - HISTOPAQUE-1077 interface. Erythrocyte contamination 
is negligible.
(3) After centrifugation, carefully aspirate, with a Pasteur pipet, the upper layer to 
within 0.5 cm of the opaque interface containing mononuclear cells. Discard upper 
layer.
(4) Carefully transfer the opaque interface, with a Pasteur pipette, into a clean 
centrifuge tube.
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(5) The cell pellet are washed 3 times with DMEM; centrifuge at 250 xg for 10
minutes. Most extraneous platelets are removed by low speed centrifugation duing 
the washing step. The cells are resuspended in DMEM. (see diagram below).
Centrifuge
Blood-
Wanonutiear
Cefis
30 Minutes
■Red Ceils
HISTOPAQUE - 1 0 7 7
Diagram of the isolation o f mononuclear cells from peripheral blood
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4-2. The alkaline phosphatase / anti-alkaline phosphatase (APAAP) method 
4-2-1. Principle of the APAAP
The alkaline phosphatase / anti-alkaline phosphatase (APAAP) method utilizes three 
reagents: Primary and secondary antibodies, and APAAP enzyme immune complex -
primary antibody is specific for the antigen on the cells. The secondary or "link" antibody 
is capable o f binding to both the primary and to the APAAP enzyme immune complex, 
because the primary antibody and the antibody against alkaline phosphatase in the 
APAAP enzyme immune complex are produced in the same animal species. The alkaline 
phosphatase enzyme is visualized via a substrate-chromagen reaction (see diagram 
below). The activity of the endogenous alkaline phosphatase is effectively inhibited by 
the use of levamisole during the colour development reaction (Erber, et al, 1984; Ponder, 
et al, 1984; Mason, 1985; Cordell, et al, 1984). Levamisole does not denature sensitive 
surface antigens.
comprising the alkaline phosphatase and an antibody against alkaline phosphatase. The
APAAP -----------------------
(enzyme immune complex)
ceil surface an..=~..
primary MAb
Diagram o f the principle o f the APAAP 
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4-2-2. Procedure of the APAAP
The monoclonal alkaline phosphatase /  anti-alkaline phosphatase (APAAP) staining 
procedure was adapted from the method o f Mason (Mason, 1985).
The use o f phosphate buffers is not recommonded since this may compete with 
phosphates in the substrate. Before fixation, stored slides were allowed to reach room 
temperature and were then unwrapped. Slides were fixed in acetone: methanol: formalin 
for 90 seconds. The excess fixative was shaken off and the slides were then immediately 
washed in Tris buffered saline for 5 minutes.
Staining step:
(1) Apply primary monoclonal antibody (see Table 4-1) - Optimum concentration o f 
mouse primary antibody is applied and incubated in a moist chamber for 30 minutes 
at room temperature. Negative controls were added TBS by omission o f this 
primary mAh stage.
(2) Slides were washed 1-2 minutes, to remove traces of unbound antibody. Draining 
and bloting slides.
(3) Apply secondary antibody (Rabbit anti-mouse immunoglobulins D AKOP ATT S 
Code No. Z 259 at 1 / 25 dilution) - Incubate with a secondary antibody in a 
moist chamber for 30 minutes at room temperature.
(4) Wash in TBS for 1-2 minutes. Draining and bloting slides.
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(5) Apply APAAP complex (DAKOPATTS Code No. D 651 at 1 /  50 dilution) and 
incubate in a moist chamber for 1 hour at room temperature.
(6 ) Wash for 1-2 minutes in TBS.
The intensity o f final staining can be greatly enhanced at this point by repeating steps
3-6. When carriying out this cycle, incubation times were reduced to 10 minutes.
(7) Add filtered alkaline phosphatase substrate contaning levamisole and incubate for 
15 minutes at room temperature, then wash the slides in TBS and tap water. 
Levamisole is used to inhibit endogenous enzyme activity.
(8 ) Counterstain - 3-5 minutes with Mayer's Hematoxylin. Rinse gently 
in running tap water. Rinse in distilled water.
(9) Mount slides with Mounting medium (Glycergel from DAKO).
APAAP staining reagents:
Fixatives Acetone : methanol: formalin = 10 : 10 : 1
Buffer Tris buffered saline (TBS)
0.05 M Tris 
0.15 M NaCl
pH 7.6 adjusted using 1 N  HC1 
Substrate Naphthol AS-MX phosphate, free acid 2  mg
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Dimethylformamide 0.2 ml 
0.1 M TRIS buffer pH 8.2 9.8 ml 
1 M  Levamisole 10 p\
Fast-Red TR salt 10 mg
Prepare this solution dissolving the Naphthol AS-MX phosphate in dimethylformamide in 
a glass tube. Dilute to 10 ml with the Tris buffer pH 8.2. Add levamisole to block 
endogenous alkaline phosphatase activity. This solution can be made up in 500 pi 
aliquots and stored at - 20 °C. Immediately before staining, dissolve the Fast-Red salt in 
the substrate solution and filter directly onto the slides.
Staining by the APAAP method utilising Fast Red chromogen causes formation from 
bright red to vivid red precipitate (depending on the amount o f antigen present) around 
the target cell membrane, whereas nuclei and negative cells remained blue only when a 
hematoxylin counterstained was used.
4-3. The principle of EIA for 6-keto-prostaglandin Fla
The assay operates on the principle of competition between a horseradish peroxidase 
(HRP) labelled 6 -keto-prostaglandin F la  conjugate and the 6 -keto-prostaglandin F la  in 
the sample for a limited number o f binding sites on the anti-6 -keto-prostaglandin F la  
rabbit antibody precoated microtitre plates (see diagram below). This provides a rapid 
and sensitive method for the determination o f 6 -keto-prostaglandin F la  at a 
concentration range o f 5 to 400 pg /  ml.
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1) One Step Incubation
The sample or standard solution is first added to the primary antibody precoated 
microtiter plate. Next, the diluted antigen-enzyme conjugate is added and the plate is 
shaken and incubated at room temperature for one hour. During the incubation, the 
competition for binding sites takes place.
2) Washing
The plate is then washed, to remove all the unbound reagents.
3) Development
The bound antigen-enzyme conjugate is detected by the addition o f enzyme substrate;
3,3-5,5' Tetramethylbenzidine (TMB) plus hydrogen peroxide (H20 2), which generate 
an optimal blue color after 30 minutes.
4) Data Collection
Absorbance is measured at 650nm with a microtiter plate reader, and the standard curve 
is used to determine the concentration o f the unknown samples. The extent of colour 
development is inversely proportional to the amount of 6 -keto-PGFla in the sample or 
standard. The sensitivity of the assay can be enhanced and terminated by the addition of 
1 N H2 S0 4 which converts the blue product to an intense yellow colour with an 
absorbance maximum at 450 nm.
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(1) One Step Incubation
(2) Washing
o-o o-o
Q iO (3) Development
u
( K )
Immobilized antibody
Subtrate
Q  0 )  Coloured product
Antigen to be assayed 
(ANALYTE)
ANTIGEN-ENZYME
(CONJUGATE)
Diagram of assay principle o f EIA for 6 -keto PGFla
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4-4. Reagents, equipment and suppliers
4-4-1 Reagents
All reagents unless otherwise indicated were obtained from Sigma Chemical Co, Poole, 
Dorset, UK.
APAAP complex 
1 mm diameter cadmium wire 
IFN-gamma ELISA kit 
6 -keto-PGFlo: ELISA kit
6 -keto-PGFla RIA kit 
PDGF RIA kit 
IL-2 test kit
DAKOPATTS, Denmark, code No. D651. 
Aldrich Chemical Company, Inc. USA.
Endogen Inc, 451 D Street, Boston, MA, USA. 
Cascade Biochem Ltd, The Innovation Centre,
University Campus Reading, Berkshire, England. 
Amersham International pic, UK.
Amersham International pic, UK.
T Cell Diagnostics, Inc. 38 Sidney Street, 
Cambridge, MA 02139
4-4-2 Equipment
Aggregometer 
Aggregometer cuvette
ADG Instruments Ltd, Codicote, Herts, UK 
ADG Instruments Ltd, Codicote, Herts, UK 
Amprep C2 100 mg minicolumn Amersham International pic, UK.
Centrifuges MSE MISTRAL 2L.
Chart recorder Talbot Instruments, Alderley Edge, Cheshire, UK.
Coulter Coulter Model S. Plus, Hialeah, Florida, USA.
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Disposable sterile pack for HOU-treatment
Quarzlampenfabrik, Dr Muller, Gmbh,
Essen, Germany.
Filter Papers Whatman, Maidstone, Kent, UK.
Gamma counter LKB.
MAXI SCREEN Combi 6 A test strip
Cambrige Selfcare Diagnostics limited, UK.
MSE Micro Centaur SANYO.
Labsystems Multiskan MCC/340.
CA Hendley, Essex Ltd, Oakwood Hill Industrial 
Estate, Loughton, Essex, England. 
Quarzlampenfabrik, Dr Muller, Gmbh, Essen, 
Germany.
Humares, Karlsruhe, Germany.
Eppendorf
302S, WATSON-MARLOW Limited, England. 
Ultraspec 4050 LKB
Aggregometer Model 1002, ADG Instruments 
Ltd, Codicote, Herts, UK.
Fisons, Leicester, UK 
MT20, Chiltem 
Grant Cambrige
Microcentrifuge 
Microtiter plate reader 
Multispot slide
Ozon-O-Med
Ozone monitor
Pipettes
Pump
Spectrophotometer 
Stirrer bar
Visbing tube 
Vorter Mixer 
Water Bath
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4-4-3 Reagents of platelet aggregation
ADP Adenosine 5'-diphosphate, sodium salt Grade III from yeast ATP, anhydrous. 
Frozen solutions at pH 6 . 8  are more stable. A 10 mmol / L stock solution in saline was 
prepared and stored in 0.5 ml aliquots at -20 °C. Solutions o f ADP for platelet 
aggregation testing were prepared at 5.0 mmol / L, 1.0 mmol / L, 0.5 mmol / L, 0.05 
mmol / L and 0.01 mmol /  L concentrations in saline (Table 4-4-3).
Collagen Type III, acid solution, from calf skin. A 10 mg / m l  stock solution was 
prepared and stored at 4°C for 2 weeks. For use, it was diluted in the PBS to obtain 
lmg / ml concentration (Table 4-4-3).
Throm bin from bovine plasma. A 50 u /ml stock solution in saline was prepared and 
stored at -20°C. For use, it was diluted in saline to obtain the concentrations o f lu  /  ml 
and 5 u /ml (Table 4-4-3).
Calcium ionophone A 23187 C a^  + M g^salt, 500 pg / ml in DMSO 
(dimethylsulphoxide ) at -20°C, diluted in saline to give 10 pg /ml, 50 pg /ml and 100 
pg /ml solutions (Table 4-4-3).
Adrenaline 1-Epinephrine bitartarate, 1 mmol /1 stock solution in saline. It was stored 
at -20°C in 0.5 ml volumes. For use, an 0.1 mmol /I solution in saline (Table 4-4-3) was 
prepared.
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